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Abstract 
 
The patency rate of small diameter synthetic bypass grafts remains poor. The aim of this 
study was to develop a biocompatible, acellular, arterial scaffold, assess the scaffolds 
regenerative capacity using ovine vascular cells and begin preliminary studies of a 
vascular tissue bioreactor for the development of a tissue engineered graft for peripheral 
and coronary arterial bypass. 
Porcine carotid arteries were decellularised using a protocol developed at the University of 
Leeds. Arteries were incubated sequentially in disodium ethylenediaminetetraacetic acid, 
hypotonic solution, sodium dodecyl sulphate [0.1% w/v], DNAse and RNAse, hypertonic 
solution and 0.1% (v/v) peracetic acid.  
To ensure decellularisation, representative arterial histological sections were stained using 
haematoxylin and eosin and 4’,6-diamidino-2-phenylindole to confirm removal of cells and 
cell nuclei. The total DNA content of treated arteries was also determined. Biocompatibility 
of the acellular scaffolds was assessed using contact and extract cytotoxicity assays using 
both primary cells (porcine and ovine endothelial cells and smooth muscle cells) and two 
distinct cell lines (murine 3T3 and BHK cells). 
Ovine endothelial cells were harvested from the femoral arteries of sheep following 
digestion with collagenase. Ovine smooth muscle cells were isolated from ovine arterial 
explant cultures. To determine correct cell phenotype, immuno-staining was performed 
using a variety of primary antibodies to vascular cell markers by indirect 
immunofluorescence. Ovine vascular cells were then seeded onto the luminal surface of 
the decellularised vessels in both a two-dimensional and three-dimensional manner. A cell 
viability assay (Live / Dead Stain ®) was performed to confirm the viability of seeded cells.                                                                                                                                    
A vascular bioreactor was successfully assembled and preliminary sterility runs were 
performed in preparation for future scaffold pre-conditioning.  
The decellularisation protocol resulted in porcine carotid arteries that were free from cells 
with >90% of the total DNA being removed. The decellularised porcine carotid artery was 
not cytotoxic to any test cells. Indirect immunofluorescence performed on the harvested 
cells confirmed correct ovine endothelial cell and smooth muscle cell phenotype after cell 
isolation using magnetic bead separation. Ovine vascular cells were successfully seeded 
onto the luminal matrix of decellularised arteries in both two-dimensional and three-
dimensional experiments. Seeded cells were viable at 48 hours post incubation. A 
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vascular bioreactor was successfully assembled and was kept free from macroscopic 
microbial contamination for a maximum of fourteen days.   
In conclusion, porcine carotid arteries were successfully decellularised using an 
established decellularisation protocol. The remaining acellular scaffolds demonstrated 
capability in allowing the attachment and proliferation of xenogeneic vascular cells onto the 
scaffold surface. Further work developing a vascular bioreactor in order assess the 
functionality and ongoing cell viability of the seeded scaffold will be needed to assess the 
efficacy of decellularised porcine carotid artery as a viable conduit for arterial bypass.        
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Chapter 1 
Literature Review 
1. Introduction 
 
Cardiovascular (CV) disease remains the most common cause of death within the Western 
population (Campbell et al., 1999). In the US, two million deaths a year are caused by CV 
disease and in the UK, one in three deaths (Punshon et al., 2008).  
The Western lifestyle of excess, lipid-laden foods, smoking and lack of exercise are the 
leading causes of CV disease (American Heart Association, 2010). In order to treat such 
prevalent disease, worldwide, over 800,000 coronary artery bypass (CABG) procedures 
and 3,000,000 peripheral bypass procedures are performed annually (Fields et al., 2002; 
Nalysnyk et al., 2003). 
Autologous saphenous vein remains the most commonly used graft for performing 
peripheral and coronary revascularisation (Izzat et al., 1994; Nigri et al., 2004). Saphenous 
vein has mechanical strength, resistance against infection and antithrombogenic 
properties. Unfortunately, in up to a third of cases, the vein is unsuitable for use or has 
been harvested previously (Sayers et al., 1998).   
For coronary bypass, if vein is not available, other conduits such as the internal mammary 
artery or radial artery may be harvested. However when multiple or revision grafts are 
required (15% of cases), there may be a lack of autogenous material, necessitating use of 
synthetic material (Farrar, 2000). For peripheral bypass, surgeons must turn to the use of 
synthetic grafts when performing bypass procedures if vein is not available. The two 
synthetic grafts which are widely used clinically in bypass surgery are polyethylene 
terepthalate (Dacron) and expanded polytetrafluroethylene (ePTFE). Synthetic medium 
and large-diameter grafts with higher flow rates and lower resistance have been shown to 
have much higher patency rates than small-diameter (SD) grafts (Kannan et al., 2005; 
Kasisis et al., 2005). The patency of synthetic SD grafts (<6mm) is poor, largely as a result 
of thrombosis and neointimal hyperplasia (NIH) within the graft (Ishii et al., 2008). At four 
years, the primary patency rates of ePTFE infra-popliteal and aorto-coronary grafts are 
12% and 14% (Weyand et al., 1999; Biancari et al., 2001). SD grafts are the conduits 
required most often for coronary and peripheral arterial revascularisation (Mitchell et al., 
2003). In addition to their poor performance when implanted into small diameter arteries, 
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synthetic grafts lack favourable biomechanical properties and display much higher rates of 
infection compared to vein grafts.   
Although vein grafts have been shown to have superior patency rates compared to 
synthetic grafts (75% patency at five years), they are not without complications, 7-13% of 
grafts occlude within the first year, 15% fail within five years and 25% fail thereafter (Hatar 
et a.l, 2007; Punshon et al., 2008; Thomas et al., 2009). Furthermore, veins produce less 
heparin sulphate, nitric oxide (NO) and tissue plasminogen activator (tPA) compared to 
arterial tissue, increasing their thrombogenic potential (Angelini et al., 1989; Cox et al., 
1991; Allaire et al., 1997). In addition, vein harvest sites are associated with wound 
complications and post-operative leg oedema.  
For both peripheral and coronary artery bypass grafting, causes of graft failure can be 
divided into early, mid-term and late. Early failure (within 30 days) is as a result of surgical 
error or graft thrombosis (Conte et al., 2002). Mid-term failure (between 3 months to 2 
years) occurs as a result of neointimal hyperplasia, a process of smooth muscle 
proliferation that occurs predominantly at/around the distal anastomosis, narrowing the 
graft lumen (Sottiurai et al., 1983; Moneta et al., 1995;). Long-term graft failure (after 2 
years) results from ongoing active atherosclerosis within the graft (Moneta et al., 1995).  
 
There is an urgent need therefore for the development of novel SD vascular grafts and 
efforts are currently focused on developing a superior SD conduit that addresses the key 
issues of biocompatibility, thrombogenicity and patency. The key attributes of an ideal 
vascular graft are given in Table (1). 
 
Non-thrombogenic Easy to manufacture 
Non-immunogenic Easy to transport 
Non-carcinogenic Easy to store 
Bacteriostatic Easy to handle 
Displays effective endothelialisation Long-term mechanical stability 
Inhibits neointimal hyperplasia Unlimited size availability 
Reasonable cost Biomechanical properties similar to 
native artery 
 
Table 1. Attributes of the ‘Ideal’ Vascular Graft.  
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1.1 Structure and function of human arterial blood vessels 
A typical artery is comprised of three main layers: the tunica intima, tunica media and 
tunica adventitia (Figure 1). The intima is made up of a monolayer of endothelial cells 
(EC), collectively called the ‘endothelium’. The integrity and function of the endothelium is 
vitally important for maintaining the haemodynamics of blood flow and the balance 
between thrombosis and fibrinolysis. The medial layer consists of smooth muscle cells 
(SMC) embedded in an extracellular matrix (ECM) of collagens (type I and III), 
proteoglycans and other proteins such as elastin. The medial layer provides mechanical 
strength and gives functionality to the artery by controlling luminal diameter. Proteoglycans 
provide resistance to compression, collagens provide tensile strength and elastin fibres 
provide recoil and deformability and determine the vessel compliance. The outer layer, the 
adventitia, is separated from the medial layer by the external elastic lamina. The adventia 
is mainly comprised of loose collagen fibres and fibroblasts. It serves to adhere the artery 
to surrounding tissue and provides access for the vasa vasorum (Mitchell et al., 2003; 
Stegemann et al., 2007).  
      
 
                                   
Figure 1. Basic cross-sectional structure of a human artery. 
Tunica adventitia 
Tunica media 
Tunica intima (lined by 
endothelium) 
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1.1.1 Importance of the endothelium  
The endothelium provides many anti-thrombogenic functions. It contains anticoagulants 
such as heparins and thrombomodulin and produces inhibitors of platelet aggregation such 
as prostacyclin (Mitchell et al., 2003; Sarkar et al., 2007). It serves an important barrier 
function between circulating proteins of the coagulation cascade and the thrombogenic 
subendothelium. Damage to, or activation of, the endothelium by procoagulants such as 
thrombin and fibrin leads to attenuation of its anti-thrombotic nature (Yang et al., 2007). 
The endothelium is also important for regulating the movement and proliferation of 
underlying SMC, by the release of transforming growth factors (Sprague et al., 2005). 
1.2 Atherosclerosis 
Atherosclerosis is the process responsible for both peripheral arterial disease (PAD) and 
coronary heart disease (CHD). It is a complex process that can be identified as early as 
infancy. Major risk factors for atherosclerosis include age, gender, smoking, 
hypercholesterolaemia, hypertension, diabetes and homocysteinaemia. The process is 
initiated by endothelial dysfunction as a result of injury (see above). The injured 
endothelium releases pro-inflammatory mediators that lead to several key processes in the 
arterial wall: 1) chronic inflammation (characterised by chronic inflammatory cell infiltrates 
such as T lymphocytes and macrophages), 2) deposition of lipid [mainly low-density 
lipoprotein (LDL)], 3) vascular SMC migration and proliferation and 4) remodelling of the 
arterial ECM. The net result of these four processes is the formation of an intimal plaque, 
characterized by a fibrous cap and a lipid-laden core (Libby et al., 2011). The mediators 
that lead to these four key events are numerous and complex and include, in particular: 
the tumour necrosis factor α (TNF-α) / NO pathway, the renin-angiotensin axis, secretion 
of matrix metalloproteinase (MMP-9 and MMP- 12), membrane receptors such as LOX-1 
(lectin-like oxidized LDL receptor-1) , RAGE (receptor for advanced glycation end 
products, TLRs (toll-like receptors) and NLRs (nod-like receptors) (Mehta et al., 2007).  
 
The atherosclerotic plaque tends to cause pathology in two main ways. The plaque can 
grow in size ultimately leading to stenotic disease and chronic ischaemia or it can undergo 
thrombosis as a result of unstable plaque rupture, leading to acute ischaemia.     
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1.2.1 Peripheral arterial disease and peripheral arterial bypass 
Almost 10 million Americans suffer currently from symptomatic PAD (Alexy et al., 2008). 
Surgical revascularisation is performed in patients with PAD who develop critical limb 
ischaemia or have severe, debilitating symptoms. For the former, a bypass procedure may 
offer the only hope against the threat of amputation. Two hundred and twenty thousand 
patients a year in the US require peripheral arterial bypass, the majority of whom will 
require infrainguinal revascularisation (National Centre for Health Statistics., 1996).  
Autologous saphenous vein is considered the gold standard graft for infrainguinal bypass 
due to superior patency rates over prosthetic grafts (Norgren et al., 2007). In the third of 
patients in whom autologous vein is not available, surgeons turn to synthetic grafts as 
alternatives. At present, ePTFE is used most frequently for infrainguinal bypass. A recent 
Cochrane review however found that Dacron had superior primary patency rates over 
PTFE in above-knee infrainguinal bypass (Twine et al., 2010). The reported patency rates 
of ePTFE, however, remain inferior when compared to saphenous vein. In above-knee 
(AK) bypass, 5-year primary patency rates of 39% have been reported for ePTFE against 
74% for saphenous vein (Klinkert et al., 2004).  In below-knee (BK) bypass, results are 
significantly worse with ePTFE demonstrating less than 50% primary patency rates at two 
years (Albers et al., 2003). For infrainguinal bypass, early and late graft occlusions remain 
the most common causes of failure (Pulli et al., 2010).  
1.2.2 Coronary heart disease and coronary artery bypass grafting 
Despite the increasing use of coronary angioplasty and stenting to treat symptomatic 
coronary heart disease, worldwide, just under a million patients still require coronary artery 
bypass grafting (CABG) each year (Nalysnyk et al., 2003). 
Grafts between 2-3 mm are most frequently required for patients undergoing CABG 
(Dempsey et al., 1998). Grafts used for CABG include autologous internal mammary 
(thoracic) artery, radial artery and saphenous vein. Arterial grafts demonstrate greater 
patency rates than saphenous vein, however, saphenous vein continues to be utilised in 
over 70% of UK CABG surgery due to its ease of accessibility, harvesting and handling 
(Izzat et al., 1994).  
When utilising saphenous vein, technical issues such as anastomotic angle, size mis-
match and thrombosis are largely responsible for the 12% of patients who develop graft 
failure within the first year (Burton et al., 2006). At ten years, 50% of vein grafts have 
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occluded due to accelerated atherosclerosis (Suma, 1999). Synthetic SD conduits are 
avoided in coronary revascularisation due to poor patency and high failure rates (Jones et 
al.,1991; Ishii et al., 2008). Comparing ePTFE with autologous saphenous vein for 
example, Hehrlein et al reported patency at one year at 86% for saphenous vein and 59% 
for ePTFE. At 4 years, Chard et al reported a patency rate of just 14% for ePTFE aorto-
coronary grafts (Hehrlein et al., 1984; Chard et al., 1987).  
Lesions within the coronary arteries are generally repaired by circulating endothelial 
progenitor cells (EPC) which are attracted to damaged epithelium by chemotaxis. As 
synthetic grafts do not release chemokines, EPC are not attracted to the graft surface and 
so thrombosis often ensues due to a lack of an EC monolayer (Hoffmann et al., 2008). 
Synthetic CABG is therefore only attempted when autogenous material is not available.  
1.2.3 Use of allogeneic tissue 
The use of cardiovascular allografts such as cryopreserved saphenous vein and 
glutaraldehyde-tanned human umbilical vein, theoretically, have two obvious advantages 
compared to synthetic graft materials. Allografts possess a functioning endothelium and 
display a reduced tendency for infection (Wilshaw et al., 2012). Unfortunately such 
materials have failed to achieve widespread clinical use due to low patency rates (19%-
42% at 6 years) and complications such as aneurysmal dilatation, calcification, 
degradation (thought to be due to elastin depletion) and allosensitisation. Aldehyde-tanned 
tissue in particular was shown to demonstrate high rates of thrombogenicity as a result of 
collagen exposure (Sawyer et al., 1987; Strobel et al., 1996; Benedetto et al., 2001; Harris 
et al., 2001; Thomas et al., 2003; Swartz et al., 2005). Furthermore, the general feeling 
from vascular surgeons when using such tissues is that the tissue handling properties and 
expense of production cannot justify their commercial use (Devine et al., 2001).  
1.3 Graft thrombosis and neointimal hyperplasia 
As discussed earlier, graft thrombosis and neointimal hyperplasia (NIH) are the two main 
processes responsible for the poor patency rates of SD grafts. 
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1.3.1 Graft thrombosis 
Formation of graft thrombus is dependent upon the inherent properties and 
thrombogenicity of the graft surface, the haemodynamics of the graft itself, the degree of 
graft healing (neo-intimal formation and endothelialisation), blood flow, surgical technique 
and the thrombotic profile of the recipient patient (Ariyoshi et al., 1997; Haruguchi et al., 
2003; Zhan et al., 2010).Graft endothelialisation is an important factor influencing 
thrombogenesis. It has been extensively shown that the generation of a confluent 
endothelium on the surface of SD synthetic grafts reduces their thrombogenicity and 
improves short and long-term patency (Zilla et al., 1994; Meinhart et al., 2001; Sarkar et 
al., 2007).   
EC are able to migrate and adhere to the graft from the anastomosis, the recipient’s 
bloodstream and from neocapillary formation (Greisler, 1982). Exposure to arterial 
pressure and flow however, significantly limits this process (Giudiceandrea et al., 1998). 
Unlike other animals, in humans, synthetic grafts display minimal rates of spontaneous 
and trans-anastomotic endothelialisation. ePTFE for example, the most favoured synthetic 
graft for peripheral revascularisation, has been shown to have poor rates of 
endothelialisation, even up to five years post-implantation (Camilleri et al., 1985; Formichi 
et al., 1988). The lack of this process is a key factor that contributes to graft thrombosis 
and NIH in synthetic grafts. 
 
1.3.1.1 Events following vascular graft implantation 
Synthetic 
The presence of a synthetic vascular graft initiates a complex system of prothrombotic 
activity within the local circulation. Following implantation, the Vroman effect leads to the 
adsorption of coagulation factors and adhesive proteins on synthetic graft surfaces such as 
glycoprotein IIb-IIIa, fibrinogen, thrombin and von Willebrand factor (Vroman, 1962; Ikeda 
et al., 1996; Spijker et al., 2003). These proteins cause adherence of platelets, leading to 
platelet aggregation and activation, and generation of further fibrin (Suzuki et al., 1996). 
Following activation, platelets will release further thrombogenic products such as 
thromboxane B2 and -thromboglobulin leading to thrombus propagation (Spijker et al., 
2003). Platelet adhesion and activation is also influenced by the ‘wettability’ of the surface 
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material. Hydrophillic materials have been shown to lead to higher rates of platelet 
adhesion whilst hydrophobic materials lead to greater rates of platelet activation (Spijker et 
al., 2002). If the Vroman process propagates exponentially, thrombosis will ensue. If it is 
limited, the laid down fibrin and proteins will form neointima, with the graft lumen remaining 
patent (Scharn et al., 2006).      
In 1979, Sauvage et al. developed the notion of a ‘thrombotic threshold velocity (TTV)’ for 
a material surface, essentially, the relationship between blood flow velocity and 
thrombosis. A higher blood flow leads to increased shear forces acting on the graft 
surface, reducing thrombus formation. Blood flow above the TTV prevents thrombosis 
whilst flow below results in thrombus formation. Pouiselles’s law states that flow through 
small diameter grafts is low. The low flow present in a SD synthetic graft therefore leads to 
less shear forces on the graft surface and may mean that the TTV for that material is not 
reached. As a consequence, thrombosis can ensue.  
Synthetic / Vein 
Implantation of either a synthetic or venous graft inevitably involves injury to native blood 
vessels. When veins are used as grafts, substantial injury can occur to the venous 
endothelium prior to implantation, during the harvesting process. Following harvesting, 
implantation of the hypoxic vein graft into the arterial circulation exposes the vein not only 
to increased pressures, but also to higher oxygen tensions within the blood. This rapid 
change in oxygen tension leads to the creation of free radical species that cause damage 
to tissue and the endothelium (Motwani et al., 1989). Following damage, endothelial cells 
up-regulate the production of adhesion molecules and procoagulants such as von-
Willebrand factor, thrombin, plasminogen activator inhibitor and tissue factor (TF). In 
addition, there is a down-regulation of antithrombotics such as thrombomodulin, NO and 
tPA expression by damaged endothelium (Motwani et al., 1989; Fields et al., 2002; 
Hagemeyer et al., 2009). Plasmin is formed from plasminogen in a fibrin environment 
mainly by the action of tPA, and to a lesser extent urokinase-type plasminogen activator 
(uPA). Plasmin acts on fibrin to cause thrombus dissolution via proteolysis (Potter et al., 
1992; Novokhatny, 2008). Loss of tPA therefore elevates the vein graft to an already 
heightened thrombotic state. When synthetic grafts are implanted, damage will occur to 
native vessels at the sites of the proximal and distal anastomosis. An important net result 
of endothelial damage in these cases is the release of TF and initiation of the TF-pathway 
of coagulation (Figure 2). Factor VII (FVII) and factor VIIa (FVIIa) from the circulation form 
30 
 
a complex with exposed TF, leading to the activation of factor X (FX) and factor IX (FIX). 
FIXa up-regulates the formation of FXa.   FXa complexes with factor V (FV) on platelet 
membranes, forming the prothrombinase complex, which cleaves prothrombin to thrombin. 
Thrombin converts fibrinogen to fibrin and activates platelets, leading to thrombus 
generation (Rubin et al., 1996). Feedback activation by thrombin of FVIII, FIX and FV 
leads to further thrombin production (Mann et al., 2003). Bound thrombin remains active 
within a clot, cleaving additional fibrinogen to fibrin. In addition, there is no inhibition by 
antithombin III on thrombin in this form. Thrombin therefore is considered a dominant 
procoagulant in the aetiology of graft thrombogenesis (Weitz et al., 1990). There is an 
inhibitory protein present in the circulation produced by the endothelium to counteract the 
TF pathway of coagulation. The tissue factor pathway inhibitor protein (TFPI) circulates 
alone or complexed with plasma lipoproteins. It binds to and inhibits the TF / FVIIa 
complex preventing FX activation. Damage to the endothelium however, leads to the 
down-regulation of TFPI expression (Broze et al., 1988; Sarkar et al., 2007).  
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Figure 2. The coagulation cascade (adapted from Sakar et al., 2007). VII to XIII, 
Prothrombin and Thrombin = coagulation factors.   
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The net effect of these complex processes following SD graft implantation is the rapid 
activation of the coagulation cascade and subsequent formation of graft surface thrombus. 
Certainly in synthetic grafts, Toursarkissian et al. (2007) have demonstrated that such 
procoagulant activity continues for at least 24 hours post-implantation. 
1.3.2 Neointimal hyperplasia 
Neointimal hyperplasia is a process that occurs in both synthetic and vein grafts and 
alongside thrombosis, is a major cause of graft failure. It predominantly occurs at sites of 
anastomoses, causing narrowing of the lumen initially and then eventually leading to 
occlusion. The pathogenesis of NIH is complex and involves the migration and proliferation 
of SMC, myofibroblasts, macrophages, platelets, inflammatory pathways and deposition of 
extracellular matrix (Schachner et al., 2006). The initiating step in the development of NIH 
is endothelial damage. Damage occurs in several ways. In vein-grafts, damage occurs 
initially during harvesting. For both synthetic and vein grafts, damage to the endothelium of 
the native artery occurs during creation of the anastomosis. Implantation of vein or 
synthetic graft into the arterial circulation leads to turbulent flow as a result of a radial 
compliance mismatch between the graft and native artery and altered or increased vessel 
wall forces and stresses (Kannan et al., 2005; Desai et al., 2010;). Such altered 
haemodynamics damages the endothelium lining the graft. Damage to endothelium has 
been shown to lead to the widespread release of factors that promote NIH. Damaged 
endothelia release inflammatory mediators, growth factors (platelet-derived growth factor, 
vascular-endothelial growth factor) and cytokines. These substances cause proliferation 
and migration of vascular SMC and myofibroblasts from the media and adventitia to the 
intima. They also promote modification of the ECM and deposition of new ECM and 
endothelial cell proliferation within the intima (Schachner, 2006; Ahanchi et al., 2010; 
Desai et al., 2010). The net effect is thickening of the ‘neointima” lining the graft, a 
reduction in cross-sectional area and eventual luminal occlusion. 
Reducing or preventing the development of NIH is an area under active research. 
Examples of simple strategies to date include external stenting of grafts, which aims to 
reduce compliance mismatch and distensibility and drug therapy with agents such as 
immunosuppressants and statins (Schachner, 2006; Desai et al., 2010). More complex 
strategies include the use of growth factor modulators, nitric oxide donors and gene 
therapy (Nigri et al., 2004). Simple surgical techniques to reduce NIH when using vein 
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grafts include minimising the handling of vein during harvesting and limiting the ischaemic 
time (Schachner, 2006).  
1.4 Strategies to improve SD arterial bypass grafting 
There are three main strategies focused on improving the outcomes of SD arterial bypass:  
1) Modification of existing synthetic grafts e.g. graft functionalisation 
2) Creation of new synthetic grafts e.g. nanocomposites 
3) Creation of engineered blood vessels or hybrid synthetic grafts using tissue 
engineering. 
With each strategy comes a large volume of research and literature too extensive to fully 
discuss here. As this thesis focuses on the third strategy, that of tissue engineering, this 
strategy forms the basis of this review. 
1.5 Tissue engineering of blood vessels 
Tissue engineering began in the late 70’s and at its simplest, is the manipulation of cells to 
create functional tissue. Cardiovascular tissue engineering techniques range from 
modifying existing synthetic grafts, creating novel functionalised acellular biological 
scaffolds derived from allogeneic arteries and fully tissue engineered blood vessels 
comprising cell-seeded natural and synthetic scaffolds.  Early and current cardiovascular 
tissue engineering strategies include the seeding of EC onto the surface of synthetic grafts 
in an attempt to recreate the innately anti-thrombogenic endothelium (‘hybrid’ grafts).  
1.5.1 Hybrid graft development 
It is now recognised that the generation of a confluent endothelium on the surface of 
synthetic grafts reduces their thrombogenicity and improves short and long-term patency. 
At present therefore, the endothelium is considered the gold-standard lining for vascular 
grafts (Zilla et al., 1994; Clowes et al., 1997; Meinhart et al., 2001; Sarkar et al., 2007). It 
was Herring et al. in 1978 who were the first to develop the idea of seeding autogenous 
EC onto the surface of prosthetic grafts in an attempt to reduce graft thrombogenicity. 
Following Herring et al. a large number of cell-seeding studies were performed in the 
1980’s and demonstrated that whilst feasible, EC-seeding and subsequent adhesion on 
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synthetic grafts was poor (Meinhart et al., 2001). During these initial studies, up to 70% of 
EC were lost from the graft surface following exposure to fluid shear forces (Rosenman et 
al., 1985).  Difficulties faced in the development of such grafts included sourcing of EC, 
growing sufficient numbers in culture and as mentioned, maximising the adherence and 
retention of EC to the graft surface (Rashid et al., 2004).  
The key elements for successful EC adherence have been suggested to be 1) the 
development of favourable interactions between the EC’s and synthetic surface, 2) 
allowing sufficient time for EC adhesion and 3) ensuring appropriate distribution and 
density of EC’s on the graft surface prior to exposure to shear forces (Pratt et al., 1988).  
Ideally, a single-stage process of EC procurement and graft seeding followed by 
implantation would be optimal for the patient. However early studies showed this technique 
to yield low EC numbers and rates of adherence (Falk et al., 1998; Giudiceandrea et al., 
1998). To combat these problems, two-stage EC seeding was developed in which the EC’s 
were first extracted and then cultured in vitro to increase cell numbers prior to seeding. 
Using this two-stage technique, the clinical series by Zilla et al. (1994), Meinhart et al. 
(1997, 2001), Deutsch et al. (1997, 1999) and Laube et al. (2000) all unanimously 
demonstrated that endothelial seeding improved patency of synthetic grafts for both 
peripheral and coronary arterial bypass. When used for infra-inguinal bypass for example, 
endothelialised ePTFE had a primary patency of 84.7% at three years, compared to 55.4% 
for standard ePTFE (Zilla et al., 1994). At nine years, the primary patency of 
endothelialised grafts was 65% compared to 16% for standard ePTFE grafts (Deutsch et 
al.,1999).The improvement in patency was not just due to a reduction in graft 
thrombogenicity, but also a result of reduced rates of SMC proliferation and NIH within the 
grafts (Clowes, 1997).  
The limitations of two-stage seeding are that it is expensive, the patient requires two 
procedures (EC procurement then implantation) and the patient must wait while the cells 
undergo culture (negating use in acute ischaemia) (Rashid et al., 2004; Punshon et al., 
2008). Furthermore, cell populations are often mixed (fibroblasts, SMC and EC) and must 
be separated prior to culture and seeding (Knetsch et al., 2004). EC maintained in culture 
have been shown to become senescent at low passage values (ten and above) and so 
rapidly become unsuitable for graft seeding (Shi et al., 2004). As a result, two-stage cell 
seeding has not been widely adopted. Current techniques are aimed at modifying the two-
stage process or creating new methods that aid endothelialisation. The seeding 
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techniques for any scaffold (biological or synthetic) can be divided simply into two broad 
categories- static or dynamic. In static seeding, the cells are simply placed in or onto the 
scaffold surface and left to attach under culture conditions. In dynamic seeding, the 
scaffold and cells undergo forces to aid attachment (radial/cyclical stress) using 
instruments such as roller plates and perfusion bioreactors. Under dynamic seeding 
conditions, greater seeding efficiencies have been reported (Hsu et al., 2005). For 
successful EC seeding of synthetic (and biological) grafts, cell densities of around 104-105 
cells.cm-2 have been reported to be required to achieve confluent graft coverage 
(Salacinski et al., 2001). At present no EC-seeded synthetic graft has achieved 
widespread clinical use. 
1.5.1.1 Cell attachment and interaction 
The formation of ECM on a graft surface is vitally important for cell attachment. The ECM 
is secreted by both EC and SMC and includes molecules such as fibronectin and collagen. 
These molecules possess surface ligands that allow for cell attachment (Yu et al., 2003; 
Wallace et al., 2007). Several studies have shown that lining a synthetic graft with SMC 
prior to the seeding of EC improves the subsequent retention of EC to the graft by limiting 
EC aniokis (apoptosis due to deficient ECM) (Yu et al., 2001, 2003). This has been 
reported to be due to the more favourable attributes that SMC possess over EC for cell 
attachment. SMC produce more ECM than EC (allowing for greater numbers of EC cell 
attachment) and have been shown to adhere more readily to graft surfaces and resist the 
shear forces of bloodflow (Yu et al., 2003). Furthermore, the ECM laid down by SMC will 
provide the graft with elastic recoil and tensile strength, two essential attributes required 
particularly in biological grafts for mechanical integrity (Stephan et al., 2006). EC 
reciprocally interact with SMC, leading to the expression of growth factors responsible for 
the maintenance of and geometric orientation of, the ECM (Aper et al., 2007).  
In their study, Yu et al. (2003) reported EC retention rates of 90% on ePTFE grafts at 24 
hours post implantation into rabbit aortas when pre-coated with SMC, compared to only a 
51% retention rate in grafts seeded with EC only.    
 
There have been concerns that lining a graft with SMC will lead to significant NIH, 
reducing the luminal diameter and subsequent graft patency. However data suggests that 
with dual seeding, the EC limit SMC migration and proliferation as they do normally in vivo 
(Fillinger et al., 1993; Powell et al., 1996). In the study by Yu et al. (2003), although 
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neointimal thickness was greater in dual seeded grafts at 30 days, at 100 days there was 
no significant difference in thickness between dual seeded or single (EC) seeded grafts.        
If dual seeding is to be used, it is important to assess the effects of such seeding on 1) 
individual cell phenotype and 2) overall thrombogenicity. Particularly as it is quite clear 
from the literature that the interactions of EC and SMC show different species-specific 
behavior (Wallace et al., 2007; Pang et al., 2010; Zhao et al., 2010). 
Pang et al. (2010) studied the thrombogenicity of a co-culture of porcine SMC and EC by 
measuring TF activity. SMC/EC co-cultures displayed higher levels of TF activity than EC 
cultured alone. The increased TF activity correlated with contraction of the SMC/EC co-
culture. Contraction of the co-culture disrupted the EC monolayer allowing the exposure of 
high levels of TF present on the surface of SMC. The authors were able to demonstrate an 
association between contraction of the co-culture with increased levels of reactive oxygen 
species. Indeed, incubating the co-culture with an antioxidant (N-acetyl-L-cysteine) lead to 
a reduction in contraction of the co-culture.  Interestingly, in a similar study using co-
cultures of human SMC and EC, Wallace et al. (2007) demonstrated a reduction in TF 
activity in co-cultures compared to an EC monolayer. These in vitro findings cannot be 
extrapolated to an in vivo model however as the cells were not seeded onto scaffolds in 
these in vitro studies and therefore the studies did not examine the effects of the scaffold 
itself on cell phenotype. Certainly in studies in which both EC and SMC have been seeded 
onto biological scaffolds, a significant reduction in thrombogenicity was seen (Tiwari et al., 
2001; Zhao et al., 2010). 
There is no definitive optimal seeding density for seeding grafts with EC and SMC in the 
literature. Optimal cell densities are dependent on many variables, including: species, type 
and processing of graft and utilisation of dual or single cell seeding. In general, cell 
densities between 104-106 cells.ml-1 tend to be used. The range of cell seeding densities 
found within the literature for both biological and synthetic grafts is demonstrated in Table 
(2).      
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Cell type Seeding Density Scaffold (all tissue 
decellularised) 
Culture Authors 
Human EC 1.1x10
4
 + - 6x10
3 
cells. cm
-1
 
Porcine carotid artery 
(luminal) 
Dynamic Heine et al
 
., 2011 
Human SMC 5.7 x10
3
 +- 2.8x10
2 
cells.cm
-1
 
Porcine carotid artery 
(adluminal) 
Dynamic Heine et al., 2011 
Human EC 
 
1.8x 10
4 
cells.ml
-1
 Porcine carotid artery 
(luminal) 
Static McFetridge et al., 2004 
Human SMC  6.7x10
4 
cells. ml
-1
 Porcine carotid artery 
(adluminal) 
Static McFetridge et al., 2004  
Ovine SMC 1 x10
6 
cells.ml
-1
 Porcine carotid artery 
(luminal) 
Static Nitsan et al., 2012 
Human EC 1 x10
6 
cells.ml
-1
 Porcine carotid artery 
(adluminal) 
Static Nitsan et al., 2012 
Human SMC & 
Fibroblasts 
1x10
6 
cells.ml
-1
 Porcine carotid artery 
(luminal) 
Dynamic Shimizu et al., 2007 
Human EC 1.2 x 10
5
 cells.cm
-1
 Porcine aorta Dynamic Bader et al., 2000 
Human saphenous 
vein EC 
5 x 10
6
 cells.ml
-1
 Porcine aorta Dynamic Amiel et al., 2006 
Ovine EC 1 x 10
7
 cells.ml
-1
 Ovine carotid artery 
(luminal) 
Static Zhao et al., 2010
 
Ovine SMC-like cells 2 x10
7
cells.ml
-1
 Ovine carotid artery 
(luminal) 
Static  Zhao et al., 2010 
Porcine SMC 6-10x10
4 
cells .cm
-1
 Porcine SMC Static Pang et al., 2010 
Porcine EPC 1x10
6 
cells.ml
-1
 Fibrin scaffold Dynamic Aper et al., 2007 
Human umbilical 
vein SMC 
10
6
-10
7 
cells.ml
-1
 Type I Collagen Static Leung et al., 2007 
Canine EC 1 x 10
6
 cells.cm
-1
 PGA/PLA Dynamic Iwai et al., 2005 
Human EC & SMC 1x10
5
 cells.cm
-1
 Polyurethane Static Rashid et al., 2008 
Human EC 6 x 10
4
cells.cm
-1 
 Polyurethane Static Hsu et al., 2005 
Human Fibroblasts, 
EC & SMC 
4.4-7.7x10
6
cells.cm
-1
 Polyurethane Dynamic Gulbins et al., 2004 
Human EC 7.6 x10
4 
cells.cm
-1
 PTFE Static Gumpenberger et al., 
2003 
Rabbit EC & SMC 3x10
5
 cells .ml
-1
 PTFE Dynamic Yu et al., 2003 
Human EC & SMC 3 x 10
5
 cells.ml
-1
 PTFE Dynamic Yu et al., 2001 
Ovine EPC 3 x 10
6 
cells.cm
-1
 Porcine heart  valve Static Lee et al., 2009 
 
Table 2. Examples of vascular-cell seeding densities used in the seeding of 
synthetic and acellular scaffolds (EC= endothelial cell, SMC = smooth muscle cell).  
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1.5.1.2 Maximising cell adhesion 
Several techniques have been developed to maximise EC adhesion and retention to 
synthetic graft surfaces, as EC adherence to such grafts is often not strong enough to 
withstand the shear stress of the blood circulation (Knetsch et al., 2004). The use of 
specific endothelial adhesion proteins such as fibrin, gelatine, laminin and the Arg-Gly-Asp 
(RGD) binding sequence of fibronectin have all demonstrated improved EC adhesion and 
retention onto synthetic grafts following seeding (Kumar et al., 2002; Hsu et al., 2003) 
Alternate strategies include the use of antibodies, electrostatic techniques, alterating graft 
porosity and graft irradiation (Bowlin et al., 2001; Gumpenberger et al., 2003; Zhang et al., 
2004; Rotmans et al., 2005).  Recent studies on EC adhesion are summarised in Table 
(3). 
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Conduit Technique Outcome In vivo / 
In vitro 
Authors 
Polyurethane Electrospun with 
gelatin to create 
composite mesh  
Improved EC adherence + proliferation 
compared to controls. 
In vitro Detta et al., 2010  
Polyurethane RGD containing 
recombinant 
protein(CBD-RGD) + 
gelatin coating 
Enhanced EC retention. 63% retention rate 
after 3 hrs perfusion. Reduced platelet 
activation + adhesion compared to controls. 
In vitro Hsu et al., 2003  
Polyurethane Rotational (dynamic) 
seeding  
90% surface cell adhesion (4mm 
polyurethane). Retention enhanced by 
perfuse culture 
In vitro Hsu et al., 2005  
PTFE UV Irradiation Increased EC adherence. Confluent EC graft 
seeding in 8 days 
In vitro Gumpenberger et 
al., 2003  
PTFE & 
Dacron 
Freeze-dried fibrin 
glue with gelatin and 
growth factor 
Improved EC adhesion and proliferation 
compared to controls. 
In vitro Kumar et a.l, 2002  
ePTFE Electrostatic seeding Increased EC seeding compared to control.  In vivo 
(Dogs) 
Bowlin et a.l, 2001  
PTFE EC seeding under 
perfusion  
Increased proliferation of EC + expression of 
fibronectin under pulsatile flow conditions 
compared to static conditions 
In vitro Rademacher et al., 
2001  
Polyurethane 
& ePTFE 
Porosity- PTFE with 
60µm and 
polyurethanes with 5-
30 µm pores 
Perigraft tissue ingrowth may accelerate 
endothelialisation. Greatest 
endothelialisation seen in 30 µm pore size 
polyurethane grafts.  
In vivo 
(Rats) 
Zang et al., 2004  
ePTFE Coated with anti-
CD34 antibodies 
85% EC coverage at 28 days implantation in 
anti-CD34 grafts compared to 32% for 
controls.  
In vivo 
(Pigs) 
Rotmans et al., 2005  
ePTFE Coated with fibrin & 
vascular endothelial 
growth factor 
No change in EC seeding density. Increased 
narrowing at proximal anastomoses and 
increased NIH in coated grafts compared to 
untreated (ePTFE) controls. 
In vivo 
(Pigs) 
Walpoth et al., 2007 
 
Table 3. Examples of techniques used to maximise endothelialisation of synthetic 
grafts (EC=Endothelial cells, RGD= Arg-Gly-Asp sequence, CBD=cellulose-binding 
domain, RPM= revolutions per minute, G-CSF= Granulocyte-colony stimulating factor, 
UV=Ultraviolet, PTFE= polytetrafluroethylene, CD= cluster of differentiation, ePTFE= 
expanded polytetrafluroethylene). 
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1.5.1.3 Cell Procurement 
The early procurement of EC/SMC for two-stage seeding required an invasive procedure 
for the patient on tissues such as vein, fat or omentum. Furthermore, often the populations 
of harvested cell lines were not pure (Tiwari et al., 2001).  
Alternate cell types have been studied in seeding experiments, such as mesothelial cells 
and stem cells (Verhagen et al., 1996; Campbell et al, 1999; Cho et al., 2005; Zhao et al., 
2010). Mesothelial cells can be harvested in high numbers, grow well in culture and 
possess anticoagulant activity (Verhagen et al., 1996). In animal studies, mesenchymal 
stem cells have been reported to be induced to differentiate into SMC and EC and thus 
may be an alternate source for the acquisition of vascular cells (Cho et al., 2005; Zhao et 
al., 2010). Once again however, invasive procedures for procurement are required. 
It is now known that human blood contains both circulating endothelial cells and EPC 
(Punshon et al., 2008). EPC have been shown to demonstrate high proliferation rates, a 
valuable trait for rapid graft endothelialisation (Avci-Adali et al., 2011). Punshon et al. 
(2008) were able to isolate both types of cell from volunteer human blood and maintain 
them in culture. Furthermore, they were able to seed the EC onto a nanocomposite graft 
(UCL-Nano™) and achieved confluent graft endothelialisation after fourteen days of 
culture.  
A great deal of research into methods of attaining a confluent endothelium is now focusing 
on the development of grafts that may self endothelialise, either by recruiting cells from the 
site of anastomosed vessel or neocapillaries or indeed by recruiting circulating progenitor 
cells. The technique consists of implanting a functionalised scaffold into the circulation 
containing various adhesion peptides (discussed earlier) that will capture circulating EPC / 
EC and allow endothelialisation to occur (Rotmans et al., 2005; Walpoth et al., 2007; Avci-
Adali et al., 2011). 
1.5.1.4 Gene therapy 
Some researchers have taken the cell-seeding of synthetic grafts one step further by 
utilising gene therapy to transduce EC with anticoagulant/antithrombotic genes in order to 
improve synthetic graft patency (Huber et al., 1995; Dichek et al., 1996; Dunn et al., 1996; 
Kimura et al., 2000). Following seeding onto synthetic grafts, it is hoped the transduced 
EC will express additional antithrombotic gene products leading to more potent inhibition of 
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thrombogenesis. Dichek et al. in 1997 successfully transduced EC from Baboons with 
retroviral vectors expressing human tPA or urokinase-type plasminogen activator 
(uPA).Transduced EC were then seeded onto collagen-coated 4 mm PTFE grafts. Grafts 
were then implanted into arterio-venous (AV) shunts created within the baboons. 
Compared to un-seeded grafts, both the tPA and uPA grafts displayed reduced levels of 
platelet and fibrin deposition secondary to a ten-fold increase in plasminogen activator. 
These effects were only observed for a 60-minute period and so it is unknown how long 
antithrombotic gene expression would continue for. Dunn et al. (1996) and Huber et al. 
(1995) however reported significantly reduced EC adherence onto Dacron and ePTFE 
grafts following seeding with EC transduced with a retroviral vector encoding tPA. In these 
studies, EC with high passage numbers were used. Kimura et al. (2000) transduced 
canine EC with tPA and LacZ, using low EC passage numbers, and found no significant 
difference in EC adhesion rates onto 4 mm ePTFE. They postulated that tPA expression 
would only affect EC adherence when EC with high passage numbers were used. 
Techniques that have shown efficacy in improving transduced-EC adherence to grafts 
include graft surface modification and [EC] seeded graft preconditioning. Falk et al. (1998) 
demonstrated increased EC retention onto ePTFE following luminal coating with 
fibronectin. Dardik et al. (1999) reported improved EC retention rates when seeded grafts 
were subjected to shear stress prior to implantation. The main limitation of using retroviral 
vectors for gene transduction is that subsequent gene expression declines rapidly within 
seven days of transduction (Quiniones et al., 1996). Therefore using grafts seeded with 
transduced EC may only be effective in reducing short-term graft failure rates.   
At present, only animal studies have been performed. Human trials involving the seeding 
of transduced EC will be some way off yet whilst further work continues on the refinement 
of conventional EC seeding. 
Limitations of synthetic hybrid grafts mainly relate to their inorganic component and include 
the ongoing risk of infection, lack of biodegradability and complete incorporation into host 
tissue and the inability to grow. Furthermore, the endothelialisation of prosthetic grafts 
often remains limited to areas adjacent to the anastomoses (Berger et al., 1972; Bader et 
al., 2000).   
It is important to iterate here that many of the principles of synthetic graft cell-seeding 
pertain to cell-seeded biological grafts and that many of the advances that have been 
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made in the development of  tissue engineered blood vessels have come from cell-
seeding research using synthetic grafts. The limitation of synthetic hybrid grafts is that 
seeded vascular cells do not remodel them as effectively as biological scaffolds (Thomas 
et al., 2003).  
1.6. Total-engineered blood vessels (TEBV) 
The ideal TEBV will integrate with host tissue, possess a functioning endothelial lining 
capable of cellular remodelling and regeneration and possess mechanical integrity (tensile 
strength and elasticity). 
It has been suggested that the development of a TEBV requires the successful integration 
of three components: scaffold, matrix and vascular cells (Baguneid et al., 2006). Weinberg 
and Bell in 1986 were the first group to develop a TEBV. They utilised a collagen gel 
scaffold seeded with bovine EC, SMC and fibroblasts. 
The importance of the ECM for cell attachment has been discussed earlier. Furthermore, 
an ideal TEBV will contain ECM proteins such as elastin and collagen in proportions 
similar to the native artery to ensure mechanical integrity (Mitchell et al., 2003). In addition 
to these roles, the ECM is essential for cellular differentiation, a function which is important 
for maintaining the correct phenotype of seeded vascular cells (Ziegler et al., 1994). It is 
not just the components of the ECM themselves that are important for this regulation of 
cellular differentiation, but also how they are geometrically configured (Bader et al., 2000). 
Although a lot of emphasis has been placed on the importance of a cellular lining for a 
TEBV, it must also be emphasised that the biocompatibility of the scaffold itself is 
extremely important for long-term graft function (Ogle et al., 2002; Walles et al., 2003; 
Baguneid et al., 2006). Immunological attack and lack of tissue ingrowth are just two 
potential mechanisms by which an implanted TEBV may degrade and fail. 
1.6.1 Techniques used to create a TEBV 
Decellularisation of natural tissue 
One of the forefront techniques in CV tissue engineering is the decellularisation of 
allogeneic and xenogeneic tissue to create acellular scaffolds. Decellularisation is the 
process of removing all cells, cellular proteins and debris and coding DNA from a tissue to 
leave an immunologically ‘inert’ scaffold comprised of ECM. Many protocols for the 
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decellularisation of tissues have been developed in the literature, however most will 
involve the use of enzymic cleavage, detergents, and hypertonic/hypotonic solutions  
The decellularisation of xenogeneic cardiovascular tissue in particular is attractive to tissue 
engineers for several reasons. Firstly, animal tissue is readily available. Secondly, the 
natural ECM of cardiovascular tissue is innately orientated to withstand pulsatile flow and 
shear stress. Thirdly, the ECM or scaffold itself can be manipulated / modified by a vast 
array of biological techniques e.g. cell seeding or binding of antibodies or antithrombotic 
agents to the luminal surface. Finally, the main ECM proteins that comprise decellularised 
cardiovascular tissue (e.g. collagen and elastin) display close sequence homology across 
species and are immunologically well-tolerated by xenogeneic recipients (Liao et al., 
2009). Decellularisation of allogeneic tissue has been shown to produce acellular scaffolds 
with reasonable biomechanical and regenerative properties (Schaner et al., 2004). 
However, the large amount of legislation governing the use of human tissue and the 
difficulty of large-scale procurement of healthy tissue from young donors (compared to 
xenogeneic tissue) currently makes its use less favourable than xenogeneic tissue.     
Early decellularised vascular xenografts lacked a cellular component and studies using 
these grafts without seeded cells demonstrated high thrombosis rates and poor patency 
(Walles et al., 2003; Hilbert et al., 2004; Zhao et al., 2010). This has led to the 
development of pre-treated or cell-seeded acellular grafts in an attempt to improve graft 
patency. For example, using heparin treated and non-heparin treated decellularised canine 
carotid arteries, Wang et al. (2007) demonstrated significantly reduced rates of thrombosis 
following implantation into rabbits (3 weeks; 4% vs 25%, 6 months; 8% vs 58%). In their 
elegant ovine study, Zhao et al. (2010) clearly demonstrated the impact of cell- seeding an 
acellular vascular xenograft to aid patency. Firstly, instead of harvesting EC and SMC cells 
directly, they harvested ovine bone marrow-derived mesenchymal stem cells (MSC) and 
were able to induce them to differentiate into endothelial-like (ELC) and smooth muscle-
like cells (SMLC). The authors then seeded the ELC and SMLC onto decellularised ovine 
carotid arteries and implanted them into the sheep that had donated the MSC. Grafts were 
assessed by angiography at two and five month’s post-implantation and then explanted at 
five months. Unseeded [control] acellular grafts were occluded at two weeks as a result of 
thrombosis. Cell-seeded grafts at both two and five months post-implantation were all 
patent and showed regeneration of intimal, media and adventitial layers.  
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Many xenogeneic tissues have been successfully decellularised for vascular tissue 
engineering and include bovine and porcine ureter, porcine arterial and venous tissue and 
canine arterial tissue (Clarke et al., 2001; Widmer et al., 2004; Wang et al., 2007; Derham 
et al., 2008; Yang et al., 2009).    
Use of autologous tissue 
The issue of scaffold biocompatibility has lead researchers to look at the feasibility of 
creating a TEBV using varying types of autologous tissue and engineering techniques. 
Instead of focusing on arterial tissue as a conduit, Schaner et al. (2004) decellularised 
human saphenous vein using a detergent (SDS) based protocol. Mechanical and 
histological assessment demonstrated preservation of strength and ECM composition of 
the decellularised vein compared to native tissue. They did not however attempt cell-
seeding of the conduit.       
Aper et al. (2007) were able to harvest both a scaffold and cells from a 100 ml peripheral 
porcine blood sample. They created a fibrin scaffold by isolating fibrinogen from the blood 
sample and mixing with a thrombin solution. The fibrin was then placed onto a customised 
mould to create a tube shape. Next, they isolated EPC from the blood sample and 
successfully seeded them onto the fibrin tubes. As is the case for many protein-based 
conduits, the mechanical properties of the tubes did not, however, match those required 
for an arterial bypass conduit. Campbell et al. (1999) created autogenous vascular grafts 
by implanting silastic tubing into the peritoneal cavity of rats for two weeks. The implanted 
tubes became coated in connective tissue and mesothelial cells. The authors removed and 
reversed the lining tissue so that the mesothelium became the inner lining of the tube. 
Histologically, the tubes possessed an inner mesothelial lining, a ‘media’ consisting of 
myofibroblasts and an ‘adventitia’ of connective tissue. The tube-grafts were implanted into 
rat carotid and rat aorta and demonstrated a 50% patency rate at 6 months. Explanted 
grafts demonstrated arterialisation and response to contractile agents.     
Although these studies fall short of creating a TEBV for wide-spread clinical use, they do 
demonstrate what can be achieved in tissue engineering using modest starting materials 
and techniques. 
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Biodegradable synthetic scaffolds 
The development of biodegradable synthetic polymer scaffolds is a viable goal in vascular 
tissue engineering. Three of the most commonly used materials include polyglycolic acid 
(PGA), polylactic acid (PLA) and polycaprolactone (PCL) (Iwai et al., 2005; Isenberg et al., 
2006; Torikai et al., 2008; Seifu et al., 2013;). Other materials have also been used such 
as bacterial cellulose (Innocente et al., 2009; Wippermann et al., 2009). The idea of a graft 
degrading over time eventually to be replaced by autologous tissue is certainly 
advantageous in terms of achieving long-term graft patency and biocompatability. Different 
materials degrade at differing rates, with polycaprolactone degrading slowly over a period 
of up to six months (Innocente et al., 2009).  
Iwai et al. (2005) fabricated a PGA/PLA collagen micro-sponge mesh and implanted two 
patches (one large and one small) into canine and porcine circulations. Grafts were 
explanted at 2 and 6 months for the small and large patches respectively and were 
analysed using histology and immunohistochemistry. Characterisation of the explanted 
mesh revealed no evidence of aneurysmal degradation, thrombus formation or neointimal 
hyperplasia. Small patches were nearly fully degraded at 2 months and demonstrated 
uniform cellularisation with both EC and SMC following immunohistochemical analysis. 
Large patches displayed similar cellular re-modelling with a confluent endothelium visible 
by scanning electron microscopy.  
At present however, much is still to be learnt with regards to the biology of synthetic 
polymer scaffold degradation. For example, what remodelling takes place post 
implantation in humans? What happens to waste products? How are they eliminated from 
the body? Do they effect cellular phenotype? Do they have any carcinogenic/toxic 
systemic effects?  PGA and PLA for example, have both been shown to create 
degradation products in vitro that induce inflammation and immunoreactivity, create acidic 
conditions, inhibit cellular proliferation and cause de-differentiation of cells (Gao et al., 
1998; Swartz et al., 2005; Seifu et al., 2013). Furthermore, the timing of degradation and 
the degree of subsequent tissue regeneration is crucial. In their study with PGA/ PLA 
scaffolds, Torikai et al. (2008) reported complete collagen regeneration in degraded 
scaffolds but insufficient elastin remodelling (compared to native tissue) at 6 months post 
implantation. Elastic discrepancies between native artery and graft will lead to compliance 
mismatch, a major factor in the pathogenesis of NIH (Desai et al., 2010).   
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A graft that degrades prior to host integration and stabilisation is doomed to fail. PGA for 
example is rapidly resorbed in vivo. Degradable scaffolds must therefore be engineered to 
degrade predictively whilst, in addition, retain some degree of biomechanical integrity. 
Furthermore, it is still not known whether the autologous tissue that forms around such 
biodegradable scaffolds can withstand systemic blood pressures in the long-term (Higgins 
et al., 2003; Torikai et al., 2008).  
Self-assembled vascular constructs 
Following on from the seminal work of Weinberg and Bell (1986), some tissue engineers 
continue to focus on the use of self-assembled tissue engineered blood vessel constructs 
(L’Heureux et al., 1998; Gauvin et al., 2010). 
To date, the best assembled TEBV was that created by L’Heureux et al. (1998) in their 
pioneering work using human umbilical vein endothelial cells (HUVEC), human SMC and 
human dermal fibroblasts. Cells were seeded separately onto gelatine-coated culture 
flasks and cultured for 30 days. Following culture, a self-assembled sheet containing cells 
and synthesized ECM was created which could be peeled away from the flask surface. 
Firstly, the fibroblast sheet was wrapped around a tubular PTFE mandrel which was then 
covered by a sheet of SMC. The construct was then placed into a bioreactor for 
preconditioning and maturation for one week (see Section 1.8 Bioreactors in tissue 
engineering). After maturation, a further sheet of fibroblasts was wrapped around the sheet 
of SMC to finally create a construct with three layers- a luminal lining of fibroblasts, a 
medial layer of SMC and a [adventitial] layer of fibroblasts. The constructs were then 
cultured for a further eight weeks. After eight weeks, constructs were seeded with HUVEC 
for one week. Subsequent histological analysis demonstrated a construct comprised of 
three layers histologically analogous to the intimal, medial and adventitial layers of an 
artery. The endothelium was metabolically active and immunostaining confirmed the 
fibroblast, SMC and EC phenotypes of each layer, together with an ECM comprised of 
components seen in typical arterial tissue (collagen I,III,IV, laminin and fibronectin). 
Biomechanical assessment of the constructs demonstrated burst pressures (a surrogate 
marker of long-term mechanical integrity) greater than the current gold standard- human 
saphenous vein ( 2594 ± 501 mmHG vs 1680 ± 307 mmHG). The graft has been used in 
early human clinical trials as an AV graft for haemodialysis access with primary patencies 
of 75% and 60% at one and six months respectively (McAllister et al., 2009).    
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Gauvin et al. (2010) recently developed a TEBV using human SMC, dermal fibroblasts and 
saphenous vein fibroblasts. Cells were seeded onto gelatine-coated culture flasks and 
cultured for 14 and 28 days. Following culture, a self-assembled sheet containing cells and 
synthesized ECM was created which could be removed and wrapped around a tubular 
mandrel. Following incubation, the constructs were subjected to biomechanical analysis. 
Although constructs demonstrated mechanical strength above human physiological 
parameters, they failed to achieve burst pressures (a surrogate marker of long-term 
mechanical integrity) comparable to the current gold standard- human saphenous vein.    
Nemcova et al. (2001) used type I collagen (porcine intestinal submucosa and bovine type 
I collagen) to assemble tubular constructs for in vivo implantation to assess their 
cellularisation ability and efficacy as vascular grafts. Porcine intestinal submucosa 
constructs (0.4cm diameter x 5cm) were implanted into the femoral arteries of mongrel 
canines for 9 weeks and then explanted for histological characterisation. One graft had 
occluded with the remaining eight remaining patent and displaying cellularisation by SMC, 
EC and myofibroblasts. Huynh et al. (1999) constructed a scaffold using both collagen 
type I from porcine intestinal submucosa and bovine type I collagen together and 
implanted them into rabbits. Once again, grafts were found to be cellularised by EC and 
SMC and displayed patency at 90 days. The burst pressure of such grafts was low 
however (931 mmHg) compared to other biomaterials such as decellularised PCA 
(2338mmHg) and human saphenous vein (1800 mmHg), which may indicate a lack of 
long-term durability (Huynh et al., 1999; Roy et al., 2005;  Seifu et al., 2013). Clearly 
longer term studies are required to assess the efficacy of such constructs.   
Fibrin constructs have also been investigated as potential vascular grafts (Swartz et al., 
2005; Yao et al., 2005). Fibrin is an attractive protein to use as it is readily available from a 
sample of patient blood, is cheap to isolate and stimulates re-modelling in a variety of cell 
types (Stegemann et al., 2007). One of the seminal experiments to date involving the 
creation of a fibrin scaffold, was that performed by Swartz and colleagues (Swartz et al., 
2005). They created a fibrin tube embedded with ovine SMC and EC and implanted them 
into the jugular vein of sheep. At 15 weeks post implantation, harvested scaffolds 
demonstrated remarkable re-modelling with the formation of collagen and elastin fibres 
and the laying down of SMC in an orientation consistent with blood flow, covered by an 
endothelial monolayer. Furthermore implanted grafts demonstrated vaso-reactivity and 
displayed patency rates similar to those of native vessels (Mehta et al., 2007). 
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The variations in the mechanical strengths of self-assembled TEBV, lack of long-term 
patency data and the time and expense required for their construction again limits their 
widespread commercial and clinical availability as a vascular graft. 
1.6.2 The use of porcine arterial tissue for vascular tissue engineering 
Porcine carotid arteries (PCA) 
PCA are ideal conduits for the tissue engineering of small-diameter vascular grafts. They 
are innately designed to function under pulsatile flow, they are readily available and have 
luminal diameters 6 mm and below.   
Recent studies have shown excellent biocompatibility of decellularised PCA with human 
vascular cells. Heine et al. (2011) successfully seeded decellularised PCA with human EC 
and SMC’s in a bioreactor under co-culture.  In the bioreactor, EC were seeded on the 
luminal surface (following pre-coating with gelatine) and the SMC on the abluminal 
surface. Re-seeded vessels demonstrated a confluent endothelial lining and vasomotor 
activity when stimulated pharmacologically.                                                                                                                
McFetridge et al. (2004) demonstrated successful seeding of both human umbilical EC 
and SMC onto the surfaces of decellularised PCA that had undergone photo-oxidative 
crosslinking.                                                                                                                             
In their exciting study, Shimizu et al. (2007) successfully seeded decellularised PCA using 
magnetically labelled human SMC and fibroblasts (Mag-TE). By incubating cells with 
magnetic nanoparticles and subjecting them to a magnetic field, they were able to achieve 
high seeding densities of 94% for SMC and 73% for fibroblasts. Initial seeding times in the 
study took hours as opposed to days for conventional [vascular cell] seeding. In their 
study, Nitsan et al. (2012) were able to recellularise decellularised PCA with human EC 
and ovine SMC using both static and dynamic seeding techniques. No difference between 
static and dynamically seeded EC was shown in terms of cell proliferation, but EC under 
perfusion conditions displayed a more uniform surface. Both statically and dynamically 
seeded EC and SMC adhered well to the scaffold surface and not only expressed new 
ECM proteins, but remodelled existing ones (collagen I,III and laminin). They were also 
able to demonstrate that co-culturing both SMC and EC in a perfusion bioreactor created a 
thicker medial layer and a more confluent endothelial monolayer on the PCA scaffold.    
 
49 
 
Biomechanical performance of porcine carotid arteries 
There is certainly varying and conflicting data within the literature regarding the 
biomechanical performance of decellularised PCA. In these studies, the decellularisation 
protocols all seem to be similar and involve osmotic, detergent, enzymic and mechanical 
steps. 
Roy et al. (2005) compared the biomechanical characteristics of decellularised PCA’s 
against fresh PCA’s in-vitro and reported significant differences between the two. The 
decellularisation process lead to a significant reduction in wall thickness, most pronounced 
at the smaller, distal end of the PCA. Decellularised arteries were able to withstand a 
mean pressure of 2338 mmHg prior to rupture, compared to 3124 mmHg for fresh arteries. 
Up to the point of rupture, all arteries remained watertight. Between physiological 
pressures of 70-150 mmHg, compliance of the decellularised arteries was 50% lower than 
fresh arteries, leading to a reduction in distensibility by a factor of three, resulting in a 
much lower increase in diameter during pressure insufflation. Although the decellularised 
arteries were stiffer then fresh arteries, they still displayed a greater level of compliance 
compared to Dacron and ePTFE.                                                                                                                                      
In their study with decellularised PCA’s, Conklin et al. (2002) reported greater compliance 
rates with decellularised PCA’s then fresh PCA’s. Over a range of 0-200 mmHg, the 
diameters of decellularised PCA increased by 88%, compared to 73% in fresh vessels. 
Shimizu et al. (2007) reported equal compliance rates in their measurements in native and 
decellularised PCA. In their study, Nitsan et al. (2012) reported no difference in elasticity 
between control, decellularised and recellularised PCA.                                                                                                            
What is clear is that removal of the cellular arterial elements leads to structural changes 
within the ECM, the degree of which will depend on each individual decellularisation 
method. Roy et al. (2005) suggested that the changes in compliance seen in decellularised 
arteries is to a large part, a result of the disruption between the bonds of SMC’s and 
elastin in the arterial walls.  
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Surface-modification of porcine carotid arteries 
As discussed earlier, many decellularised conduits that do not undergo surface 
modification or cell-seeding display high rates of thrombosis (Walles et al., 2003; Hilbert et 
al., 2004; Zhao et al., 2010). The alternative to cell-seeding is to bind antithrombotic 
agents to the graft wall to reduce overall thrombogenicity. Liao et al. (2009) were able to 
successfully bind heparin to the surface of decellularised porcine carotid arteries using 
covalent linkage between carboxyl groups of amino acids and hydroxylamine sulphate and 
heparin.  Following the addition of fresh canine blood on the surface of heparin-bound and 
control decellularised arteries, control segments demonstrated 100% clot formation at 60 
minutes, compared to 0% for heparin-bound segments. The authors then attached the 
heparin-bound and control arteries to femoral arteriovenous conduits of male baboons and 
measured (radio-labelled) platelet-deposition onto the grafts surfaces. At 60 minutes, there 
was a 54% reduction of platelet deposition on the surface of heparin-bound grafts 
compared to controls.  
The use of heparin may not be restricted to merely performing an anticoagulant effect for 
the surface of biological grafts. In addition, it may aid the cell-seeding of such grafts. 
Following endothelial seeding, heparin present on the graft lumen may reduce early 
thrombus formation until a confluent endothelium is generated, thereby preventing early 
failure of cell-seeded grafts (Wissink et al., 2000). Furthermore, bound heparin serves as a 
substrate for heparin-binding growth factors such as vascular endothelial growth factor and 
basic fibroblast growth factor (bFGF) which can recruit SMC and EC to the graft surface 
creating a potentially autogenous self-seeding graft (Liao et al., 2009). Wissink et al. 
(2000) were indeed able to show such an effect using heparin-bound collagen films. The 
authors loaded bFGF onto heparin-bound and control collagen films and seeded HUVEC 
onto the collagen surfaces. They demonstrated increased bFGF binding and release and 
improved proliferation of HUVEC on the heparin-bound collagen films compared to 
controls.     
Using PCA as a starting material, Hinds et al. (2006) were able to create a porcine elastin 
composite graft composed of porcine elastin and acellular porcine small intestinal 
submucosa (SIS). Tensile strength and burst pressures were comparable to native 
vessels. Following implantation as carotid interposition grafts in swine, the composite 
grafts remained patent longer than [ePTFE] controls (5.23 hours compared to 4.15 hours). 
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The study was limited however by the lack of assessing the capability of cells to seed onto 
the composite surface. Furthermore, the time and cost of vessel processing would be 
unlikely to make the composite a viable clinical product.    
 
Decellularised porcine aorta 
Bader et al. (2000) were able to decellularise porcine aortas using only enzymic cleavage 
with trypsin to reduce alterations in scaffold structure. They then successfully seeded the 
acellular scaffold with human EC and myofibroblasts. Using static culture conditions, only 
a poor EC monolayer covered the acellular scaffold specimens. When the seeded 
specimens were placed in a bioreactor for dynamic culturing, a fully confluent layer of EC 
developed. Furthermore, the EC were shown to secrete NO, an important compound in 
vascular biology, suggesting retention of cell phenotype.  
Amiel et al. (2006) decellularised porcine aortic segments (3-4mm internal diameter 
segments) using a more ‘ conventional ’, detergent based decellularisation protocol and 
successfully seeded human saphenous vein EC onto the scaffold surface. Seeded 
scaffolds possessed respectable burst pressures (> 1300 mmHg) and demonstrated vaso-
reactivity. 
These studies highlight two important points. Firstly, human vascular cells can be seeded 
onto acellular arterial porcine tissue and secondly, the importance of shear stress for EC 
retention and differentiation. 
Decellularised porcine iliac artery 
Kaushal et al. (2001) decellularised porcine iliac artery and were able to seed ovine EPC 
onto the scaffold surface. Once seeded, scaffolds were implanted into the carotid arteries 
of sheep and demonstrated a minimum patency of four months together with development 
of a medial layer.  
The studies using decellularised porcine material discussed above demonstrate two key 
attributes, firstly, that porcine tissue can be effectively decellularised using a range of 
protocols. Secondly, once decellularised, such scaffolds demonstrate effective seeding 
rates. Porcine arterial tissue therefore would seem to be a sensible starting material in the 
development of a tissue-engineered SD graft. 
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1.7 Limitations of using xenogeneic tissue 
 
With the use of any xenogeneic tissue comes the risk of disease transmission. When using 
porcine tissue for example, there is a risk of porcine endogenous retrovirus transmission 
(Bader et al., 2000). It is vitally important therefore that xenogeneic tissue is effectively 
decellularised to remove any functional DNA to eliminate viral pathogens. Effective 
sterilisation is also important to prevent disease transmission. Again, many techniques for 
scaffold sterilisation exist in the literature, ranging from chemical sterilants to ethylene 
oxide (Derham et al., 2008; Zhao et al., 2010). Whatever type of xenogeneic tissue used 
and decellularisation protocol followed, it is vital that subsequent scaffolds are fully 
characterised to ensure sufficient decellularisation. One protein in particular, must be 
removed from xenogeneic tissue to prevent immunoreactivity and subsequent rejection- 
the α-gal epitope. This carbohydrate epitope is present on the glyco-proteins/lipids of all 
non-primate mammals, some monkeys and prosimians such as lemurs and bushbabies. 
Humans possess abundant circulating IgG antibodies against the α-gal epitope and so for 
xenogeneic tissue to be tolerated, the α-gal epitope must be removed during the 
decellularisation process (Galili, 2005).  
 
1.8 Bioreactors in tissue engineering 
 
Bioreactors range from basic to extremely complex and sophisticated instruments and are 
designed to reproduce an in-vivo environment that closely mimics target cell/organ 
physiology. There are rapidly becoming increasingly critical pieces of apparatus for 
vascular tissue engineering as they allow preconditioning of seeded conduits prior to in-
vivo implantation (Goldstein et al., 2009). All bioreactors, no matter how sophisticated 
follow a basic design: a pump to propel circulating fluid / medium, a reservoir to contain the 
fluid /medium and a perfusion chamber to house the scaffold /construct. Large and 
expensive components should ideally be safe to sterilise to allow repeated use (Lee et al., 
2009).  Butler et al. (2009) describe the ideal characteristics that a bioreactor should 
possess, most importantly, a controlled culture environment and an ability to reproduce 
identical mechanical stimulation to tissue constructs.   
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1.8.1 Bioreactor Design 
The culture environment within the bioreactor is extremely important as this will ultimately 
dictate whether seeded cells on a conduit will survive and maintain a correct phenotype. 
Temperature, humidity, O2 and CO2 levels (for acid / base balance) must be optimised 
whilst ensuring the environment remains free from contamination by micro-organisms. 
Appropriate circulating medium is needed to provide nutrition to cells and to remove waste 
products of cellular metabolism. The flow, pulsatility and shear stress provided by the 
circulating medium is important as they pre-condition the cells and construct (Rademacher 
et al., 2001; Rashid et al., 2008).    
Preconditioning describes an in vitro process whereby a tissue-engineered construct is 
subjected to pulsatile flow and pressure to optimise the mechanical and biological 
characteristics of the construct (Rademacher et al., 2001; Rashid et al., 2008).  Pulsatility 
creates and exposes hydrostatic pressure, circumferential stretch and importantly, shear 
stress to the seeded cells and ECM (Lehoux et al., 2006). Shear and cyclic stress is 
extremely important for tissue-engineered constructs as it enhances SMC and EC 
adhesion, regulates their differentiation, gene expression, viability and proliferation, and 
mechanically orientates the cells and ECM components (Dardik et al., 1999; Fisher et al., 
2001; Rademacher et al., 2001; Rashid et al., 2004, 2008; Isenberg et al., 2006; Lee at al., 
2009). The molecular biology of preconditioning remains far from understood, but 
increased NO production and expression of NO synthase and matrix metalloproteinase-9 
appear to be important (Baguneid et al., 2004)  
Gambillara et al. (2008) demonstrated the importance of cyclic stress on the vascular ECM 
of PCA in their ex-vivo study. They reported a 50% increase in matrix metalloproteinase 
(MMP) expression and activation in PCA exposed to low rates of cyclic stretch compared 
to normal physiological levels. MMP’s are a group of proteases that can degrade the ECM, 
a process which could prove disastrous for a tissue-engineered construct in terms of 
cellular retention and mechanical integrity.      
Optimal preconditioning parameters have not yet been defined and will likely differ for each 
type of construct. It does seem however that exposing a construct to a regimen of 
gradually increasing shear stress as opposed to constant [low stress] prior to exposure to 
physiological pressures results in greater cell attachment (Fillinger et al., 1993; Kaushal et 
al., 2001). An explanation for this is that by gradually increasing shear stress, the cells of 
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the construct have time to synthesise adhesion factors and ECM which allows for more 
effective cell-cell and cell-construct attachment (Fillinger et al., 1993).   
Carnagey et al. (2003) used flow preconditioning to assess EC coverage on both a 
decellularised biological graft (ovine carotid artery) and a fibrin treated PTFE (4 mm) graft. 
Firstly, control experiments (seeded grafts with no flow preconditioning) demonstrated that 
biological grafts had an EC coverage rate up to 50% greater than the fibrin treated PTFE 
grafts. Secondly, following six hours of gradually increasing flow preconditioning (to a 
maximum flow rate of 300 mls.min-1) biological grafts demonstrated a 24% increase in EC 
coverage compare to controls grafts. 
Yazdani et al. (2009) demonstrated improved SMC proliferation and creation of a medial 
layer on decellularised PCA following preconditioning in a bioreactor for 1-2 weeks. 
Yazdani and colleagues have also demonstrated that bioreactor preconditioning improves 
EC adherence to the surface of decellularised PCA using in vivo and ex-vivo models. 
Furthermore, they found less blood product absorption to grafts exposed to higher rates of 
shear and cyclic stress, thereby lowering their thrombotic potential (Yazdani et al., 2010).   
1.9 Aims and objectives 
There is a clear, clinical need for a SD vascular graft if greater patency rates are to be 
achieved in vascular bypass. The presence of a functioning endothelium on the surface of 
the graft is clearly paramount in achieving superior patency rates over conventional grafts.  
Tissue engineering strategies have all shown promise in producing an endothelial lined-SD 
graft. The decellularisation and subsequent re-cellularisation of analogous biological 
tissues appears to be one strategy that shows particular promise.  
Porcine arterial tissue, amoungst others, can be successfully decellularised and performs 
biomechanically similar to native tissue.                   
  
The overall aim of this research was to develop an acellular biological vascular scaffold 
and develop methods for the seeding of the scaffolds with vascular cells with a view to 
future development of a tissue-engineered SD bypass graft.  
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Specific objectives: 
 
 To decellularise porcine carotid arteries using a proprietary decellularisation 
protocol to create an acellular scaffold. 
 
 To determine the success of the decellularisation process using a robust array of 
characterisation techniques. 
 
 To determine the biocompatibility of the acellular scaffolds using cell lines and 
primary [vascular] cells.  
 
 To isolate ovine EC and SMC and maintain them in culture. 
 
 To develop a reproducible protocol to confirm ovine vascular cell phenotype. 
 
 To perform two-dimensional (2D) static seeding of the acellular scaffolds with ovine 
vascular cells and if successful, subsequently characterise seeded scaffolds. 
 
 To use knowledge gained from two-dimensional seeding, to develop approaches 
for three-dimensional (3D) dynamic seeding of the acellular scaffolds with ovine 
vascular cells and determine the viability and characteristics of the seeded cells. 
 
 To commission a perfusion bioreactor for conditioning of the cell seeded acellular 
scaffolds. 
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Chapter 2 
Materials and Methods 
2.1 Materials 
All glassware used was purchased from Fisher Scientific unless otherwise stated. 
 
2.1.1 Chemicals and reagents 
 
Chemicals and reagents used throughout the study are listed in Table (4). 
 
Chemical/Reagent Cat No. Supplier 
Acetone LS8/1970/G European Bios 
Anti-Fibroblast Microbeads 130-050-601 Miltenyli Biotec 
Anti-FITC Microbeads 130-048-701 Miltenyli Biotec 
Aprotonin (10000 KIU.ml-1 AP012 Mayfair house 
ATPLite-M assay 6016941 Perkin-Elmer 
Bovine serum albumin (BSA) A7030-100G Sigma-Aldrich 
Calcium acetate C/0920/50 Thermo Fisher Scientific Ltd. 
Calcium chloride C-7902 Sigma-Aldrich 
Citric acid (anhydrous) BP339-500 Thermo Fisher Scientific Ltd. 
Collagen gel N/A N/A 
Collagenase type 2 filtered (273 U/ml) GEC2 MP Biomedical 
Cyanoacrylate contact adhesive  Z105902-1EA Sigma-Aldrich 
DABCO (1,4-diazobicyclo-(2,2,2)-
octane 
290734 Sigma-Aldrich 
DAPI stain (4’,6-Diamidino-2-
phenylindole Dihydrochloride) 
D9564 Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) D26650 Sigma-Aldrich 
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Disodium ethylenediaminetetraacetic 
acid (EDTA) 
E/P140/53 Thermo Fisher Scientific Ltd. 
DNAase  DN25-1 Sigma-Aldrich 
DNeasy kit 69504 Qiagen 
DPX mountant M81330/C Thermo Fisher Scientific Ltd. 
Dulbecco’s Modified Eagle Medium BE12-604F Lonza 
Dulbecco’s PBS (DPBSa) tablets BR0014 Oxoid 
Dulbecco’s PBS (DPBSa) with calcium  
and magnesium 
BE17-512F Lonza 
Dulbecco’s PBS (DPBSa) without 
calcium and magnesium 
17-512F Lonza 
Endothelial cell growth supplement E2759 Sigma 
Eosin 1.09844.1000 VWR International 
Ethanol (100%;v/v) E/0555DF/25 Thermo Fisher Scientific Ltd. 
Foetal calf serum French Lonza 
Gentamycin sulphate 345810 VWR International 
Giemsa stain 352603R VWR International 
Glutaraldehyde 111-30-8 Sigma-Aldrich 
Glycerol (100%;v/v) G9012 Sigma-Aldrich 
Haematoxylin PS50/C European Bios 
Heparin (1000U/ml) 009878-06 Leo 
Hydrochloric acid (6 M) 2611.5000 VWR International 
Hydrogen peroxide H1009 Sigma-Aldrich 
ImmEdge Hydrophobic Barrier Pen H-4000 Vector Laboratories 
L-Glutamine (200mM) 25030032 Lonza 
Liquid nitrogen  BOC 
LIVE/DEAD ® Viability/Cytotoxicity Kit L3224 Invitrogen 
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M-199 Medium 12-119F Lonza 
Magnesium chloride 22321-1000 Thermo Fisher Scientific Ltd. 
Methanol 0428 Genta Medical 
Methylated Spirits GPS1000-K Biostain Ready reagents 
Molecular grade water W4502-1L Sigma-Aldrich 
Neutral buffered formalin (10%; w/v) BFN250 Genta Medical 
Osmium tetroxide 20816-12-0 Sigma-Aldrich 
Paraffin wax PS138/E Thermo Fisher Scientific Ltd. 
Penicillin/streptomycin solution 
(10,000U.ml-1 penicillin and 
10,000U.ml-1 streptomycin) 
DE17-602E Lonza 
Peracetic acid 269336 Sigma-Aldrich 
Polymyxin B 81334-5G Sigma-Aldrich 
RNase A (17,500 U) 19101 Qiagen 
Scott’s tap water PS138/E Thermo Fisher Scientific Ltd. 
Sodium acetate S/2080/60 Thermo Fisher Scientific Ltd. 
Sodium azide 438456 Sigma-Aldrich 
Sodium chloride 42429-5000 Thermo Fisher Scientific Ltd. 
Sodium dodecyl sulphate (SDS) 71727 Sigma-Aldrich 
Sodium heparin 1000U/ml 018891-04 Leo 
Sodium hydrogen carbonate 102475W VWR International 
Sodium hydroxide S/4920/53 Thermo Fisher Scientific Ltd. 
Trizma base T-1503 Sigma-Aldrich 
Trypsin (porcine pancreas) 1001005154 Sigma-Aldrich 
Trypan blue (0.4%) 72-57-1 Sigma-Aldrich 
Tween 20 P1379 Sigma-Aldrich 
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Ultra vision One detection system: 
HRP Polymer 
DAB Plus substrate 
 
TL-125-HLJ 
TA-125-HDX 
Thermo Scientific 
Vancomycin hydrochloride 861987-1G Sigma-Aldrich 
Xylene LS81950/G Genta Medical 
Zinc acetate 383317 Sigma-Aldrich 
Zinc chloride 96470 Fluka 
 
Table 4. Chemicals and reagents used throughout the study. 
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2.1.2 Antibodies 
 
Antibodies used throughout the course of these studies are listed in Table (5). 
 
Anti-Sheep CD31: FITC antibody MCA1097F AbD Serotec 
CD31 antibody M0823 Dako 
Goat anti-mouse antibody A11017 Invitrogen 
Goat anti-rabbit antibody A11070 Invitrogen 
Isotype control antibody (IgG1) MO75-4 MBL International 
Isotype control antibody (IgG2) MO75-1 MBL International 
Smooth Muscle Myosin-Heavy Chain      
antibody 
MAB3570 Chemicon International 
Von Willebrand Factor antibody Nr.A0082 Dako 
α-Smooth Muscle Actin antibody A2547 Sigma-Aldrich 
 
Table 5. Primary and secondary antibodies used throughout the study. 
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2.1.3 Materials 
 
Materials used in the course of these studies are listed in Table (6). 
 
Material Cat No. Supplier 
250ml sterile containers CON7580S Scientific Laboratory Supplies 
2ml cryovials 72.380.992 Sarstedit 
3T3 cells (+3) 89022402 National Collection of Type 
Cultures 
75ml  tissue culture flask  TKT-130-210-T Thermo Fisher Scientific Ltd. 
BHK cells (21, clone 13) 85011433 National Collection of Type 
Cultures 
Culture slides tissue culture 4 wells 734-0088 VWR International 
Delrin holding pc Cross Tech Custom Made 
Delrin Three way pc Cross Tech Custom Made 
Filter Flask Pyrex CLS5340500 Sigma 
Fine tip stainless steel forceps E12 R.A. Lamb 
Glass coverslips MIC3228 Scientific Laboratory Supplies 
Glass troughs E105 Raymond A Lamb 
Histology moulds E10.8/4161 Raymond A lamb 
Long hair brush No6 E6  R.A. Lamb 
Micro tube I 1.5ml, loop cap- Simport 212-9573 VWR International 
Microtome Blades SD3050835 Fisher Scientific 
One-way valves (luer fittings) K-30600-01 Cole-palmer 
Plastic histology cassettes CMB-160-030R Thermo Fisher Scientific Ltd. 
Polycarbonate Y-branch fitting K-30526-06 Cole-parmer 
PP Male Luer Plug EW-45503-56 Cole-parmer 
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PP 3-way stopcocks 4mm K-06225-40 Cole-parmer 
PTFE thread seal tape EG-08782-27 Cole-parmer 
Six-well culture plates 140675 Thermo Fisher Scientific Ltd. 
Slide Holder E102 Raymond A Lamb 
Stainless steel rod Cross Tech Custom Made 
Sterile containers (150ml) CON7570S Scientific Laboratory Supplies 
Superfrost Microscope Slide MIC3040 SLS 
TopSeal 96 well plate 6005185 Perkin Elmer 
Twistit stopper Filter Flask EW-62992-26 Cole-parmer 
Two-way valves (luer fittings) K-30600-03 Cole-parmer 
Tubing #1 (0.125 ID) 95702-05 Cole-parmer 
Tubing #2 (0.188 ID) 95702-10 Cole-parmer 
Universal tube CON9000 Scientific Laboratory Supplies 
White, 96 well tissue culture plate 6005680 Perkin Elmer 
 
Table 6. List of materials used throughout the study. 
 
2.1.4 Equipment 
 
Equipment used during the course of these studies is listed in Table (7). 
 
Equipment Model Supplier 
Aspirator Vacusafe Comfort IBS (Integra Biosciences) 
Automatic pipettes Various Gilson 
Balance GR-200-EC AND 
Centrifuge Microcentaur MSE 
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Class II Safety cabinet CL2 Heraeus 
Confocal microscope LSM510 META Zeiss 
Digital colour camera Evolution MP5 Media Cybernetics 
Dissection equipment Various Thermo Fisher Scientific Ltd. 
Dissection kit N/A Thackeray 
Histology water bath MH8515 Barnstead Electrothermal 
Hot wax oven E18/31 Raymond A Lamb 
Hotplate E18/1 R.A. Lamb 
Image-Pro Plus Version 5.1 Media Cybernetics 
Incubator Heraeus Jencons PLC 
Inverted microscope IX71 Olympus UK 
Liquid nitrogen dewar Various Various 
MACS®  MiniSeperator 130-042-102 Miltenyli Biotec 
MACS®  MS Columns 130-042-201 Miltenyli Biotec 
Magnetic stirrer CB161 Stuart scientific 
Motor-bioreactor GP232004 Baldor motors 
Motor control-bioreactor BC138 Baldor motors 
Microtome RM2125 RTF Leica 
Microwave MOL5137 Scientific Laboratory Supplies 
Nanodrop spectrophotometer ND-100 Labtech 
Orbital incubator shaker SI50 Stuart Scientific 
Orbital shaker KSI30B IKA 
pH meter 3510 Jenway 
Pipette boy Integra acu Integra Bioscience 
Roller Mixer SRT6D Stuart 
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Scanning electron microscope CamScan 3-30BM Obducat CamScan Ltd 
Sputter-Coater 208HR Cressington 
Table shaker Ks 130 IKA 
Tissue processor TP11020 Leica 
Top Count C9902 NXT Perkin Elmer 
Upright fluorescent microscope BX51 Olympus UK 
Wax dispenser E66 Raymond A Lamb 
Whrli mixer CM-1 Thermo Fisher Scientific Ltd. 
 
Table 7. List of equipment used throughout the study. 
 
2.2 Stock solutions 
Antibiotic solution (300 U.ml-1 streptomycin, 300 U.ml-1 penicillin) 
Penicillin/streptomycin solution (15 ml) was added to 500 ml DPBS containing calcium and 
magnesium. The solution was stored at 4°C for a maximum of one week. 
Bovine serum albumin (BSA) solution (5 mg.ml-1 BSA) 
Bovine serum albumin (250 mg) was dissolved into 50 ml of distilled water using a 
magnetic stirrer. The solution was then passed through a 0.2 µm pore size filter into a 
sterile container.    Aliquots (5ml) were placed into sterile universals and stored at -20°C 
for up to six months. 
Dulbecco’s phosphate buffered saline (DPBSa) 
Five Oxoid Dulbecco’s PBS tablets were dissolved in 500 ml of distilled water using a 
magnetic stirrer. Whilst stirring, the pH was adjusted to lie within the range of 7.2-7.4 by 
adding drops of either 6 M hydrochloric acid or 6 M sodium hydroxide. The solution was 
then autoclaved at 121°C, 15psi, for twenty minutes. Solutions were stored for up to one 
month at room temperature. 
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Disinfection solution 
Vancomycin hydrochloride (10 mg.ml-1; 2.5 ml), 2.5 ml of gentamycin sulphate                 
(0.5 mg. ml-1) and 2 ml of polymyxin B (0.2 mg. ml-1) were added to 100 ml of DPBSa. 
Using a magnetic stirrer, the pH was adjusted to lie within the range of 7.2-7.4 by adding 
drops of either 6 M hydrochloric acid or 6 M sodium hydroxide. The solution was then 
passed through a 0.2 µm pore size filter into a sterile container. The volume was then 
made up to 500 ml using sterile DPBSa. The solution was used immediately. 
EDTA solution (200 mM) 
EDTA (74.4 g) was dissolved into 1 L of distilled water using a magnetic stirrer and stirrer 
bar. The pH was adjusted to lie within the range of 7.2-7.4 by adding drops of either 6 M 
hydrochloric acid or 6M sodium hydroxide. The solution was then autoclaved at 121°C, 
15psi, for twenty minutes. Solutions were stored for up to one month at room temperature. 
DPBSa and EDTA ( 2.7 mM; 0.15; w/v) 
Five Oxoid Dulbecco’s PBS tablets were dissolved together with 0.5 g of EDTA in 500 ml 
of distilled water using a magnetic stirrer. The pH was adjusted to lie within the range of 
7.2-7.4 by adding drops of either 6 M hydrochloric acid or 6 M sodium hydroxide. The 
solution was then autoclaved at 121°C, 15psi, for twenty minutes. Solutions were stored 
for up to one month at room temperature. 
DPBSa EDTA (2.7mM) containing aprotonin (10KIU.ml-1) 
Aprotonin (500 µl) was drawn up aseptically using a sterile needle and syringe. The 
aprotonin was then aseptically delivered into 500 ml of autoclaved DPBSa EDTA. 
Solutions were stored for up to one month at 4°C if required.   
Sodium dodecyl sulphate (SDS) solution (10%; v/v SDS)  
SDS (1 g) was dissolved into 10 ml of distilled water using a magnetic stirrer.  
SDS hypotonic buffer (0.1%; w/v SDS 10 mM tris, 2.7 mM EDTA, 10 KIU.ml-1 
aprotonin) 
SDS solution (5 ml) was added to 495 ml of autoclaved hypotonic buffer. The solution was 
used immediately. 
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Hypertonic solution (50 mM tris, 1.5 M sodium chloride) 
Sodium chloride (87.66 g) and 6.06 g of tris were dissolved in 900 ml of distilled water. The 
pH was adjusted to lie within the range of 7.5-7.7 by adding drops of either 6 M 
hydrochloric acid 6 M sodium hydroxide. A further 100 ml of distilled water was then added 
to make the volume up to one litre. The solution was then autoclaved at 121°C, 15psi, for 
twenty minutes and stored at room temperature for up to one month. 
Hypotonic buffer (10 mM tris, 2.7 mM EDTA, 10 KIU.ml-1 aprotonin) 
Trizma base (1.21 g) and 1 g of EDTA were dissolved in 900 ml of distilled water using a 
magnetic stirrer. The pH was adjusted to lie within the range of 8-8.2 by adding drops of 
either  6 M hydrochloric acid or 6 M sodium hydroxide. A further 100 ml of distilled water 
was then added to make the volume up to one litre. The solution was then autoclaved at 
121°C, 15psi, for twenty minutes. Solutions were stored at room temperature for up to one 
month. Aprotonin solution (1ml; 10,000 KIU/ml) stock was added aseptically immediately 
prior to use.   
DNAase stock solution 
DNAase was rehydrated to a final concentration of 10,000 U.ml-1 using 5 mM sodium 
lactate, 1 mM calcium chloride and 50% (v/v) glycerol.  The solution was then passed 
through a 0.2 µm pore size filter into a sterile container and placed in labeled aliquots and 
frozen at -20°C.  
DNAase diluent (5 mM sodium acetate, 1 mM calcium chloride, 50%; w/v glycerol) 
Sodium acetate (0.68 g) and 0.11 g of calcium chloride were dissolved in 500 ml of 
distilled water using a magnetic stirrer. Glycerol (500ml) was added to the solution which 
was then inverted to mix. The pH was adjusted to lie within the range of 4-5 by adding 
drops of either 6 M hydrochloric acid or 6 M sodium hydroxide. The solution was stored at 
room temperature for up to three months. 
RNAase A stock solution 
RNAase was rehydrated to a final concentration of 100 U.ml-1 using distilled water. The 
solution was then passed through a 0.2 µm pore size filter into a sterile container and 
placed in labeled aliquots and frozen at -20°C. 
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Nuclease solution (50 mM tris, 50 µg.ml-1 BSA, 50 U.ml-1 DNAase, 1 U.ml-1 RNAase) 
The solution was made aseptically in a class II safety cabinet. Trizma base (6.1 g) and 2 g 
of magnesium chloride were dissolved in 80 ml of distilled water using a magnetic stirrer. 
The pH was adjusted to lie within the range of 7.5-7.7 by adding drops of either 6 M 
hydrochloric acid or 6 M sodium hydroxide. A further 910 ml of distilled water was added to 
the solution to make up the volume to 990ml. The solution was then autoclaved at 121°C, 
15psi, for twenty minutes. Prior to use, 10 ml of stock BSA solution was defrosted and then 
added to 975 ml of solution.  10 ml of RNAase stock (100U.ml-1) and 5 ml of DNAase 
(10,000 U.ml-1) were then added to the solution. The solution was used within ten minutes 
of preparation. 
Peracetic acid (PAA) solution (0.1%; v/v) 
PAA solution (1.57 ml) was added to 500 ml of autoclaved DPBSa. The pH was adjusted 
to lie within the range of 7.2-7.5 by adding drops of either 6 M hydrochloric acid or 6 M 
sodium hydroxide. Solutions were used within one hour of preparation. 
DAPI dye solution (1 mg.ml-1) 
Following receipt of DAPI (10 mg), 10 ml of nuclease free water (1 mg.ml-1) was 
immediately added. The solution was then stored at -20°C in a foil-wrapped container for a 
maximum of six months. 
DAPI working dye solution (0.1 µg.ml-1) 
DAPI dye solution (20 µl) was added to 200 ml of dye buffer in a dark bottle. The bottle 
was inverted to mix. Whilst stirring, the pH was adjusted to 7.4 by adding drops of either 6 
M hydrochloric acid or 6 M sodium hydroxide. The solution was used immediately. 
2.5% (w/v) DABCO  
1,4-diazobicyclo-(2, 2, 2)-octane (2.5 mg) was dissolved in 100 ml of  0.1 M sodium 
hydrogen carbonate using a magnetic stirrer. The pH was adjusted to 9 by adding pellets 
of sodium hydroxide. The solution was stored for up to three months at room temperature. 
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DABCO: glycerol mountant 
 DABCO (10 ml) 2.5% (w/v) was mixed with 90 ml of glycerol using a magnetic stirrer. The 
solution was stored at 4°C in a foil-wrapped bottle for up to three months. 
Sodium hydrogen carbonate buffer (0.1 M) 
Sodium hydrogen carbonate (4.2 g) was dissolved into 500 ml of distilled water using a 
magnetic stirrer. The pH was adjusted to 9 by adding pellets of sodium hydroxide whilst 
stirring. The solution was stored for up to three months at room temperature. 
Sodium hydroxide solution (6 M)  
Sodium hydroxide (120 g) was added to 500 ml of distilled water using a magnetic stirrer. 
The solution was stored for up to three months at room temperature. 
Sodium chloride solution (3 M)   
Sodium chloride (175.32 g) was dissolved into 1 L of distilled water and autoclaved at 
121°C, 15psi for 20 minutes. The solution was stored for a maximum of one month. 
Endothelial cell culture medium (M-199, 20% (v/v) FBS, 100 U.ml-1 penicillin and        
100µg.ml-1 streptomycin, 2mM L-glutamine, 30 U.ml-1 heparin, endothelial growth 
factor supplement) 
The M-199 Medium, penicillin/streptomycin solution, L-glutamine solution and FBS were all 
pre-warmed to 37°C. To 100 ml of M-199 culture medium, 20 ml of FBS, 1.2 ml of 
penicillin/streptomycin, 1.2 ml of L-glutamine, 3 ml of sodium heparin (30 U.ml-1) and 1 ml 
of 100X endothelial growth factor supplement were added. The solution was mixed and 
stored at 4°C for a maximum of one week. 
3T3, BHK and SMC culture medium (10% FBS, 2 mM L-glutamine, 100 U.ml-1 
penicillin and 100µg.ml-1 streptomycin). 
The Dulbecco’s modified Eagle’s medium, penicillin/streptomycin solution, L-glutamine 
solution and FBS were all prewarmed to 37°C. Under aseptic precautions in a class II 
safety cabinet, 55 ml of FBS, 5.5 ml each of penicillin/streptomycin and L-glutamine 
solutions were added to 500 ml of Dulbecco’s modified Eagle’s medium. The medium was 
stored for a maximum of one week at 4°C.   
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Dimethyl sulfoxide (40% v/v) 
Dimethyl sulfoxide [(DMSO), 8 ml] was added to 12 ml of Dulbecco’s modified Eagle’s 
medium and then filter-sterilised into a sterile universal.  
Acetone: methanol solution 
Acetone (100ml) was added to methanol (100ml) for immediate use. 
Tris solution (2 M) 
Trizma base (242.26 g) was added to 500 ml of distilled water and mixed using a magnetic 
stirrer. The pH was adjusted to 7.6 using 6 M hydrochloric acid or 6 M sodium hydroxide 
and then made up to 1 L using distilled water. The solution was then autoclaved at 121°C, 
15psi for 20 minutes. The solution was stored for a maximum of one month. 
Tris solution (0.1 M) 
Trizma base (12.1 g) was dissolved in 1 L of distilled water using a magnetic stirrer. The 
solution was then autoclaved at 121°C, 15psi for 20 minutes. 
Tris buffered saline (TBS) 
To create TBS, 25 ml of tris solution (2 M) was added to 50 ml of sodium chloride (3 M) 
and mixed using a magnetic stirrer. The volume was then made up to 1 L using distilled 
water.  The pH was adjusted to 7.6 using 6 M hydrochloric acid or 6 M sodium hydroxide. 
The solution was then autoclaved at 121°C, 15psi for 20 minutes and stored for a 
maximum of one month.  
TBS containing 0.05 % (w/v) Tween 20  
One litre of TBS was mixed with 500 µl of Tween 20 using a magnetic stirrer. The pH was 
adjusted to 7.6 using either 6 M hydrochloric acid or 6 M sodium hydroxide. The solution 
was stored for up to three months at room temperature. 
Dye buffer (10 mM Tris, 1 mM Na2EDTA, 1 mM NaCl)  
Trizma base (1.211 g), 0.3724 g of EDTA and 0.0058 g of sodium chloride were all 
dissolved in one litre of distilled water using a magnetic stirrer. The solution was then 
autoclaved at 121°C, 15psi, for twenty minutes in a dark bottle and stored for up to six 
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months at room temperature. Just prior to use, the pH was adjusted to 7.4 by adding drops 
of either 6 M hydrochloric acid or 6 M sodium hydroxide. 
Antibody diluent (TBS, 0.1 % (w/v) BSA, 0.1 % (w/v) sodium azide) 
To create the diluent, 600 µl of sodium azide (10%; (w/v) and 59.1 ml of TBS were mixed 
with 300 µl of BSA (5 %; w/v) using a magnetic stirrer. The pH was adjusted to 7.6 using 
either 6 M hydrochloric acid or 6 M sodium hydroxide. The solution was stored for up to 
three months at 4°C. 
Sodium azide (10%; w/v) 
Sodium azide (10 g) was dissolved into 100 ml of distilled water using a magnetic stirrer 
and autoclaved at 121°C, 15psi for 20 minutes. The solution was stored for a maximum of 
one month at room temperature.  
Glutaraldehyde solution (2.5%; v/v glutaraldehyde)  
Glutaraldehyde (10 ml, 50%; v/v) was added to 100 ml of DPBSa. The solution was then 
made up to a final volume of 200 ml with distilled water. 
Collagenase stock solution (1% collagenase type 2, 273 U.ml-1) 
DPBSa (5 ml) without calcium or magnesium was added to 50 mg of collagenase type 2 
and mixed until the collagenase had dissolved. The solution was stored at -20°C. 
Collagenase working solution (0.1% collagenase type 2, 2.73 U.ml-1) 
Collagenase stock solution (1 ml) was added to 9 ml of DPBSa without calcium and 
magnesium. The solution was used on the same day of production. 
Magnetic separation buffer solution (BSA 5%; w/v) 
EDTA (0.25 g) and BSA (12.5 ml) were added to 250 ml of DPBSa. The pH was adjusted 
to 7.2 
Hydrogen peroxide solution (3%; v/v) 
Hydrogen peroxide (20 ml, 30%;v/v) was added to 180 ml of distilled water. 
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Citrate buffer (10 mM citric acid, 0.05% (v/v) Tween 20) 
Citric acid (1.92 g) and Tween 20 (0.5 ml) were dissolved in 1 L of distilled water. The pH 
was adjusted to pH6 using sodium hydroxide (6 M).    
Trypsin working solution (0.1% (v/v) trypsin) 
Porcine trypsin (100 mg) was dissolved in 10 ml of distilled water. Next, calcium chloride 
(100mg) was dissolved in 10 ml of distilled water. Then 1 ml of trypsin stock solution (1%) 
and 1 ml of calcium chloride solution (1%) was added to 10 ml of distilled water. The pH 
was adjusted to pH7.8 using sodium hydroxide (6 M). 
Zinc fixative solution 
Calcium acetate (0.5 g) was dissolved in 1 L of 0.1 M Tris solution using a magnetic stirrer. 
The pH was adjusted to 7-7.4 using either 6 M hydrochloric acid or 6 M sodium hydroxide. 
Next, 5 g of zinc acetate followed by 5 g of zinc chloride was added to the solution using a 
magnetic stirrer. 
2.3 Methods 
2.3.1 pH measurement  
The pH measurement of all solutions was performed using a Jenway 3020 pH meter. 
Calibration was performed with pH 4, 7 and 10 buffer solutions. The pH of solutions was 
altered by adding either hydrochloric acid (6 M) or sodium hydroxide (6 M) in a dropwise 
fashion.  
2.3.2 Bright field microscopy 
Bright field microscopy was performed using an upright fluorescent BX51 microscope 
(Olympus, UK). For fluorescent microscopy, a vertical illuminator (BX51-RFA) was used. 
Images were captured using a digital colour camera (Evolution MP5, Media Cybernectics) 
in combination with Image-Pro Plus (Version 5.1, Media Cybernetics) software. 
2.3.3 Scanning electron microscopy and tissue preparation 
All steps were performed in a fume cupboard. 
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Specimens were placed into six-well plates. To fix the specimens, 2 ml of 2.5% (v/v) 
glutaraldehyde in DPBSa was added to each well for 24 hours at 4°C. Once fixed, the 
glutaraldehyde was removed and the segments washed with sterile DPBSa. Specimens 
were post-fixed in 2 ml of 1% (v/v) osmium tetroxide in DPBSa for 24 hours at room 
temperature.  
Specimens were then dehydrated using ascending concentrations of acetone. To begin 
dehydration, 2 ml of 20% (v/v) acetone was added to each well for 30 minutes at room 
temperature. This step was then repeated for 40%, 60%, 80% and 100% acetone. 
Following dehydration, specimens were critical-point dried using a Polaron E3000 critical 
point drying machine using liquid carbon dioxide as the transition fluid. Each section was 
then mounted onto a 13 mm pin stub using carbon cement and coated in platinum using a 
Cressington 208HR  sputter-coater. Specimens were then examined using a CamScan 3-
30BM scanning electron microscope at a working distance of between 5-10 mm. Images 
were captured using Image Pro Plus software. 
 2.4 Sterilisation 
2.4.1 Moist heat sterilisation 
All solutions, bioreactor components and other materials not suitable for dry heat 
sterilisation were autoclaved at 121°C at fifteen pounds per square inch (psi) for twenty 
minutes. 
2.4.2 Dry heat sterilisation 
Items suitable for dry heat sterilisation included dissection instruments and multi-spot glass 
slides. Items were placed in an oven at 160°C for four hours. 
2.4.3 Filter sterilisation 
Small volume solutions and solutions unsuitable for moist heat sterilisation were passed 
through a 0.2 µm filters. 
2.5 Tissue procurement 
Porcine carotid arteries from English White Pigs were delivered from Sykes House Farm 
(Thorp Arch, Wetherby, UK) one day post-slaughter. Arteries were delivered with laryngeal 
and thoracic structures still attached. Residual and adventitial tissue was removed from 
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the arteries using sharp dissection. Arteries were then immediately washed three times in 
sterile DPBSa with EDTA (2.7 mM) and aprotonin (10 KIU.ml-1)] at 4°C for 30 minutes to 
remove any tissue debris and inhibit endogenous protease activity. Arteries were then 
placed in labeled sterile universals and stored at - 80°C ready for use.   
 
2.6 Histological techniques 
2.6.1 Specimen processing and fixation for paraffin wax embedding 
 
The middle and distal ends of both decellularised and fresh arteries were analysed. Using 
a scalpel, each artery was cut in half. Samples (5 mm) were then cut from the distal ends 
of the two cut halves of each decellularised artery. Each tissue sample was placed into 
labeled individual plastic histology cassettes. The cassettes were placed into a metal 
holding basket and placed in a tissue processor. Program one was selected, which 
immersed the samples for an hour under vacumn into the following solutions:  
 
1. 10% (w/v) neutral buffered formalin  at 21°C 
2. 70% (v/v) ethanol    at 21°C  
3. 90% (v/v) ethanol    at 21°C 
4. 100% (v/v) ethanol    at 21°C 
5. 100% (v/v) ethanol    at 21°C 
6. 100% (v/v) ethanol    at 21°C 
7. Xylene      at 21°C 
8. Xylene      at 21°C 
9. Xylene      at 21°C 
10. Paraffin wax     at 50°C 
11. Paraffin wax     at 50°C 
12. Paraffin wax.     at 50°C 
 
After completion of program one, the cassettes were removed from the tissue processor 
and transferred into fresh molten wax inside a wax oven. Metal wax block moulds were 
filled with molten wax and then specimens were positioned carefully into the centre of each 
mould, with the lumen facing upwards. The moulds were then placed onto ice packs to 
solidify the wax at the bottom of each mould (to hold the specimen in the correct 
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orientation). The plastic histology cassettes were then placed on top of the moulds and 
topped up with further molten wax. The moulds were then left to cool and harden at room 
temperature. After cooling, the wax block was removed from the mould, leaving it attached 
to the cassette base. Excess wax was removed from the edges of the cassette base using 
the flat edge of a metal spatula. 
Blocks were then placed into the microtome and cut into 5 µm sections at an angle of 5°. 
Sections were removed and placed onto the surface of a hot water-bath at 45°C until 
wrinkles within the wax had disappeared. Sections were then collected onto labeled glass 
slides and placed onto hotplate rails at 50°C to dry for three hours. 
 
 2.6.2 Haemotoxylin and Eosin (H& E) staining of paraffin wax embedded tissue 
samples 
Once the sections had dried they were placed in a slide holder and immersed into two 
consecutive pots of (dewax) xylene for ten minutes each. Sections were consecutively 
placed into separate pots of 100% ethanol for three, two and two minutes respectively. 
Sections were then placed in 70% (v/v) ethanol for two minutes and then immersed into 
running tap water for three minutes. Following this, sections were immersed into 
haemotoxylin for one minute and then immersed into running tap water, until water drained 
clear. Sections were placed in eosin for three minutes. Sections were placed again in 70% 
(v/v) ethanol for five seconds and then placed into consecutive pots of 100% ethanol for 
one, two and three minutes respectively. Sections were immersed into two consecutive 
pots of clean xylene for ten minutes each. Sections were mounted using glass coverslips 
and DPX mountant and left in a fume cupboard to dry for four hours.   
 
2.6.3 DAPI staining of paraffin wax embedded tissue samples 
Embedded tissue sections were stained using DAPI to visualise double-stranded DNA and 
cell nuclei. Slides were placed in a slide holder and immersed into two consecutive pots of 
(dewax)  xylene for ten minutes each. Sections were consecutively placed into separate 
pots of 100% ethanol for three, two and two minutes respectively. Sections were placed in 
70% (v/v) ethanol for two minutes and then immersed into running tap water for three 
minutes. In a dark room, the sections were immersed into 200 ml of DAPI working solution 
(0.1 μg.ml-1) and incubated at room temperature for ten minutes. Sections were washed 
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three times in DPBSa for ten minutes in the dark. Sections were mounted using 1,4-
diazobicyclo-(2,2,2)-octane( DABCO): glycerol mountant and glass cover slips. Sections 
were viewed using an upright fluorescent microscope and DAPI filter. Images were 
captured using a digital camera and Image-Pro Plus v 5.1.  
 
2.6.4 Specimen processing and zinc fixation for paraffin wax embedding 
Specimens (5mm) were cut from the distal end of each artery. Each tissue sample was 
then placed into labeled individual plastic histology cassettes. The cassettes were placed 
into zinc fixative solution for 24 hours at room temperature. The cassettes were placed into 
a metal holding basket and placed in a tissue processor. Program three was selected, 
which immersed the samples for an hour under vacumn into the following solutions: 
1. 70% (v/v) ethanol    at 21°C  
2. 90% (v/v) ethanol    at 21°C 
3. 100% (v/v) ethanol    at 21°C 
4. 100% (v/v) ethanol    at 21°C 
5. 100% (v/v) ethanol    at 21°C 
6. Xylene      at 21°C 
7. Xylene      at 21°C 
8. Xylene      at 21°C 
9. Paraffin wax     at 50°C 
10. Paraffin wax     at 50°C 
11. Paraffin wax.     at 50°C 
 
After completion of program three, the specimens were wax embedded and sectioned as 
described in Section 2.6.1. H & E and DAPI staining was then performed as described in 
Sections 2.6.2-2.6.3. 
2.7 Cell culture 
All materials, equipment, reagents and solutions used are listed in Sections 2.1-2.2. 
All methods were performed using full aseptic precautions in a class II safety cabinet.  
76 
 
2.7.1 Cell maintenance 
Spent culture medium was aspirated from each T75 flask and replaced with 10 ml of cell-
specific medium every 48 hours. 
2.7.2 Cell passage 
Cells were passaged when they became 70-80% confluent in the flasks. Medium was 
removed from the flasks carefully to prevent disruption of the cell monolayer. The flask 
surface was then washed with 10 ml of DPBSa without calcium or magnesium for five 
minutes. Trypsin (3 ml) was then added to each T75 flask of cells. Flasks were then gently 
rocked to ensure uniform coverage of the cell monolayer and incubated at 37°C with 5% 
(v/v) CO2 in air for five minutes. Following incubation the sides of the flasks were gently 
tapped to dislodge the cells. Cell detachment was confirmed using an inverted 
microscope. Cell-specific medium (10 ml) was then added dropwise into the flask with 
contents then being placed into a sterile universal. To remove the trypsin and create a cell 
pellet, the solution was centrifuged at 150 g for ten minutes. Following centrifugation, the 
supernatant was removed and the cell pellet was resuspended in 1 ml of fresh medium. 
The cell suspension was diluted by addition of a further 4 ml of medium. The diluted cell 
suspension was then placed into a new, sterile T75 flask and placed back into incubation 
at 37°C with 5% (v/v) CO2 in air.    
2.7.3 Cell storage in liquid nitrogen  
A cell pellet was created using the procedure described above for cell passage. The cell 
pellet was then resuspended in cell-specific medium (12 ml) containing 10% (v/v) dimethyl 
sulfoxide (DMSO). The following stages were performed quickly due to the toxicity of 
DMSO to the cells. The cell suspension was then aliqoted into 1 ml cryovials labelled with 
the cell name, date and passage number. The cryovials were then placed into a Mr Frosty 
containing isopropranol and stored at -80°C overnight. Cryovials were then placed in a 
cell-specific liquid nitrogen dewar for long-term storage. A cell log form was completed to 
allow update of the digital cell log database.  
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2.7.4 Cell resurrection 
Cell-specific culture medium was pre-warmed to 37°C. The digital cell log database was 
inspected to confirm position of required cells. Cryovials were then warmed to room 
temperature and the cell suspension transferred into a sterile universal. Immediately, 10 ml 
of warmed medium was added dropwise (to prevent cell shock) into the universal. The 
suspension was then centrifuged at 150 g for ten minutes to remove the DMSO. Following 
centrifugation, the supernatant was removed and the cell pellet was resuspended in 1 ml 
of fresh medium. A further 9 ml of medium was then added to the universal and contents 
placed into a T75 flask. Cells were then incubated at 37°C with 5% (v/v) CO2 in air and 
observed for growth. 
2.7.5 Cell counting 
A cell pellet was created using the procedure described above for cell passage. Cell 
specific medium (8 ml) was then added to create a cell suspension. Trypan blue (10 μl) 
was mixed with 90 μl of cell suspension in a sterile bijou. A haemocytometer was cleaned 
with 70% (v/v) ethanol and then a glass cover slide was placed over the top. 
Approximately 10-15 μl of the cell suspension containing trypan blue was then placed 
under the coverslip to lie over the central, triple-ruled area of the haemocytometer. Cells 
present in five of the twenty-five squares within the haemocytometer were counted using a 
cell counter (cells containing trypan blue were not counted as these represented non-
viable cells). In order to calculate the number of cells present per ml of suspension, the 
following working was used. 
Within the central ruled area of the haemocytometer, there were nine large squares each 
of 1 mm2. The depth of the counting chamber with the glass coverslip appropriately in 
place was 0.1 mm. Therefore cells lying within one of the nine large squares came from a 
volume of 0.1 mm3. Counting five of the twenty-five smaller squares was equivalent to 
counting 1/5 of 0.1 mm3. The number of cells in 0.1 mm3  was multiplied by 104  to estimate 
number of cells.ml-1. Finally if only five small squares were counted, to estimate the 
number of cells per ml this was multiplied by 5 x 104 to estimate the number of cells.ml-1. 
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2.7.6 Cell viability assay 
2.7.6.1 Live / Dead ® Assay to assess for cell viability 
The Live/Dead ® stain was prepared using DPBSa, 1 mM calcein AM and 1 mM ethidium 
homodimer-1. Sections of seeded scaffold (2 cm x 2 cm) were cut from the main scaffold 
and placed into individual wells of a six-well plate. Live / Dead ® stain solution was added 
into each well to completely cover the tissue. The plate was then incubated in the dark at 
room temperature for 45 minutes. The tissue was then washed three times using TBS (pH 
7.6) for ten minutes on a plate rocker. The tissue was then wet mounted with DPBSa onto 
a microscope slide and covered with a glass coverslip. The tissue was viewed using a 
confocal microscope and a conventional fluorescent long pass filter. 
2.8 Vascular cell harvest (ovine and porcine) 
2.8.1 Tissue procurement and preparation 
Fresh ovine and porcine hind-legs were delivered by a local abattoir (John Penny & Sons, 
Leeds, UK) immediately following slaughter. The superficial femoral artery from each leg 
was harvested using sterile dissecting instruments within a class II safety cabinet to 
minimize contamination.  Once excised, the arteries were placed immediately into sterile 
DPBSa to wash away any adherent clot or tissue debris. Arteries were then incubated in 
an antibiotic solution (streptomycin 300 U.ml-1, 300 U.ml-1 penicillin) at 37°C for two hours.  
2.8.2 Endothelial cell isolation  
Following incubation, one end of the artery was tied off using a silk suture. A blunt needle 
was placed into the other end with a silk suture tied loosely around both artery and needle. 
A syringe containing collagenase solution (0.1% collagenase type II 273 U.ml-1) was then 
attached to the needle and the contents then injected into the arterial lumen. The needle 
was then removed and the suture tightened to maintain the collagenase solution within the 
arterial lumen. The vessel containing collagenase was then incubated at 37°C for thirty 
minutes. 
Following incubation, the vessel was cut along its axis and the contents emptied into a 
sterile universal tube. The arterial lumen was then washed with 10 ml of DPBSa to flush 
out any remaining endothelial cells. The collected cell suspension was then centrifuged at 
250 g for 10 minutes. After centrifugation, the supernatant was discarded and the cells 
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washed in 20 ml of M-199 medium. Cells were then re-suspended in endothelial culture 
medium and split into two T75 culture flasks. Flasks were then incubated at 37 °C in 5% 
(v/v) CO2 in air with the culture medium being changed every 48 hours. Flasks were 
examined for evidence of endothelial cell attachment, characterised initially by the growth 
of cells in colonies. Once cells had reached near-confluence, the characteristic 
‘cobblestone’ appearance of an EC monolayer was observed.  
2.8.3 Isolation of smooth muscle cells 
The remaining arterial segments from the isolation of EC were macerated using a sterile 
scalpel blade and then placed into a T75 culture flask together with 10 ml of SMC medium 
and incubated at 37°C in 5% (v/v) CO2 in air. Medium was changed every 48 hours. Flasks 
were examined from 72 hours to assess for SMC migration from the explant onto the flask 
surface.  
2.9 Data analysis and statistics 
All statistical analyses were performed using Microsoft Excel 2010 software. All values 
were displayed as the mean ± 95 % confidence intervals.  To assess statistical 
significance between groups, a student’s t-test was used to analyse data with two sets of 
mean values and a one way analysis of variance (ANOVA) test was use assess data with 
more than two sets of mean values. Following ANOVA, individual differences between 
group means were determined using the t-method to obtain the minimum significant 
difference. A p-value of <0.05 was considered statistically significant. 
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Chapter 3 
Decellularisation and characterisation of porcine carotid arteries 
 
3.1 Introduction 
For the tissue engineering of SD grafts, the approach taken was to decellularise porcine 
carotid arteries since they are the correct diameter (<6 mm), are readily available and have 
been shown to be amenable to varying decellularisation protocols in the literature 
(McFetridge et al., 2004; Roy et al., 2005; Heine et al., 2011; Nitsan et al., 2012). The 
Institute of Medical and Biological Engineering (IMBE) at the University of Leeds had 
previously developed a decellularisation protocol that had been used to successfully 
decellularise a number of allogeneic and xenogeneic tissues (without significant alteration 
in tissue biomechanics) including heart valves, pericardium, amniotic membrane and 
ureter (Booth et al., 2002; Wilcox et al., 2003; Wilshaw et al., 2006; Derham et al., 2008).  
The aim of decellularisation is to remove all cells from a tissue whilst preserving the 
composition of the remaining ECM. For this project therefore, the use of xenogeneic artery 
was an obvious choice given that its ECM is innately designed to withstand and adapt to 
the haemodynamics of blood circulation. In addition, the ECM proteins of arteries display 
close sequence homology across species, which has obvious importance in 
biocompatibility (Gilbert et al., 2006). The ultimate goal at present in cardiovascular tissue 
engineering is to be able to re-cellularise a decellularised scaffold with vascular cells not 
only to provide a functioning endothelium, but also to give the scaffold functionality. 
Although decellularisation protocols differ within the literature, re-cellularisation studies on 
decellularised arteries have consistently shown successful re-cellularisation of scaffolds 
using a variety of cell types, most importantly, vascular cells. (Conklin et al., 2002; 
McFetridge et al., 2004; Shimizu et al., 2007; Dahan et al., 2011; Heine et al., 2011).  
 
3.2 Aims and Objectives 
 
The aims and objectives of this chapter were: 
 
1. To decellularise porcine carotid arteries 8-11cm in length 
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2. To determine the extent of decellularisation using histological analysis and DNA 
quantification 
 
3. To determine the biocompatibility of decellularised arteries to ISO standard cell lines 
(BHK and 3T3 cells). 
 
4. To determine the biocompatibility of decellularised arteries to (native) primary porcine 
vascular cells   
 
3.3 Experimental approach 
The standard iMBE decellularisation protocol was used in an attempt to decellularise the 
porcine carotid arteries.  
Once the arteries had been harvested and prepared, they were sequentially washed in a 
series of buffers to decellularise the tissue. The first step was to wash the arteries in 
antibiotic solution to reduce the bio-burden. Arteries were then treated with EDTA to 
loosen the vascular cells from the extracellular matrix by inhibiting integrin function. 
Arteries were then washed in hypotonic buffer followed by low concentration SDS. The 
hypotonic buffer caused the cells to swell and then burst. SDS, a detergent, solubilised the 
cell membranes. These two steps were then repeated. The next step was treatment with a 
nuclease solution containing RNase and DNase enzymes to digest DNA and RNA. 
Arteries were then washed in a hypertonic buffer to remove any hydrophobic substances 
from the arteries such as the α-gal epitope. The α-gal epitope is a carbohydrate present on 
glycoproteins expressed by cells of non-primate mammals. It is not present in humans; 
indeed, all humans produce an antibody to the epitope (Galili, 2005). For the penultimate 
step, arteries were treated with PAA. PAA efficiently removes any residual cellular 
remnants and sterilises the tissue. The final step was three terminal washes with DPBSa 
to remove any residual cell debris.  
To confirm decellularisation, histological staining methods and DNA quantification were 
used. H&E and DAPI stains were used to confirm decellularisation histologically. Both 
haemotoxylin and DAPI bind to nuclear (acidic) material and so demonstrate any cell 
nuclei remaining in the tissue. DNA quantification was also performed to assess the 
removal of nuclear material. To quantify the DNA remaining within the tissue, a standard 
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DNA extraction kit was used to extract DNA into solution. The concentration of the DNA in 
solution was then measured using spectrophotometry. In total, eight batches of between 2-
22 porcine carotid arteries were subject to the decellularisation protocol in this study. 
Once the porcine carotid arteries were successfully decellularised, the biocompatibility of 
the decellularised arteries was assessed using contact and extract cytotoxicity assays 
using two cell lines (murine 3T3 cells and BHK cells) and porcine EC and SMC.  3T3 and 
BHK cells are recommended by the ISO to assess the biocompatibility of medical devices. 
3.4 Materials and Methods 
All equipment, reagents, materials and solutions used in the study are listed in Chapter 2. 
The porcine cells were kindly gifted by a fellow University of Leeds MD student (Mr Taha 
Khan). They were harvested using the techniques described in Chapter 2.8 and 
subsequently characterised to confirm vascular cell phenotype.   
3.4.1 Tissue procurement and preparation 
Porcine carotid (PC) arteries were procured and prepared as described in Section 2.5. In 
total, 79 PC arteries were used in this study.   
3.4.2 Decellularisation of porcine carotid arteries    
All incubations in the process were performed using 200 ml of solution, with agitation at 
240 rpm with the exception of the nuclease step, which was at 80 rpm. Prior to each 
incubation, the arteries were placed in sterile 250 ml containers. Two to four arteries were 
used in the first four decellularisation runs. Between six to twenty-two arteries were used in 
the proceeding runs (exact number based on artery availability at the time). Details of all 
solutions used are listed in Chapter 2, Section 2.2. 
Frozen porcine carotid arteries were thawed in an incubator at 37°C for twenty minutes. 
Following thawing, the arteries were washed in disinfectant solution and incubated for 30 
minutes at 37°C. Arteries were then incubated in EDTA solution for 24 hours at 4°C. 
Arteries were then incubated in hypotonic buffer for 24 hours at 4°C. Arteries were then 
incubated in 0.1% (w/v) SDS in hypotonic at 37°C for 24 hours. Arteries were then once 
again incubated in hypotonic solution at 4°C for 24 hours. Arteries were then incubated in 
DPBSa EDTA solution with aprotonin for 56 hours at 4°C. Arteries were then incubated in 
0.1% (w/v) SDS in hypotonic buffer at 37°C. The arteries were then incubated three times 
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in DPBSa solution at 37°C for 30 minutes each. The arteries were then incubated in 
nuclease for three hours at 37°C. Following nuclease incubation, the arteries were 
incubated three times in DPBSa EDTA solution with aprotonin at 37°C for 30 minutes 
each. Arteries were then incubated in hypertonic buffer for 24 hours at 37°C. The arteries 
were then incubated three times in DPBSa EDTA solution with aprotonin at 37°C for 30 
minutes each. The arteries were then sterilised in 0.1% (v/v) PAA solution for three hours 
at 27°C. The final two steps were performed aseptically in a class II safety cabinet. The 
arteries were incubated three times in DPBSa EDTA solution with aprotonin at 37°C for 30 
minutes each. For the final step in the decellularisation process, the arteries were 
incubated with DPBSa for 24 hours at 4°C. Arteries were stored in DPBSa solution at 4°C 
until required, for a maximum of three months.  
3.4.3 Characterisation of decellularised arteries 
To determine whether decellularisation was successful, the processed arteries were 
characterised histologically using H&E and DAPI staining and DNA content was quantified. 
To ensure fully representative analysis, samples were taken from the end and middle 
section of each artery.     
 3.4.3.1 Histological characterisation  
Processed arteries were compared to fresh control arteries using the histological 
techniques described in Chapter 2, Sections 2.6.1-2.6.3  
3.4.3.2 Isolation and quantification of total DNA  
The DNeasy kit (Qiagen) was used for this process.  
Four (25 mg) sections from two decellularised arteries (two end sections and two middle 
sections) and four (25 mg) sections from two control arteries were macerated using a 
scalpel. Each sample of tissue was then placed in a labeled 1.5 ml micro-centrifuge tube. 
Buffer ATL (180 μl) and 20 µl of proteinase K were added to the tubes. The contents of 
each tube were mixed thoroughly using pulsed-vortexing for 10 seconds. All tubes were 
then incubated in a waterbath at 56°C for three and a half hours to achieve complete 
tissue lysis. 
Buffer AL (200 μl) was then added to each tube and then mixed using pulse-vortexing, and   
200 µl of ethanol (100%; v/v) was added to each tube. Tubes were mixed using pulse-
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vortexing immediately following addition of ethanol to ensure a homogenous solution. 
Each sample was then placed in a DNeasy mini spin column and placed in a 2 ml 
collecting tube. Samples were then centrifuged at 6000 x g for one minute. The flow-
through material was then discarded and the samples were placed in new collection tubes. 
Buffer AW1 (500 µl) was added to each tube and centrifuged again at 6000 x g for one 
minute. Flow-through was again discarded and the samples transferred to new collection 
tubes. Buffer AW2 (500 µl) was added to each tube, centrifuged this time at 16,000 x g for 
three minutes, to dry the DNeasy membrane. Again flow-through was discarded and 
samples placed into 2ml micro-centrifuge tubes. Buffer AE (100 µl) was then added onto 
the DNeasy membrane. Samples were incubated at room temperature for one minute and 
then centrifuged at 6000 x g for one minute. This time, flow-through was not discarded. A 
further 100 µl of Buffer AE was added to the samples which were again centrifuged at 
6000 x g for one minute following incubation at room temperature. This latter step was 
performed twice in order to maximise DNA yield. The resultant DNA samples were stored 
for a short period at 4°C prior to quantification. The concentration of DNA in each sample 
was determined by loading 2 µl aliquots onto a Nanodrop™ spectrophotometer (which 
determined absorbance at 260 nm wavelength of light). Nuclease free water from the 
DNeasy kit was used to blank. Each sample was tested in triplicate. The concentration of 
each sample was normalised for volume and initial tissue mass to determine DNA 
concentration in µg.mg-1. 
3.4.4 Assessment of the biocompatibility of decellularised porcine carotid arteries 
3.4.4.1 Extract cytotoxicity 
This procedure describes the process of assessing the cytotoxicity of decellularised 
porcine carotid artery using adherent 3T3 cells, BHK cells, porcine EC and SMC compared 
to a positive control of 40% (v/v) DMSO and negative control of culture medium. Any 
soluble components present in the artery were extracted and cultured with a monolayer of 
cells. The ATP content of the cells was then determined as an indicator of cell viability. 
The procedure was performed using full aseptic precautions in a class II safety cabinet.  
Three [300 mg] sections from three separate decellularised arteries from batch 8 were 
macerated using a scalpel and placed into a sterile labeled bijou containing 3 ml of DMEM. 
The tissue and medium was then incubated at 37°C with agitation at 240 rpm for 72 hours. 
Following this, the supernatant from each bijou was aspirated and divided into three sterile 
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microtubes. To ensure sterility, a specimen of supernatant from each bijou was plated onto 
four different agar plates each- fresh blood agar, heated blood agar, nutrient agar and 
Sabouraud dextrose agar which were then placed to culture. All plates except the latter 
were incubated at 37°C, the Sabouraud dextrose agar plate was incubated at 30°C. The 
extracts were stored at -20°C ready for use. Plates were inspected at 48 hours to confirm 
no growth had occurred. Subconfluent 3T3 cells (Passage [P] =13), BHK cells (P=12), 
porcine EC (P=2) and SMC (P=3) were subcultured into pre-labeled white 96 well tissue 
culture plates (n= 3 replicates). Cells were placed in labeled wells to test both extract 
samples and in wells for positive and negative controls. Cells were then incubated in 5% 
(v/v) CO2 at 37°C until approximately 80% confluent. On the day of the assay, the extracts 
were defrosted ready for use. The medium was aspirated from each well in the culture 
plate and replaced with 100 µl of culture medium containing twice the normal FBS 
concentration (110 ml ; Section 2.2). For the medium-only controls, 200 µl of culture 
medium was placed into each set of wells (Section 2.2). Each extract (100 µl) was then 
placed into labeled wells in the well plate. Culture media (100 µl) was placed in labeled 
wells together with 100 µl of DMSO for the positive control. The plate was then incubated 
for 48 hours in 5% (v/v) CO2 in air at 37°C. After incubation, the well-plate was ready for 
the ATPLite-M assay to quantify ATP levels. 
ATPLite-M reagents were equilibrated to room temperature. The lyophilised substrate 
solution was reconstituted by adding 5 ml of substrate buffer. The contents of all wells 
were then aspirated and replaced with 50 µl of DMEM. Following this, 50 µl of mammalian 
cell lysis solution was then added to each well and agitated at 500 rpm for five minutes. 
Following agitation, 50 µl of substrate solution was added to each test well and again 
agitated at 500 rpm for five minutes. After agitation, luminescence was determined using 
TopCount. Data (counts per second) was analysed using one-way ANOVA. 
3.4.4.2 Contact cytotoxicity assay 
This procedure describes the process of assessing the cytotoxicity of decellularised 
porcine carotid artery using adherent 3T3 cells, BHK cells, porcine EC and SMC compared 
to collagen type I and cyanoacrylate contact adhesive. This assay tests for any toxic 
components leeching from the intact tissue. The procedure was performed using full 
aseptic precautions within a class II safety cabinet.   
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Three 10 mm2 sections from two separate decellularised arteries from batch 4 were cut 
using a scalpel and placed in sterile DPBSa to prevent dehydration. For the positive 
control, a drop of cyanoacrylate contact adhesive was placed into the centre of one well in 
a six-well plate. As the negative control, 20 µl of collagen gel neutralized with 10 µl of 
sodium hydroxide (0.1 M) was placed into the centre of a well within a six well plate. One 
of the square sections of artery was then placed into the centre of one of the wells using 
the collagen gel and sodium hydroxide as an adhesive (2:1 ratio). All wells were then 
washed three times for ten minutes using sterile DPBSa. 3T3 cells (P=13) were harvested 
from culture and suspended in culture medium . 3T3 cells (1 ml) were then added to each 
well. Cells were then incubated in 5% (v/v) CO2 in air at 37°C for 48 hours. The whole 
process was repeated using BHK cells (P=12) and porcine EC (P=2) and SMC (P=3). 
Following incubation, the plates were examined under a microscope and examined for 
changes in cell morphology and density. Medium was then aspirated from the wells which 
were then washed with sterile DPBS containing calcium and magnesium. 
The cell layers were then fixed using 10% (v/v) neutral buffered formalin for ten minutes. 
Following fixation, the formalin was removed and then the cell layer was stained using 
Giemsa solution for five minutes. Each well was then rinsed in running tap water until it ran 
clear. The plate was then left to air dry. Once dry, the plate was again examined using 
microscopy for changes in cell morphology and density and for cell growth to the edges of 
the arterial specimen. Images were then taken using a digital microscope.  
3.5 Results  
3.5.1 Histological evaluation of decellularised porcine carotid arteries [Batches 1-3] 
The first three batches of treated arteries were incompletely decellularised. Figure (3) 
shows H&E and DAPI staining of representative samples from batches 1-3 confirming the 
presence of cell nuclei remaining in all three arterial layers as compared to controls, 
although the cell density in each layer was less then untreated controls.  
87 
 
  
  
 
 
 
 
  
Figure 3. Representative sections of porcine arteries from decellularisation Batches 
1-3 stained with H&E and DAPI. A; Fresh PCA (H&E), B; Treated PCA (H&E). Both 
micrographs clearly demonstrate the presence of cell nuclei through all layers of the 
arterial wall in both control and treated specimens. C; Fresh PCA (DAPI), D; Treated PCA 
(DAPI). DAPI staining confirms the presence of DNA (indicating cellular nuclear material) 
again through all layers of the arterial wall in both control and treated specimens.  
 
3.5.2 Total DNA content of decellularised porcine carotid arteries [Batches 1-3] 
Unsurprisingly, only an average DNA removal of 12-28% was achieved during the first 
three decellularisation batches (Figure 4), which was well below the target of >90% DNA 
removal. 
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Figure 4. DNA content of fresh and decellularised porcine carotid artery from 
Batches    1-3.  Data is expressed as the mean [n=6 (two decellularised arteries and two 
control arteries from each batch tested) ± 95% confidence limits].  End; end of artery, Mid; 
middle of artery. 
3.5.3 Histological evaluation of decellularised porcine carotid arteries [Batches 4-8] 
Following analysis of the histological sections from batches 1-3, it was felt that the failure 
to decellularise was as a result of insufficient detergent (SDS) activity on the cell 
membranes, most likely as a result of error in preparing the SDS solution. The error was 
likely as a result of the filtration step where SDS is passed through a 0.2µm filter. To 
confirm whether it was an error with filtration of the SDS, it was decided to add 1g of SDS 
powder directly into one litre of sterile hypotonic buffer. Following this modification, the 
following five subsequent decellularisation batches all demonstrated successful 
decellularisation of arteries and so this method of SDS production was adopted throughout 
the rest of the study. As can be seen in Figures (5) and (6), H&E staining of the end and 
middle sections of representative samples from batchs 4-8 demonstrate a complete lack of 
cell nuclei in all three arterial layers, confirming successful decellularisation. 
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Figure 5. Representative end sections of porcine arteries from decellularisation 
Batches 4-8 stained with H&E. A; Fresh PCA (H&E) demonstrating the presence of 
nuclear material in all arterial layers, B; Decellularised PCA (H&E) Batch 4, C; 
Decellularised PCA (H&E) Batch 5, D; Decellularised PCA (H&E) Batch 6, E; 
Decellularised PCA (H&E) Batch 7, F; Decellularised PCA (H&E) Batch 8. Micrographs B-
F demonstrate a lack of cell nuclei in all layers of the arterial wall, representing successful 
decellularisation.  
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Figure 6. Representative middle sections of porcine arteries from decellularisation 
Batches 4-8 stained with H&E. A; Fresh PCA (H&E) demonstrating the presence of 
nuclear material in all arterial layers, B; Decellularised PCA (H&E) Batch 4, C; 
Decellularised PCA (H&E) Batch 5, D; Decellularised PCA (H&E) Batch 6, E; 
Decellularised PCA (H&E) Batch 7, F; decellularised PCA (H&E) Batch 8. Micrographs B-F 
demonstrate a lack of cell nuclei in all layers of the arterial wall, representing successful 
decellularisation. 
DAPI staining of the end and middle sections of representative samples from batchs 4-8 
also demonstrated a complete lack of cell nuclei in all three arterial layers, confirming 
 F  E 
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successful decellularisation (Figures 7-8). Autofluorescence was seen secondary to 
residual SDS within the ECM of the scaffolds following the decellularisation process.  
  
  
  
  
  
  
Figure 7. Representative end sections of porcine arteries from decellularisation 
Batches 4-8 stained with DAPI. A; Fresh PCA (DAPI) demonstrating the presence of 
nuclear material in all arterial layers, B; Decellularised PCA (DAPI) Batch 4, C; 
Decellularised PCA (DAPI) Batch 5, D; Decellularised PCA (DAPI) Batch 6, E; 
Decellularised PCA (DAPI) Batch 7, F; Decellularised PCA (DAPI) Batch 8. Micrographs 
B-F demonstrate a lack of nuclear staining (cell nuclei) in all layers of the arterial wall, 
representing successful decellularisation. 
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Figure 8. Representative middle sections of porcine arteries from decellularisation 
Batches 4-8 stained with DAPI. A; Fresh PCA (DAPI) demonstrating the presence of 
nuclear material in all arterial layers, B; Decellularised PCA (DAPI) Batch 4, C; 
Decellularised PCA (DAPI) Batch 5, D; Decellularised PCA (DAPI) Batch 6, E; 
Decellularised PCA (DAPI) Batch 7, F; Decellularised PCA (DAPI) Batch 8. Micrographs 
B-F demonstrate a lack of nuclear staining (cell nuclei) in all layers of the arterial wall, 
representing successful decellularisation. 
3.5.4 Total DNA content of decellularised porcine carotid arteries [Batches 4-8] 
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Following the modification of the SDS step in the decellularisation protocol, an average 
DNA removal of 90-99% was achieved during the last five decellularisation batches, 
successfully reaching the target of >90% DNA removal (Figure 9). 
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Figure 9. DNA content of fresh and decellularised porcine carotid artery from 
(representative) Batch 7. Data is expressed as the mean [n=3 (three decellularised 
arteries and three control arteries) ± 95% confidence limits. * Significantly different to 
control (Student’s t-test)].  End; end of artery, Mid; middle of artery. 
 
3.5.5 Summary of results for decellularised porcine carotid arteries [Batches 1-8] 
Characterisation of arteries from the first three batches of arteries confirmed a lack of 
decellularisation likely as a result of ineffective detergent activity on the cell membranes 
(Figures 3-4). Following modification of the SDS step, the subsequent five batches of 
arteries were all successfully decellularised (Figures 5-9).    
The data from the analysis of eight batches of arteries subject to decellularisation are 
presented in Table (8). The means of the controls for both mid and end sections (for each 
separate batch) were used to calculate the percentage DNA removal. It can be seen that 
  *            * 
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once the decellularisation process was successful (Run’s 4 and onwards), the target DNA 
removal rate of ≥ 90% was achieved (range 90-99.5%). 
Decellularisation Batch Arterial 
Portion 
H & E DAPI Mean DNA 
content 
(µg.mg-1) n=3 
% DNA 
removal 
1 (Control artery 1) End + + 0.5 - 
1 (Control artery 1) Mid + + 0.38 - 
1 (Control artery 2) End + + 1.14 - 
1 (Control artery 2) Mid + + 0.57 - 
1 (Decell artery 1) End + + 0.72 12.2 
1 (Decell artery 1) Mid + + 0.34 28 
1 (Decell artery 2) End + + 0.03 97 
1 (Decell artery 2) Mid + + 0.87 0 
2 (Control artery 1) End + + 0.34 - 
2 (Control artery 1) Mid + + 0.29 - 
2 (Control artery 2) End + + 0.37 - 
2 (Control artery 2) Mid + + 0.37 - 
2 (Decell artery 1) End + + 0.44 0 
2 (Decell artery 1) Mid + + 0.47 0 
2 (Decell artery 2) End + + 0.44 0 
2 (Decell artery 3) End + + 0.27 25 
2 (Decell artery 4) End + + 0.35 3 
3 (Control artery 1) End + + 0.50 - 
3 (Control artery 1) Mid + + 0.49 - 
3 (Control artery 2) End + + 0.73 - 
3 (Control artery 2) Mid + + 0.66 - 
3 (Decell artery 1) End + + 1.08 0 
3 (Decell artery 1) Mid + + 0.72 0 
3 (Decell artery 2) End + + 0.71 0 
3 (Decell artery 2) Mid + + 0.66 0 
4 (Control artery 1) End + + 0.75 - 
4 (Control artery 1) Mid + + 0.64 - 
4 (Control artery 2) End + + 0.6 - 
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4 (Control artery 2) Mid + + 0.7 - 
4 (Decell artery 1) End - - 0.06 91 
4 (Decell artery 1) Mid - - 0.04 94 
4 (Decell artery 2) End - - 0.06 91 
4 (Decell artery 2) Mid - - 0.07 90 
5 (Control artery 1) End + + 0.74 - 
5 (Control artery 1) Mid + + 0.66 - 
5 (Control artery 2) End + + 0.59 - 
5 (Control artery 2) Mid + + 0.82 - 
5 (Decell artery 1) End - - 0.01 98.5 
5 (Decell artery 1) Mid - - 0.02 97.3 
5 (Decell artery 2) End - - 0.02 97 
5 (Decell artery 3) End - - 0.02 97.3 
5 (Decell artery 4) End - - 0.01 98.5 
5 (Decell artery 5) End - - 0.05 92.5 
5 (Decell artery 6) End - - 0.03 95.5 
6 (Control artery 1) End + + 0.64 - 
6 (Control artery 1) Mid + + 0.34 - 
6 (Control artery 2) End + + 0.99 - 
6 (Control artery 2) Mid + + 0.86 - 
6 (Decell artery 1) End - - 0.03 96.3 
6 (Decell artery 1) Mid - - 0.03 95 
6 (Decell artery 2) End - - 0.005 99.4 
6 (Decell artery 2) Mid - - 0.003 99.5 
6 (Decell artery 3) End - - 0.02 97.5 
6 (Decell artery 4) End - - 0.02 97.5 
6 (Decell artery 5) End - - 0.03 96.3 
6 (Decell artery 6) End - - 0.005 99.4 
6 (Decell artery 7) End - - 0.03 96.3 
7 (Control artery 1) End + + 0.5 - 
7 (Control artery 1) Mid + + 0.75 - 
7 (Control artery 2) End + + 0.72 - 
7 (Control artery 2) Mid + + 0.63 - 
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7 (Decell artery 1) End - - 0.02 96.7 
7 (Decell artery 1) Mid - - 0.01 98.5 
7 (Decell artery 2) End - - 0.02 96.7 
7 (Decell artery 2) Mid - - 0.004 99.4 
7 (Decell artery 3) End - - 0.01 98.3 
7 (Decell artery 4) End - - 0.02 96.7 
7 (Decell artery 5) End - - 0.02 96.7 
7 (Decell artery 6) End - - 0.01 98.3 
7 (Decell artery 7) End - - 0.04 93.5 
7 (Decell artery 8) End - - 0.04 93.5 
7 (Decell artery 9) End - - 0.02 96.7 
7 (Decell artery 10) End - - 0.05 92.2 
7 (Decell artery 11) End - - 0.04 93.5 
7 (Decell artery 12) End - - 0.04 93.5 
7 (Decell artery 13) End - - 0.003 99.5 
7 (Decell artery 14) End - - 0.04 93.5 
7 (Decell artery 15) End - - 0.03 95 
7 (Decell artery 16) End - - 0.01 98.3 
7 (Decell artery 17) End - - 0.007 98.9 
7 (Decell artery 18) End - - 0.02 96.7 
7 (Decell artery 19) End - - 0.04 93.5 
7 (Decell artery 20) End - - 0.006 99 
8 (Control artery 1) End + + 0.62 - 
8 (Control artery 1) Mid + + 0.76 - 
8 (Control artery 2) End + + 0.59 - 
8 (Control artery 2) Mid + + 0.75 - 
8 (Decell artery 1) End - - 0.03 95.1 
8 (Decell artery 1) Mid - - 0.05 93.5 
8 (Decell artery 2) End - - 0.02 96.7 
8 (Decell artery 2) Mid - - 0.02 97.4 
8 (Decell artery 3) End - - 0.02 96.7 
8 (Decell artery 4) End - - 0.05 92 
8 (Decell artery 5) End - - 0.03 95 
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8 (Decell artery 6) End - - 0.03 95 
8 (Decell artery 7) End - - 0.04 93.5 
8 (Decell artery 8) End - - 0.01 98.4 
8 (Decelll artery 9) End - - 0.04 93.5 
8 (Decell artery 10) End - - 0.02 97.4 
8 (Decell artery 11) End - - 0.03 95 
8 (Decell artery 12) End - - 0.04 93.5 
8 (Decell artery 13) End - - 0.04 93.5 
8 (Decell artery 14) End - - 0.04 93.5 
8 (Decell artery 15) End - - 0.03 95 
8 (Decell artery 16) End - - 0.05 93.5 
8 (Decell artery 17) End - - 0.05 93.5 
8 (Decell artery 18) End - - 0.04 93.5 
8 (Decell artery 19) End - - 0.03 95 
8 (Decell artery 20) End - - 0.03 95 
8 (Decell artery 21) End - - 0.03 95 
8 (Decell artery 22) End - - 0.05 93.5 
 
Table 8. Characterisation of fresh and decellularised arteries from eight different 
batches. ( +ve = H & E or DAPI staining confirmed presence of cell nuclei; -ve = H & E or 
DAPI staining confirmed absence of cell nuclei).   
 
3.5.6 Biocompatibility of decellularised porcine carotid arteries  
3.5.6.1 Extract biocompatability 
Prior to performing the extract biocompatibility assays, extract samples from 
decellularisation run 5 were plated on agar and incubated to confirm a lack of gross 
microbial contamination.  Following 48 hours incubation, no visible bacterial or fungal 
growth was seen on the fresh blood agar, heated blood agar, nutrient agar and Sabouraud 
dextrose plates (Figure 10). 
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Figure 10. Agar plates with representative samples of decellularised arterial extracts 
from decellularisation run 5. A; Sabouraud dextrose agar, B; Nutrient agar, C; Fresh 
blood agar, D; Heated blood agar. All plates demonstrated a lack of microbial growth at 48 
hours.   
The extracts were then tested for their effects on the growth of BHK cells, 3T3 cells and 
porcine EC and SMC over 48 hours. Cell growth was assessed by ATP assay. No 
significant difference (one-way ANOVA) was seen in ATP levels (n = 3 replicates 
[decellularised arteries 1-3]) between the extracts and the negative control (normal cells in 
cell-specific medium) confirming a lack of cytotoxicity of any soluble components of the 
arteries to BHK cells, 3T3 cells porcine EC and SMC. Significant differences were seen 
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with the positive control and medium-only wells compared to the negative control following 
statistical analysis using one-way ANOVA and post hoc testing (Figures 11-14).  
 
 
 
 
Figure 11. Extract cytotoxicity of decellularised PC arteries to 3T3 cells. Data 
represents mean values ± 95 % confidence limits (n = 3 replicates). * Significantly lower 
than negative control (one-way ANOVA and post hoc testing p < 0.05).   
 
 
 
 
 
 
*              * 
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Figure 12. Extract cytotoxicity of decellularised PC arteries to BHK cells. Data 
represents mean values ± 95 % confidence limits (n = 3 replicates). * Significantly lower 
than negative control (one-way ANOVA and post hoc testing p < 0.05).   
 
 
 
 
 
 
 
 
*              * 
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Figure 13. Extract cytotoxicity of decellularised PC arteries to porcine endothelial 
cells. Data represents mean values ± 95 % confidence limits (n = 3 replicates). * 
Significantly lower than negative control (one-way ANOVA and post hoc testing p < 0.05).   
 
 
 
 
 
 
 
 
  *      * 
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Figure 14. Extract cytotoxicity of decellularised PC arteries to porcine smooth 
muscle cells. Data represents mean values ± 95 % confidence limits (n = 3 replicates). * 
Significantly lower than negative control (one-way ANOVA and post hoc testing p < 0.05).   
 
3.5.6.2 Contact Biocompatability 
All contact assays demonstrated clear growth of cells to the arterial edges with no evident 
change in cellular morphology. The results demonstrated a lack of cytotoxicity of the 
decellularised arteries to 3T3 cells, BHK cells and porcine EC and SMC (Figures 15-18). 
In Figure (15), clear growth is visible to the edge of the artery (B) with retention of the 
spindle-shaped appearance and size typical of 3T3 monolayers, as seen in 
photomicrograph A. Confluent growth is visible across collagen gel (C), again 
demonstrating a spindle-shaped appearance of the cells. No cell growth is visible near 
cyanoacrylate (D).    
   
*       *     
**    
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Figure 15. Contact cytotoxicity of decellularised PC arteries to 3T3 cells. A; 3T3 cells 
in culture demonstrating spindle-shaped morphology, B; Decellularised artery, C; Collagen 
gel, D; Cyanoacrylate. 
In Figure (16), clear growth is visible to the edge of the artery in (B) with retention of the 
cobblestone appearance and size typical of BHK monolayers as seen in photomicrograph 
A. Confluent growth is visible across collagen gel (C), again demonstrating a cobblestone 
appearance of the cells. No cell growth is visible near cyanoacrylate (D). 
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Figure 16. Contact cytotoxicity of decellularised PC arteries to BHK cells. A; BHK 
cells in culture demonstrating cobblestone appearance, B; Decellularised artery, C; 
Collagen gel, D; Cyanoacrylate. 
In Figure (17), clear growth is visible to the edge of the artery in (B) with retention of the 
cobblestone appearance and size typical of EC monolayers, as seen in photomicrograph 
A.  Confluent growth is visible across collagen gel (C), again demonstrating a cobblestone 
appearance of the cells. No cell growth is visible near cyanoacrylate (D). 
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Figure 17. Contact cytotoxicity of decellularised PC arteries to porcine endothelial 
cells. A; PC EC in culture demonstrating cobblestone appearance, B; Decellularised 
artery, C; Collagen gel, D; Cyanoacrylate. 
In Figure (18), clear growth is visible to the edge of the artery in (B) with retention of the 
spindle-shaped appearance and size typical of SMC monolayers, as seen in 
photomicrograph A. Confluent growth is visible across collagen gel (C), again 
demonstrating a spindle-shaped appearance of the cells. No cell growth is visible near 
cyanoacrylate (D). 
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Figure 18. Contact cytotoxicity of decellularised PC arteries to porcine smooth 
muscle cells. A; Porcine SMC in culture demonstrating spindle-shaped morphology, B; 
Decellularised artery, C; Collagen gel, D; Cyanoacrylate.  
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3.6 Discussion 
The aim of decellularisation is to remove all cellular and nuclear material from a tissue, 
whilst, minimising disruption of scaffold architecture and preserving components of the 
ECM. The technique developed by iMBE involves physical, chemical and enzymatic 
methods.   
After a minor modification in the production of the SDS solution, all subsequent 
decellularisation runs resulted in acellular scaffolds, confirmed by histological absence of 
cell nuclei and DNA quantification. A small amount of residual SDS was retained within the 
ECM following decellularisation and this was responsible for the autofluorescence seen 
within the scaffolds following DAPI staining. The amount of SDS retained in decellularised 
tissues is small however and well below cytotoxic levels (Gratzer et al., 2006).      
Histological assessment of the acellular scaffolds also confirmed excellent preservation of 
the histioarchitecture of the scaffold with a tri-layer structure remaining intact following the 
decellularisation process. Demonstrating the preservation of the remaining ECM was 
important for two reasons, firstly, the ECM contains the structural proteins that will give the 
artery biomechanical strength (e.g. elastin, collagen, laminin). Secondly, an intact ECM is 
essential for future re-cellularisation of the scaffolds as vascular cells will adhere to the 
ECM via integrin binding. Integrins are transmembrane glycoproteins found on the surface 
of cells, the ligands of which include collagen, fibronectin and laminin. They have many 
functions in addition to mediating cell-ECM binding, they are also important in signal 
transduction pathways that regulate the migration and proliferation of cells (Kokubo et al., 
2007).          
Decellularisation of batches 4-8 of arteries resulted in removal rate of 90% or greater 
porcine DNA levels. Removal of remnant DNA is important for several reasons, most 
importantly to prevent an innate reaction following implantation into a xenogeneic recipient 
[ECM components share close sequence homology across species and are therefore 
immune-tolerated (Gilbert et al., 2006)]. Furthermore, retainment of large fragments of 
DNA within the scaffold could incite calcification within the scaffold matrix leading to a 
marked effect on the biomechanical durability and function of the scaffold (Wilshaw et al., 
2011). Many decellularisation protocols exist within the literature and most utilise physical, 
mechanical, osmotic, enzymic and detergent based treatments. The iMBE protocol uses 
all modalities and has shown effective decellularisation of a number of tissues (Booth et 
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al., 2002, Wilcox et al., 2003, Wilshaw et a.l, 2006, Derham et al., 2008), now including 
porcine carotid artery.  
Decellularised scaffolds were assessed for and found to be biocompatible with ISO 
standard cell lines and primary porcine vascular cells. Porcine cells were used in the 
assays in addition to cell lines as they could provide initial data on scaffold biocompatibility 
to primary [vascular] cell lines, and in particular, to the primary vascular cells originating 
from the pre-treated decellularised scaffold. Ensuring the scaffolds were biocompatible 
was essential to ensure that the decellularisation process had not inferred any toxicity to 
the acellular scaffolds.     
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Chapter 4 
Ovine vascular cell characterisation 
4.1 Introduction 
The importance of an endothelial lining and presence of SMC in providing a TEVG with 
antithrombotic characteristics and functionality has been discussed in Chapter 1. Given 
that the decellularised scaffolds are of porcine origin, it was important to attempt cell 
seeding of the scaffolds with cells from a different species to investigate the 
biocompatibility of the scaffold to xenogeneic vascular cells. When deciding on a species 
for testing a vascular scaffold, several important factors must be taken into account. Cost 
is always important in research, animals such as sheep and pigs are more economical 
compared to non-human primates and canines. Secondly, for the assessment of 
thrombogenicity, the haematology and haemodynamics of the species must either be 
comparable to that of the human circulation or possess key attributes that highlight either 
limitations or superiority of the vascular scaffold. Sheep have a clotting system that is 
closer to that of a human when compared to canines and pigs (Konya et al., 2008). They 
also possess similar systolic and diastolic blood pressures and heart rates (Bianco et al., 
2004). The ovine circulation possesses a higher number of platelets with high 
adhesiveness compared to many species, including human                                              
(3-8 x 105.ml-1 vs 2-5 x 105.ml-1). Furthermore, the fibrinolytic system in sheep is less 
pronounced than human. The net effect of these differences is that the ovine circulation is 
more coaguable than the human circulation (Gross, 1994; Bianco et al., 2004). This fact is 
important when assessing the antithrombogenic attributes of a vascular graft following 
implantation, as if indeed the scaffold does display antithrombogenic efficacy in a 
hypercoaguable circulation, it may be predicted to do so in a lesser coaguable system i.e. 
human.         
Very little work has been performed on the characterisation of ovine vascular cells in the 
literature. Almost all research has involved the use of primary antibodies to specific cell 
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markers. Furthermore, many of the antibodies are manufactured for reactivity to epitopes 
expressed in humans and other species, and cross-reactivity to ovine cells is often 
unknown. In reviewing the literature available for ovine cell characterisation, 
unsurprisingly, anti-VWF was the most commonly used antibody to identify EC in view of 
its specificity. For SMC, anti-SMC α-actin was the most commonly used antibody (Abdi et 
al., 1995; Grooby et al., 1997; Afting et al., 2003; Zhao et al., 2010). 
Other markers that have been used successfully for vascular ovine cell characterisation 
are listed below in Table (9).  
Cell marker Function Antibody (Ab) Authors 
Smooth Muscle 
Myosin Heavy Chain 
(MHC-B) 
Biomarker for SMC 
proliferation 
             _ Hutanu et al., 2007  
VCAM-1 (CD31) Vascular cell adhesion  Mouse anti-human  Ab to 
VCAM-1 (IgG1) 
Grooby et al., 1997  
P-selectin (CD62P) Vascular cell adhesion  Mouse anti-human Ab to P-
Selectin (IgG1) 
Grooby et al., 1997  
CD29 (Integrin β1 
subunit) 
Cell adhesion molecule Anti-CD29 Mouse IgG Grooby et al., 1997  
 
Table 9. Antibodies that have shown specificity for ovine vascular cells in the 
literature (SMC=smooth muscle cell, VCAM= vascular cell adhesion molecule, Ab= 
antibody, Ig= Immunoglobulin, CD = cluster of differentiation).  
Morphological appearances have also been used for EC characterisation. EC at 
confluence are often described as being ‘cobblestone’ in appearance (Abdi et al., 1995; 
Grooby et al., 1997; Ovine fibroblasts commonly contaminate EC populations, however 
they can be differentiated from EC by their elongated shape and swirling growth pattern 
(Grooby et al., 1997). Based on research in the literature, antibody stocks and traditional 
EC and SMC markers known for humans, characterisation was performed using indirect 
immunofluorescence to identify antibodies that could be used to confirm correct cell 
phenotype (Blann et al, 2003; Orrico et al., 2010).   
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4.2 Aims and Objectives 
The aim of this chapter was to determine the phenotype of isolated ovine vascular cells 
using indirect immunofluorescence. The objectives were:  
1)  To isolate ovine vascular cells (EC and SMC) from ovine superficial femoral arteries  
2)  To develop a protocol to phenotype ovine EC and SMC. 
3)  To determine and ensure the purity of harvested ovine cells. 
4)  To investigate the biocompatibility of the decellularised PC arteries to ovine vascular 
cells 
4.3 Materials and Methods 
All equipment, reagents, materials and solutions used in the study are listed in Chapter 2. 
Three separate characterisation experiments using ovine vascular cells were performed in 
the study. 
4.3.1 Tissue procurement and preparation 
Four fresh ovine hind-legs (male, Texel breed, aged approximately ten months) were 
delivered by a local abattoir (John Penny & Sons, Leeds, UK) immediately following 
slaughter. The superficial femoral artery from each leg was harvested using sterile 
dissecting instruments within a class II safety cabinet to minimise contamination.  Once 
excised, the arteries were placed immediately into sterile DPBSa to wash away any 
adherent clot or tissue debris. Arteries were then incubated in antibiotic solution (DPBSa, 
streptomycin 300 U.ml-1, 300 U.ml-1 penicillin) at 37°C for two hours. Four arteries in total 
were used during the study.  
Ovine vascular cells were isolated twice using the techniques described in Section 2.8. 
Figure (19) demonstrates the appearance of the isolated ovine vascular cells in culture. 
Photomicrograph A demonstrates the typical cobblestone monolayer appearance of EC in 
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culture. Photomicrograph B demonstrates the typical spindle-shaped appearance of SMC 
in culture. 
  
 
Figure 19. Photomicrographs of isolated ovine EC and SMC in culture. A; Ovine EC 
in culture.  B; Ovine SMC in culture  
 
4.3.2 Characterisation of ovine vascular cells using indirect immunofluoresence  
Details of all reagents used in the study can be found in Chapter 2, Section 2.2. 
Multi-spot glass slides were cleaned with 70% (v/v) ethanol, covered in foil and then 
sterilised using dry heat. Confluent ovine SMC and EC were then harvested and 
centrifuged to obtain a cell pellet. The cells were then suspended in 1ml of medium with 20 
µl of the resulting cell suspension of each being subcultured onto the surface of each spot 
of the glass slide. Slides were then incubated for 48 hours at 37°C in 5% (v/v) CO2  in air 
using the appropriate culture medium for each cell type. After incubation, the culture 
medium was aspirated and the cells were fixed in acetone: methanol (1:1) for one minute. 
After being left to air dry for five minutes, the slides were then washed gently in running tap 
water for ten minutes. Following this, the slides were then washed in tris buffered saline 
(TBS) for five minutes. After washing, the cells were then ready to receive the primary or 
isotype control antibodies. Prior to adding antibody, each specific primary antibody was 
diluted to its working concentration using antibody diluent. Once the correct concentration 
B A 
113 
 
for each antibody was achieved, 20 µl of primary antibody solution was carefully placed 
onto each spot (see Table [10] and [11] for antibodies used with concentrations). Slides 
were then incubated in the dark, in a moist environment, at room temperature, for one 
hour. Following incubation, slides were washed twice for ten minutes in TBS-Tween using 
agitation at 40 rpm. Following this, slides were washed twice for ten minutes in TBS using 
agitation at 40 rpm. Following the washes, the fluorescently labelled secondary antibodies 
against the primary antibodies were diluted to their working concentration using antibody 
diluents (see Table [12] for secondary antibodies used). Once the correct concentration for 
each antibody was achieved, 20 µl of fluorescently labelled antibody solution was carefully 
placed onto each spot. Slides were then incubated in the dark, in a moist environment, at 
room temperature, for thirty minutes. Following incubation, slides were washed twice for 
ten minutes in TBS-Tween using agitation at 40 rpm. Following this, slides were washed 
twice for ten minutes in TBS using agitation at 40 rpm. Following washes, the slides were 
then placed into 200 ml of DAPI dye buffer to counterstain the cells. The slides were 
incubated with the DAPI dye buffer for ten minutes in the dark. Following incubation, each 
slide was washed three times in DPBSa for ten minutes, again in the dark. After washing, 
slides were mounted with a glass cover slip using DABCO: glycerol mountant. Slides were 
then viewed as soon as possible using an upright fluorescent microscope and a DAPI 
filter. Images were captured in black and white using a digital camera. Image- Pro Plus v 
5.1. software was then used to colour anti-actin and anti-myosin antibody staining red and 
all other antibodies green. The primary and secondary antibodies used in the 
characterisation of ovine cells from ovine vascular cell isolation run one and two are shown 
in Table’s (10-12).  
Antigen Type Isotype Dilution Positive Control  tissue  
CD31 
 
Mouse anti-human IgG1κ 1:20 Porcine EC 
VWF Rabbit anti-human Polyclonal 1:200 Porcine EC 
α-Smooth Muscle Actin Mouse (PAN) 
antibody 
IgG1 1:400 Porcine SMC 
Smooth Muscle Myosin 
(Heavy Chain) 
Mouse anti- human IgG1 1:100 Porcine SMC 
Isotype Control 
 
Mouse IgG1  1:20 - 
 
Table 10. Details of primary antibodies used in the characterisation of cells from 
isolation run one (CD= cluster of differentiation, Ig= immunoglobulin, EC= endothelial 
cell, SMC= smooth muscle cell, VWF= von Willebrand factor).  
114 
 
 
Antigen Type Isotype Dilution +ve control  tissue 
CD31: FITC 
 
Mouse anti-sheep IgG2 1:10 Ovine EC 
VWF Rabbit anti-human Polyclonal 1:200 Porcine EC 
α-Smooth Muscle Actin Mouse (PAN) 
antibody 
IgG2 1:400 Porcine SMC 
Smooth Muscle Myosin 
(Heavy Chain) 
Mouse anti- human IgG1 1:100 Porcine SMC 
Isotype Control 
 
Mouse IgG1  1:20 - 
Isotype Control Mouse IgG2 1:20 - 
 
Table 11. Details of primary antibodies used in the characterisation of cells from 
isolation run two (CD= cluster of differentiation, FITC= fluorescein isothiocyanate, Ig= 
immunoglobulin, EC= endothelial cell, SMC= smooth muscle cell, VWF= von Willebrand 
factor). 
Type Conjugate Isotype Dilution 
Goat anti-mouse: FITC 
 
Alexa Fluor 488 IgG 1:200 
Goat anti-rabbit: FITC 
 
Alexa Fluor 488 IgG 1:200 
 
Table 12. Details of secondary antibodies used in all characterisation runs (Ig= 
immunoglobulin). 
4.3.3 Purification of ovine vascular cells using magnetic bead separation 
All methods were performed using full aseptic precautions in a class II safety cabinet.  
Ovine EC and SMC were placed into suspension using techniques described in Section 
2.7. Two sets of magnetic beads and one antibody were used: Anti-Sheep CD31: FITC 
antibody, Anti-FITC Microbeads and Anti-Fibroblast Microbeads. As characterisation 
demonstrated mixed ovine SMC and EC, an Anti-Sheep CD31: FITC antibody and Anti-
FITC microbead was used to separate these two cell types. In addition, an Anti-Fibroblast 
microbead was used to deplete any fibroblasts contained within the cultures as they are 
known to commonly contaminate harvested vascular cell populations.     
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4.3.4 Fibroblast depletion of ovine SMC and ovine EC 
A buffer solution was prepared containing DPBSa, EDTA 2.7 mM and 0.5% (w/v) BSA. 
Ovine cells were diluted to a final density of 1 x 105 cells.ml-1 in cell-specific medium within 
a sterile universal. The cell suspension was then centrifuged for ten minutes at 100 xg. 
Supernatant was then discarded. The cell pellet was then resuspended in 80 μl of buffer 
solution. Next, 20 μl of Anti-Fibroblast Microbeads were added to the cell suspension and 
incubated for 30 minutes at room temperature. Cells were then washed by adding 1 ml of 
buffer and centrifuged at 100 x g for ten minutes. Supernatant was discarded and the cell 
pellet was then resuspended in 1 ml of buffer. The cell suspension was then loaded into a 
MACS® MS column which had been pre-washed with buffer and placed onto a magnetic 
MiniMACS® separator.  The suspension was then passed through the MACS® MS column 
and MiniMACS® separator with the (unlabelled, ovine vascular cell) effluent being collected 
below in a sterile bijou. For purity, the process was repeated three times using a separate 
MACS® MS column each time. Immediately following separation, the cells were placed into 
T75 flasks containing 10 ml of cell-specific medium and placed into culture until 
subconfluent. Flasks were examined to confirm cell growth. 
4.3.5 Purification of ovine SMC and ovine EC   
A buffer solution was prepared containing DPBSa, EDTA 2.7 mM and 0.5% BSA. Ovine 
cells were diluted to a final density of 1 x 105 cells.ml-1 in cell-specific medium within a 
sterile universal. The cell suspension was then centrifuged for ten minutes at 100 x g. 
Cells were then resuspended in 300 μl of buffer.  A 1:10 dilution of Anti-Sheep CD31:FITC 
Microbeads was made using the buffer solution. Then 10μl of Anti-Sheep CD31:FITC 
Microbeads / 100 μl cell suspension was added to the cell suspension (100 μl of cell 
suspension= 30 μl of Anti-Sheep CD31:FITC Microbeads ) and incubated in the dark at 
room temperature for 30 minutes. Cells were then washed by adding 2 ml of buffer and 
centrifuged at 300 x g for ten minutes to remove unbound Anti-Sheep CD31:FITC 
antibody. Supernatant was then discarded and the cell pellet was then resuspended in 270 
μl of buffer. Next, 30 μl of Anti-FITC Microbeads was added to the cell suspension and 
incubated at 4°C for 15 minutes on an orbital shaker. Following incubation, cells were 
washed by adding 2 ml of buffer and centrifuging at 300 x g for 10 minutes. Supernatent 
was then discarded and the cell pellet was resuspended in 500 μl buffer.  
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To isolate ovine SMC, the SMC cell suspension was loaded into a MACS® MS column 
which had been pre-washed with buffer and placed onto a magnetic MiniMACS® 
separator.  The suspension was then passed through the MACS® MS column and 
MiniMACS® Seperator with the (unlabelled, ovine SMC) effluent being collected below in a 
sterile bijou. For purity, the process was repeated three times using a separate MACS® MS 
column each time. Immediately following separation, the cells were then placed into a T75 
flask containing 10 ml of SMC medium and placed into culture until subconfluent. Flasks 
were examined to confirm cell growth. 
To isolate ovine EC, the EC cell suspension was loaded into a MACS® MS column which 
had been pre-washed with buffer and placed onto a magnetic MiniMACS® separator. The 
suspension was then passed through the MACS® MS column and MiniMACS® separator 
with the effluent (containing any potential ovine SMC) being discarded. The MACS® MS 
column (containing labeled ovine EC) was rinsed with 2 ml of EC culture medium three 
times to wash the isolated EC into a sterile universal. The EC cell suspension (6 ml) was 
placed into a T75 flask containing 4 ml of EC medium and placed into culture. Flasks were 
examined to confirm cell growth.  
4.3.6 Biocompatibility of porcine carotid arteries to ovine vascular cells 
Contact and extract cytotoxicity assays were performed once pure isolates of ovine SMC 
(P=4) and EC (P=4) were confirmed. The techniques used were identical to those 
described in Sections 3.4.4.1-3.4.4.2. 
4.4 Results 
4.4.1 Ovine vascular cell characterisation from cell isolation run one  
For the characterisation of isolated ovine cells from the first run, antibodies currently in 
laboratory stock were used to assess for any cross-reactivity to the sheep cells. The 
primary and secondary antibodies used in the characterisation of ovine cells from isolation 
run one are shown in Table’s (10) and (12).  
Figures (20-21) show a lack of reactivity of ovine SMC’s to conventional EC markers (anti-
CD31 and anti-VWF antibodies). Ovine EC demonstrated reactivity with anti-VWF antibody 
only. Positive staining to both markers in the positive controls (porcine EC) was seen. 
VWF was not expressed uniformly at all times by the Weibal-Palade bodies within EC, 
hence the scattered but characteristic positive staining pattern. No staining was seen in 
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the isotype control confirming lack of reactivity of the secondary antibody with the ovine 
vascular SMC.   
  
  
 
Figure 20. Indirect immunofluorescent antibody labelling with anti-CD31 antibody. A; 
Negative ovine SMC staining with anti- CD31, B; Negative ovine EC staining with anti-
CD31, C; Positive staining of porcine EC with anti-CD31, D; Isotype control.  
A B 
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Figure 21. Indirect immunofluorescent labeling with anti-VWF antibody. A; Negative ovine 
SMC staining with anti- VWF, B; Positive ovine EC staining with anti-VWF, C; Positive staining 
of porcine EC with anti-VWF, D; Isotype control.  
 
Figures (22-23) show reactivity of ovine SMC’s and the positive controls (porcine SMC) to 
conventional SMC markers [anti-SMC α-actin and anti-SMC Myosin (Heavy Chain) antibodies]. 
Negative staining to both markers was seen for ovine EC. No staining was seen in the isotype 
control confirming specific binding of antibody.  
A B 
C D 
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Figure 22. Indirect immunofluorescent antibody labelling with anti-SMC α-actin antibody. 
A; Positive ovine SMC staining with anti-SMC α-actin antibody, B; Negative ovine EC staining 
with anti-SMC α-actin antibody, C; Positive porcine SMC staining with anti-SMC α-actin, D; 
Isotype control.  
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Figure 23. Indirect immunofluorescent antibody labelling with anti-SMC Myosin 
(Heavy Chain) antibody. A; Positive ovine SMC staining with anti-SMC Myosin (Heavy 
Chain) antibody, B; Negative ovine EC staining with anti-SMC Myosin (Heavy Chain) 
antibody, C; Positive porcine SMC staining with anti-SMC Myosin (Heavy Chain) antibody, 
D; Isotype control.  
Results from the first characterisation experiments demonstrated that isolated cells 
showed positivity to traditional vascular cell markers e.g VWF for EC and actin and myosin 
A B 
D C 
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for SMC. Anti-CD31 did not cross react with ovine EC and this was not completely 
unexpected as the antibody data-sheet did not confirm goat or sheep cross-reactivity with 
the antibody. A second isolation run of ovine vascular cells was performed to confirm the 
isolation techniques were reproducible and to assess further primary antibodies for cross 
reactivity to ovine vascular cells in an attempt to demonstrate more robust confirmation of 
vascular cell phenotype. 
 
4.4.2 Ovine vascular cell characterisation from cell isolation run two 
 
An ovine specific anti-CD31 antibody was purchased and used to characterise the 
phenotype of isolated ovine EC. Figure (24) demonstrates confluent staining of ovine EC 
to anti-CD31 antibody. No staining was seen for the isotype control confirming specific 
binding of primary antibody. 
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Figure 24. Direct Immunofluorescent antibody labelling with anti-sheep-CD31 
antibody. A; Negative ovine SMC staining with antisheep-CD31 antibody, B; Positive 
ovine EC staining with antisheep-CD31 antibody, C; Isotype control.  
Ovine SMC’s once again demonstrated reactivity to anti-SMC α-actin and anti-SMC 
myosin (Heavy Chain) antibodies as in run one (Figures 25 and 27).  
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Figure (26) however demonstrated some positivity of the ovine EC isolates to anti-SMC 
myosin (Heavy Chain) antibody. As the results from both run one and two had confirmed 
specificity of the antibody for ovine SMC, the positive staining seen in this experiment was 
likely due to the presence of ovine SMC’s within the EC isolates confirming a mixed 
population of cells.  
  
  
Figure 25. Indirect immunofluorescent antibody labelling with anti-SMC myosin 
(Heavy Chain) antibody. A; Positive ovine SMC staining with anti-SMC myosin (Heavy 
Chain) antibody, B; Negative ovine EC staining with anti-SMC myosin (Heavy Chain) 
antibody, C; Positive porcine SMC staining with anti-SMC myosin (Heavy Chain) antibody, 
D; Isotype control. No staining is seen confirming specific binding of primary antibody. 
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Figure 26. Indirect immunofluorescent antibody labelling with anti-SMC myosin 
(Heavy Chain) antibody labeling against ovine EC.  Photomicrographs A-D all 
demonstrate negative staining of antibody for ovine EC but demonstrate positive staining 
of ovine SMC confirming a mixed population of both ovine EC and SMC. 
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Figure 27. Indirect immunofluorescent antibody labelling with anti-SMC α-actin 
antibody. A; Negative ovine EC staining with anti-SMC α-actin antibody, B; Positive ovine 
SMC staining with anti-SMC α-actin antibody, C; Positive porcine SMC staining with anti-
SMC α-actin, D; Isotype control. No staining is seen confirming specific binding of primary 
antibody.  
A B 
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Using antibodies that had been successfully used to identify ovine vascular cells in the 
literature and antibodies available in laboratory stock, a successful characterisation 
protocol was developed to identify both ovine SMC and EC. The results from cell isolation 
run two (the cells of which were for storage in liquid nitrogen for future studies) confirmed 
mixed cell populations. In an attempt to achieve pure cell isolates, it was decided to isolate 
cells using magnetic beads with bound (cell-specific) ligand and then re-characterise the 
cells using indirect immunofluoresence. Briefly, this involved incubating (ovine vascular) 
cell suspensions with magnetic beads bound with ligand and then passing the suspension 
through a magnetic column. This lead to either retention or depletion of a specific cell type 
based on the bound ligand. A more detailed description of magnetic bead separation is 
described in Section 4.3.3.    
4.4.3 Characterisation of ovine vascular cells following magnetic bead purification  
To assess whether magnetic bead separation had achieved pure cell isolates, cells were 
examined in culture for typical cellular morphology and underwent characterisation using 
immunofluoresence. 
As shown in Figure (28), separated ovine SMC successfully grew in culture (the typical 
spindle shaped monolayer appearance of SMC in culture was clearly evident). 
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Figure 28. Magnetic-bead separated ovine SMC in culture displaying typical 
morphological (spindle shaped) appearances.    
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Unfortunately, despite two attempts of magnetic bead separation, separated EC failed to 
survive in culture. This was either as a result of experimental error or toxicity to one of the 
reagents used in the experiments. The photomicrographs in Figure (29) clearly show a 
lack of cell adherence to the flask surface with dead cells visible within the medium. 
 
  
 
Figure 29. Appearance of ovine EC following 48 hours in culture post magnetic-bead 
separation. A; Ovine cells in culture following the first magnetic-bead separation. B; Ovine 
cells in culture following the second magnetic-bead separation.  
 
4.4.4 Characterisation of gifted ovine vascular cells  
To expedite progress of the study, a fellow (PhD) student within IMBE (Mr Robert Guilliatt), 
kindly gifted cultures of harvested pure isolates of ovine EC (P=4). To confirm pure 
isolates, gifted EC were scrutinised in the same manner as SMC, namely by morphological 
examination of cells in culture and by indirect immunofluoresence. The typical 
‘cobblestone’ monolayer appearances of the gifted ovine EC is shown in Figure (30). 
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Figure 30. Gifted ovine EC in culture displaying typical (cobblestone) morphological 
appearances.    
As the appearances of both SMC and EC displayed typical morphological appearances for 
their cell type, the cells then underwent characterisation using immunofluoresence to 
known reactive primary antibodies.   
Figures (31) demonstrates confluent staining of gifted ovine EC to anti-sheep CD31 
antibody. Figure (32) demonstrates clear, positive staining of the Weibal-Palade bodies 
present within EC to anti-VWF antibody. Both markers specific for EC demonstrated 
A 
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positivity thereby confirming the phenotype of gifted cells to be those of EC origin. No 
staining was seen in the isotype controls, confirming specific binding of primary antibody. 
 
  
 
 
 
 
Figure 31. Direct immunofluorescent antibody labelling with antisheep-CD31 
antibody. A; Negative ovine SMC staining with antisheep-CD31 antibody, B; Positive 
ovine EC staining with antisheep-CD31 antibody, C; Isotype control. 
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Figure 32. Indirect immunofluorescent antibody labelling with anti-VWF antibody. A; 
Negative ovine SMC staining with anti- VWF, B; Positive ovine EC staining with anti-VWF. 
C; Positive staining of porcine EC with anti-VWF, D; Isotype control.  
 
Figures (33-34) again show reactivity of ovine SMC’s and the positive controls (porcine 
SMC) to conventional SMC markers [anti-SMC α-actin and anti-SMC Myosin (Heavy 
Chain) antibodies]. Negative staining to both markers was seen in the ovine EC 
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populations confirming the presence of pure cell isolates. No staining was seen in the 
isotype control confirming specific binding of antibody.  
 
  
  
 
Figure 33. Indirect immunofluorescent antibody labelling with anti-SMC α-actin 
antibody. A; Positive ovine SMC staining with anti-SMC α-actin antibody, B; Negative 
ovine EC staining with anti-SMC α-actin antibody, C; Positive porcine SMC staining with 
anti-SMC α-actin, D; Isotype control.  
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Figure 34. Indirect immunofluorescent antibody labeling with anti-SMC Myosin 
(Heavy Chain) antibody. A; Positive ovine SMC staining with anti-SMC Myosin (Heavy 
Chain) antibody, B; Negative ovine EC staining with anti-SMC Myosin (Heavy Chain) 
antibody, C; Positive porcine SMC staining with anti-SMC Myosin (Heavy Chain) antibody, 
D; Isotype control.  
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4.4.5 Biocompatibility of porcine carotid arteries to ovine vascular cells 
4.4.5.1 Extract biocompatability 
Prior to performing the extract biocompatibility assays, extract samples from 
decellularisation run 5 were plated on agar and incubated to confirm a lack of gross 
microbial contamination.  Following 48 hours incubation, no visible bacterial or fungal 
growth was seen on the fresh blood agar, heated blood agar, nutrient agar and Sabouraud 
dextrose plates 
The extracts were tested for their effects on the growth of ovine EC and SMC over 48 
hours. Cell growth was assessed by ATP assay. No significant difference (one-way 
ANOVA) was seen in ATP levels (n = 3 replicates [decellularised arteries 4-6]) between 
the extracts and the negative control (normal cells in cell-specific medium) confirming a 
lack of cytotoxicity of any soluble components of the arteries to ovine EC and SMC. 
Although not significant, increased levels of ATP were seen in the presence of extract (2) 
for both ovine EC and SMC. Significant differences were seen with the positive control and 
medium-only wells compared to the negative control following statistical analysis using 
one-way ANOVA and post hoc testing (Figures 35 – 36).  
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Figure 35. Extract cytotoxicity of decellularised PC arteries to ovine endothelial 
cells. Data represents mean values ± 95 % confidence limits (n = 3 replicates). * 
Significantly lower than negative control (one-way ANOVA and post hoc testing p < 0.05).   
 
 
 
 
 *       * 
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Figure 36. Extract cytotoxicity of decellularised PC arteries to ovine smooth muscle 
cells. Data represents mean values ± 95 % confidence limits (n = 3 replicates). * 
Significantly lower than negative control (one-way ANOVA and post hoc testing p < 0.05).   
 
4.4.5.2 Contact biocompatability 
All contact assays demonstrated clear growth of cells to the arterial edges with no evident 
change in cellular morphology. The results demonstrated a lack of cytotoxicity of the solid 
components of the decellularised arteries to ovine EC and SMC (Figures 37-38).    
Figure (37) shows clear growth visible to the edge of the artery in (B) with retainment of 
the cobblestone appearance and size typical of EC monolayers, as seen in 
photomicrograph A. Confluent growth was visible across collagen gel (C), again 
demonstrating a cobblestone appearance. No cell growth was visible near cyanoacrylate 
(D). 
 
*       * 
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Figure 37. Contact cytotoxicity of decellularised PC arteries to ovine endothelial 
cells. A; Ovine  EC in culture demonstrating cobblestone appearance, B; Decellularised 
artery, C; Collagen gel, D; Cyanoacrylate.  
Figure (38) demonstrates clear growth visible to the edge of the artery in (B) with 
retainment of the spindle-shaped appearance and size typical of SMC monolayers, as 
seen in photomicrograph A. Confluent growth was visible across collagen gel (C), again 
demonstrating a spindle-shaped appearance. No cell growth was visible near 
cyanoacrylate (D). 
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Figure 38. Contact cytotoxicity of decellularised PC arteries to ovine smooth muscle 
cells. A; Ovine SMC in culture demonstrating spindle-shaped morphology, B; 
Decellularised artery, C; Collagen gel, D; Cyanoacrylate.  
 
4.5 Discussion 
It is intended that any future in vivo work with the decellularised PC artery will use an ovine 
model. To allow accurate experimentation with ovine vascular cells, it was essential to 
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confirm that harvested vascular cells were pure isolates with the correct vascular cell 
phenotype prior to commencing further tests. 
Standard, well described techniques were used to isolate vascular cells- collagenase 
degradation to release EC and the explant method of SMC migration onto a surface. 
Morphologically, both techniques appeared to successfully demonstrate the presence of 
ovine EC and SMC in culture. In the few experiments available in the literature on ovine 
vascular cell characterisation, indirect immunoflurescent antibody labeling was the primary 
technique used to confirm correct cell phenotype and so this was the method adopted in 
this study (Grooby et al., 1997; Orrico et al., 2010).  
Two well-known EC-specific cell markers are VWF and CD31 and as such were chosen as 
the primary markers to confirm EC phenotype. Von Willebrand factor is a large 
glycoprotein made within the Weibal-Palade bodies of mature EC (Orrico et al., 2010). It is 
intimately involved in platelet adhesion. In all characterisation experiments, anti-VWF 
antibody (rabbit anti-human) showed specificity to both porcine (positive control) and ovine 
EC, demonstrating that the sequence homology for VWF shares epitopes between 
mammalian species.    
CD31 also known as (PECAM-1) is a protein expressed in high amounts on the surface of 
endothelial cells and is involved in many processes related to angiogenesis and platelet 
function. In the first characterisation run, an anti-CD31 primary antibody (mouse anti-
human) was used with unknown specificity for ovine CD31. This antibody failed to bind to 
ovine EC cells confirming that sheep CD31 did not express the same epitope to human 
CD31. A similar finding has been seen in a previous work on ovine EC characterisation 
(Hoerstrup et al., 2000). In subsequent characterisation runs therefore, an ovine specific 
anti-CD31 antibody was purchased which did subsequently bind to and show specificity for 
ovine EC and was used for the remainder of the study.      
 
Based on evidence in the literature for the characterisation of vascular SMC (Abdi et al., 
1995; Grooby et al., 1997; Afting et al., 2003; Zhao et al., 2010) two antibodies were used 
to characterise the harvested ovine SMC, anti-SMC α-actin antibody and anti-SMC Myosin 
(Heavy Chain). SMC α-actin and SMC Myosin (Heavy chain) are filamentous proteins 
heavily involved in the contractility of smooth muscle and are highly conserved across 
species. In all characterisation experiments antibodies to both proteins demonstrated 
specificity to both porcine (positive control) and ovine SMC.     
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Unfortunately despite developing a successful characterisation protocol for ovine SMC and 
EC, the results from the first two characterisation runs did confirm mixed cell populations 
of both SMC and EC (Figure 26). This is a well-known and common complication seen 
when harvesting and isolating cells of all types, including vascular. For future seeding 
experiments to be accurate, it was essential that cell populations were pure. In order to 
achieve pure isolates, magnetic-bead separation was chosen as it is one of a number of 
established biochemical techniques used to achieve pure cell isolates. The technique itself 
is technically difficult and time-consuming. It was felt that attempting to purify existing 
harvested vascular cells that had been correctly identified by phenotype was a more 
sensible and time- saving approach than repeating (and subsequently re-characterising) 
numerous cell harvestings. It was decided to deplete fibroblasts from all populations in 
addition to producing pure cell isolates as it is well know that fibroblasts commonly 
contaminate harvested vascular cell populations. The results from magnetic bead 
separation were mixed. Magnetic bead separation of ovine EC was not successful as in 
both experiments, the ovine EC were non-viable following the experiment. This was likely 
secondary to experimental error or possible toxicity to the reagents used. Ovine SMCs did 
survive the process and were found to be pure isolates. It is difficult to say here accurately 
whether magnetic bead separation was successful at all, as characterisation experiments 
had only demonstrated contamination of EC populations with SMC and not vice versa i.e. 
harvested SMC populations may have been pure to begin with. Gifted ovine EC however 
were subsequently shown to be pure following characterisation.  
In future, if further cell isolation experiments were required, the approach used would be to 
use an alternate and ultimately more accurate technique for cell purification such as flow 
cytometry. In flow cytometry, a fluorescent cell sorter is used to seperate cells suspended 
in solution that have been antibody labelled, using laser detection.  
Table (13) below summarises the immune-reactivity of primary antibodies used in the 
study to characterise ovine EC and SMC. 
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Antibody Ovine EC Ovine SMC 
Anti-CD31: FITC + - 
Anti- Von Willebrand factor + - 
Anti-smooth muscle cell myosin (Heavy Chain) - + 
Anti-smooth muscle cell α-actin antibody - + 
 
Table 13. Demonstration of reactivity of laboratory stock and specifically purchased 
primary antibodies to ovine vascular cells. 
As pure isolates of both EC and SMC were available and phenotypically characterised, 
work could now continue on assessing the biocompatibility of ovine cells to the 
decellularised PCA scaffolds. Extract and contact cytotoxicity assays were used to assess 
the biocompatibility of the scaffolds.     
The acellular PCA scaffolds were biocompatible to both types of ovine vascular cells, an 
essential finding when considering that future in vivo work with the decellularised porcine 
carotid arteries will be based upon using an ovine animal model. Both extract and contact 
cytotoxicity assays clearly demonstrated a lack of cytotoxicity to the ovine cells of the solid 
and soluble components of the PC arteries. Following the successful purification of ovine 
vascular cell populations and their biocompatibility with decellularised PC arteries, it was 
then possible to begin re-cellularisation experiments. 
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Chapter 5 
Cell seeding of acellular porcine scaffolds using ovine vascular 
cells 
5.1 Introduction 
The importance of an endothelium lining and the benefits of dual-cell seeding with EC and 
SMC in the development of a vascular biological graft were discussed in detail in Chapter 
(1). Based on literature reports, a seeding density between 103-105 cells.ml-1 has been 
most often used for seeding both biological and synthetic small-diameter conduits [Chapter 
(1)]. It was therefore decided to seed the cells characterised in Chapter (4) onto the arterial 
segments produced in Chapter (3) across this range to determine the optimum seeding 
density. The strategy behind this approach was based on range of cell densities reported 
in the literature in which both surfaces of decellularised PCA have been used to seed the 
cells (McFetridge et al., 2004; Shimizu et al., 2007; Heine et al., 2011; Nitsan et al., 2012).  
2D cell seeding experiments were performed initially to determine whether ovine vascular 
cells could successfully attach to the surfaces of the acellular porcine scaffolds and 
secondly, to determine optimal seeding densities for subsequent 3D dynamic cell seeding. 
If 3D seeding was attempted, it was decided to perform ‘dynamic’ 3D seeding of the 
scaffolds (using a roller-mixer) as current literature reports have demonstrated greater 
seeding efficiencies when this technique is utilised (Hsu et al., 2005). 
 
5.2 Aims and Objectives 
The aim of this chapter was to assess the ability of ovine vascular cells to successfully 
adhere to the acellular porcine arterial scaffold. The objectives were:  
1) To determine the ability of ovine vascular cells to adhere to the surfaces of 
decellularised PCA using a two-dimensional static seeding approach. 
2) To determine optimal seeding densities should two-dimensional static seeding 
experiments confirm successful adherence. 
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3) If two-dimensional seeding was successful, to determine the ability of ovine vascular 
cells to successfully adhere to the surfaces of decellularised PCA using a dynamic three-
dimensional seeding approach.     
4) If three-dimensional dynamic seeding was successful, to perform dynamic three-
dimensional dual-cell seeding.  
 
5.3 Materials and Methods 
5.3.1.Two-dimensional (2D) cell seeding of acellular scaffolds using ovine vascular 
cells  
All methods were performed using full aseptic precautions in a class II safety cabinet.  
Six acellular porcine scaffolds from decellularisation batch seven were divided 
longitudinally along their length using dissecting scissors. Each scaffold was then cut into 
two 2 cm x 1 cm lengths, giving twelve sections of scaffold in total.  
 
5.3.1.1 Seeding method for ovine SMC 
In the initial ovine SMC seeding experiment, seeding was performed on both the luminal 
and adluminal surfaces of the scaffold.  
Each scaffold segment was placed individually into a well of a six-well plate. In two well 
plates, the luminal surfaces of the scaffolds were facing upwards. In the third, the 
adluminal surface was facing upwards. In total, four sections of scaffold were placed 
individually into wells within a six well plate (one control segment for medium only and 
three ‘test’ segments for cell seeding).  
A sterile oval stainless steel seeding ring (Figure 39) was then placed on the surface of 
each scaffold segment. To ensure an adequate seal was created between segment and 
ring, 400 μl of cell-specific medium was placed into each seeding ring. Rings were 
adjusted if any leak of medium was noted. Once all scaffold segments had seeding rings 
containing medium, the well-plates were incubated for thirty minutes at 37°C 
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Figure 39. Metallic seeding ring demonstrating hollow centre. 
Whilst the well-plates were incubating, ovine SMC were prepared for seeding. Ovine SMC 
were placed into suspension following the previously described method in Section’s 2.7.2 
and 2.7.5 and counted using a haemocytometer. Cells were diluted to each cell density 
using cell-specific medium. For SMC seeding, the two well-plates containing luminal and 
adluminal scaffold segment surfaces were used. The medium was aspirated from each of 
the seeding rings within the wells. For both well-plates, the scaffold segment in the top left 
was used as the control segment/well. Into the control well, 200 μl of SMC medium was 
placed. Next 200 μl of SMC suspension at each density (7.9 x 103cells.ml-1, 7.9 x 
104cells.ml-1, 7.9 x 105 cells.ml-1) was placed into the remaining three seeding rings in each 
of the two well-plates. Following incubation, all three well plates were labeled with each 
cell density in preparation for seeding (Figure 40). Once the seeding process was 
complete, all three well plates were placed in culture at 37°C with 5% (v/v) CO2 in air for 48 
hours. Following incubation, seeded segments were processed for evaluation using 
scanning electron microscopy (Section 2.3.3).    
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Figure 40. Schematic appearance of acellular arterial segments for 2D seeding. 
 
5.3.1.2 Seeding method for ovine EC 
For the ovine EC seeding experiments, only the luminal surface was used. The seeding 
method and cell-densities used were identical to those described in Section 5.3.1.1. 
5.3.1.3 Analysis of cell seeded scaffolds by SEM 
It was decided to characterise the 2D seeded scaffolds with SEM using the technique 
described in Chapter 2, Section 2.3.3. SEM would allow accurate visualisation of the 
scaffold surface and demonstrate the adherence and level of confluence of seeded cells 
 
5.3.2 Three dimensional dynamic seeding of acellular porcine scaffolds using ovine 
vascular cells  
5.3.2.1 Seeding method for EC and SMC 
All methods were performed using full aseptic precautions in a class II safety cabinet.  
Results from 2D seeding found that the optimal seeding density was 7.9 x 104 cells.ml-1. In 
the first experiment six acellular tubular scaffolds were used in total (three for ovine SMC 
Artery segment 
with seeding ring 
Medium Only 
103 104 105 
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seeding and three for ovine EC seeding). Prior to seeding, scaffolds were washed 
overnight at 4°C in sterile DPBSa. Following washing, scaffolds were cut into 8 cm 
sections. One end of the scaffold was ligated 2 cm from the distal end using a 3/0 silk 
suture. Cell-specific medium was then injected into the scaffold using a 5 ml syringe to 
check for any leaks at the ligated end. If leaks were found, a further suture was applied. 
Next, ovine EC and SMC were placed into suspension following the previously described 
passage method and diluted to a density of 7.9 x 104 cells.ml-1 using freshly made cell-
specific medium. Then, 4 ml of cell suspension was injected into each scaffold using a 5 
ml syringe at the open end. Next, the open end of the scaffold was ligated with a 3/0 silk 
suture 2 cm from the open end, leaving a 4 cm section of scaffold containing cell 
suspension. Next, 12 ml of fresh cell-specific medium was placed into six sterile universals 
followed by one minute of sparging with 5% (v/v) CO2 with air to prevent cellular hypoxia. 
Seeded vessels (n=6) were then placed horizontally within each universal. The universals 
containing the seeded vessels were then placed horizontally on a roller mixer set at 5 rpm 
in an incubator at 37°C with 5% (v/v) CO2 in air. Seeded scaffolds were incubated for 48 
hours on the roller mixer and sparged with 5% (v/v) CO2 in air for one minute every 24 
hours to prevent cellular hypoxia.  
To assess for the viability of 3D seeded cells, a Live/ Dead ® Assay was used using the 
techniques described in Section 5.3.2.3. 
5.3.2.3 Analysis of cell seeded scaffolds by LIVE/DEAD ® cell assay  
A Live/Dead ® assay was used to characterise the 3D seeded scaffolds as in addition to 
demonstrating the adherence and level of confluence of seeded cells, the assay would 
also assess the viability of seeded cells. The assay uses two compounds- calcein-AM and 
ethidium homodimer-1. Calcein is a fluorescent (green) complex that is actively 
transported across a cell membrane and is such, only transported intra-cellularly in living 
cells. Ethidium homodimer-1 is a membrane-impermeable fluorescent (red) compound 
which binds to intra-cellular DNA. It therefore can only enter dead cells (due to a disrupted 
cell membrane).   
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5.3.3 Three dimensional dual dynamic cell seeding of decellularised porcine carotid 
arteries using ovine vascular cells  
5.3.3.1 Seeding method for EC and SMC  
All methods were performed using full aseptic precautions in a class II safety cabinet.  
In total, three acellular scaffolds were used in the experiment. Ovine SMC were seeded 
first onto the scaffold lumen as they proliferate and adhere faster than ovine EC, laying 
down a matrix that should allow greater EC adherence and proliferation (see Chapter 1).  
Prior to seeding, scaffolds were washed overnight at 4°C in sterile DPBSa. Following 
washing, scaffolds were cut into 8 cm sections. One end of the scaffold was ligated 2 cm 
from the distal end using a 3/0 silk suture. DPBSa  was then injected into the scaffold 
using a 5 ml syringe to check for any leaks at the ligated end. If leaks were found, a further 
suture was applied. Next, ovine SMC were placed into suspension following the previously 
described passage method and diluted to a density of 7.9 x 104 cells.ml-1 using freshly 
made cell-specific medium. Then, 4 ml of cell suspension was injected into each scaffold 
using a 5 ml syringe at the open end. Next, the open end of the scaffold was ligated with a 
3/0 silk suture 2 cm from the open end, leaving a 4 cm section of scaffold containing cell 
suspension. Next, 12 ml of fresh cell-specific medium was placed into six sterile universals 
followed by one minute of sparging with 5% (v/v) CO2 with air to prevent cellular hypoxia. 
Seeded vessels (n=3) were then placed horizontally within each universal. The universals 
containing the seeded vessels were then placed horizontally on a roller mixer set at 5 rpm 
in an incubator at 37°C with 5% (v/v) CO2 in air. SMC seeded scaffolds were incubated for 
48 hours on the roller mixer at 5 rpm and sparged with 5% (v/v) CO2 in air for one minute 
every 24 hours to prevent cellular hypoxia.  
Following 48 hours of incubation, the scaffolds were removed from culture. The proximal 
suture from each scaffold was removed and the SMC medium was emptied from the 
scaffold lumen. Next, a suspension of ovine EC was injected gently into the lumen of the 
scaffolds using the same technique described above for ovine SMC seeding. The open 
end was again ligated using a 3/0 silk suture. Scaffolds were then placed into culture for 
72 hours with CO2 and air sparging every 24 hours to prevent cellular hypoxia. 
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5.3.3.2 Analysis of the cell seeded scaffolds using histological evaluation  
A Live / Dead ® assay was initially performed to assess seeded scaffolds for                   
re-cellularisation and cell viability, however this failed to demonstrate the presence of 
adherent cells. Scaffolds were therefore characterised histologically with H&E and DAPI 
using staining of tissue sections described in Sections 2.6.2 - 2.6.3. It was decided to 
assess dual-seeded scaffolds using H&E and DAPI staining as histological analysis would 
demonstrate the presence of seeded cells and assess the scaffolds in cross-section, 
thereby assessing the level of penetrance of seeded cells. It would also allow any future 
immunohistochemical analysis of the seeded scaffolds to confirm vascular cell phenotype.    
5.4 Results    
5.4.1 Two dimensional cell seeding of acellular scaffolds using ovine vascular cells  
The appearance of the luminal and adluminal surfaces of unseeded acellular scaffolds 
visualised by SEM is shown in Figure (41). Photomicrograph A displays a relatively 
smooth luminal surface with intimal folds of the basement membrane, with an absence of 
adhered cells. Photomicrograph B shows an adluminal surface, rough and loosely 
organised in texture with visible collagen fibrils from the advential surface, again devoid of 
cells.  
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Figure 41. SEM images of acellular porcine scaffolds. A; Control scaffold (luminal). B; 
Control scaffold (adluminal). Both images show an absence of visible cells. 
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5.4.1.1 Ovine SMC  
The appearances of SMC seeded onto the luminal surfaces of acellular scaffolds using 
three different seeding densities (7.9 x 103, 104, 105 cells.ml-1) were visualised by SEM and 
are shown in Figures (42-44). 
At a seeding density of 7.9 x 103 cells.ml-1, clear colonies of adhered SMC were visualised 
on the luminal surface of the scaffold by SEM after 48 hours incubation. There was 
however, a lack of confluence of the seeded cells (Figure 42). 
At a seeding density of 7.9 x 104 cells.ml-1, complete confluent growth of the seeded area 
by SMC was visualised on the luminal surface of the scaffold at 48 hours incubation. 
Confluent growth extending beyond the boundaries of the seeded area was seen (Figure 
43). 
At a seeding density of 7.9 x 105 cells.ml-1, complete confluent growth of the seeded area 
by SMC was seen on the luminal surface of the scaffold at 48 hours incubation. Evidence 
of cell debris accumulating on the luminal surface was seen (Figure 44).  
Figure (45) clearly demonstrates that the adluminal surface was sub-optimal as compared 
to the luminal surface for 2D seeding. At each seeding density, cells can be seen on the 
adluminal surface but do not appear to spread into confluent areas along the matrix to the 
level seen for luminal seeding. 
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Figure 42. SEM images of SMC seeded (luminal) acellular scaffold using a seeding 
density of 7.9 x 103 cells.ml-1 after 48 hours incubation. A & B; Seeded scaffold 
(luminal) demonstrating spreading colonies of SMC but a lack of confluence over the 
seeded area. 
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Figure 43. SEM image of SMC seeded (luminal) acellular scaffold using a seeding 
density of 7.9 x 104 cells.ml-1 after 48 hours incubation.  Confluent growth of SMCs is 
seen within the seeded area with outward extension of growth.  
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Figure 44. SEM image of SMC (luminal) seeded acellular scaffold using a seeding 
density of 7.9 x 105 cells.ml-1 after 48 hours incubation. Confluent growth is seen with 
accumulation of cellular debris on the luminal surface.  
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Figure 45. SEM images of SMC seeded (adluminal) acellular scaffold. A; Adluminal           
surface seeded at a density of 7.9 x 103 cells.ml-1 after 48 hours incubation. B; Adluminal           
surface seeded at a density of 7.9 x 104 cells.ml-1 after 48 hours incubation. C; Adluminal           
surface seeded at a density of 7.9 x 105 cells.ml-1 after 48 hours incubation. In all 
photomicrographs, populations of cells are seen but fail to display areas of spreading, 
confluent growth and penetration.  
A seeding density of 7.9 x 103 cells.ml-1 of SMC resulted in relatively small areas of cell 
adherence onto the luminal surface of the scaffolds and would likely result in poor 
penetration into the scaffold  when faced with pulsatile flow in a bioreactor. A seeding 
density of 7.9 x 104 cells.ml-1 onto the luminal surface appeared superior, with large areas 
of spreading cells. A seeding density of 7.9 x105 cells.ml-1 onto the luminal surface resulted 
in overconfluence which could potentially lead to over-competition for space, leading to 
rapid cell death.  
C 
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Adluminal seeding of ovine SMC cells did not demonstrate the the level of cell adhesion 
and spreading, the cells appeared very small and rounded indicating lack of adhesion to 
the scaffold at all three seeding densities.This may well have been due to that fact that the 
adventitial surface was composed of a matrix that appeared more disorganised as 
compared to the smooth, ordered, basement membrane of the internal elastic lamina of 
the intimal surface.  
 
5.4.1.2 Ovine EC  
The appearance of EC seeded onto the lumen of acellular scaffolds using three different 
seeding densities (7.9 x 103, 104, 105 cells.ml-1) and visualised by SEM is shown in Figures 
(46-48). 
At a seeding density of 7.9 x 103 cells.ml-1, clear colonies of adhered EC were visualised 
on the luminal surface of the scaffold by SEM after 48 hours incubation. There was 
however, a lack of confluence of the seeded cells, highlighted more clearly in 
photomicrograph B (Figure 46). 
 
 
 
 
Colony of ovine EC 
A 
157 
 
 
 
Figure 46. SEM images of EC seeded acellular scaffolds using a seeding density of 
7.9 x 103 cells.ml-1 after 48 hours incubation. A; Luminal surface of seeded scaffold 
demonstrating colony of EC. B; Seeded scaffold, lower magnification than A. 
At a seeding density of 7.9 x 104 cells.ml-1, the EC are spreading out and developing much 
greater areas of confluence on the luminal matrix (area bound by rectangle) than at a 
density of 7.9 x 103 cells.ml-1 (Figure 47). 
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Figure 47. SEM images of EC seeded acellular scaffold using a seeding density of 
7.9 x 104 cells.ml-1 after 48 hours incubation. A; Luminal surface of seeded scaffold 
demonstrating large area of spreading, confluent growth of EC. B; Seeded scaffold as A, 
higher magnification. 
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At a seeding density of 7.9 x 105 cells.ml-1, overconfluent growth of the seeded area by EC 
was seen, with scattered areas of cell clustering on the luminal surface of the scaffold at 
48 hours incubation (Figure 48).  
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Figure 48. SEM images of EC seeded acellular scaffold using a seeding density of 
7.9 x 105 cells.ml-1 after 48 hours incubation. A; Luminal surface of seeded scaffold 
demonstrating overconfluent growth and cell clustering. B; Seeded scaffold as A, higher 
magnification. 
Similar findings were seen to those of the SMC seeding experiments. A seeding density of 
7.9 x 103 cells.ml-1 resulted in relatively small areas of cell adherence onto the surface of 
the scaffolds. A seeding density of 7.9 x 104 cell.ml-1 appeared superior, with large areas of 
spreading cells. A seeding density of 7.9 x105 cells.ml-1 resulted in overconfluence  
potentially leading to over-competition for space.  
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5.4.2 Three dimensional cell seeding of acellular scaffolds using ovine vascular 
cells  
A seeding density of 7.9 X 104 cells.ml-1 for both cell types, seeded onto the luminal 
surface of the acellular scaffolds was felt to be the most suitable surface and density for 
3D cell seeding; as experimental results had clearly demonstrated a significant number of 
cells adhered to the luminal surface and would be more likely to stand up to the forces of 
pulsatile flow within a bioreactor whilst having space for proliferation.   
 
5.4.2.1 Ovine EC  
Ovine EC successfully seeded onto the luminal surface in all three scaffolds as seen by 
the typical “cobblestone” appearance of a confluent EC monolayer on the luminal surface 
of each scaffold (Figures 49-51). In all three replicate scaffolds, the majority of cells were 
stained with calcein-AM (green), indicating that these EC were viable at 48 hours. In 
Figure (40), red staining from ethidium homodimer-1 was not seen indicating that no dead 
cells were present in the characterised area.     
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Figure 49 . Photomicrographs of scaffold (1) seeded with EC and stained using the 
Live / Dead ® assay. Photomicrographs A + B demonstrate confluent EC staining with 
calcein AM. 
Photomicrographs A + B in Figure (50) show large areas of confluent EC stained with 
calcein AM (green) indicating that the majority of seeded cells were viable on this scaffold. 
There are small areas of ethidium staining (red) indicating the presence of dead cells on 
the scaffold.  
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Figure 50. Photomicrographs of scaffold (2) seeded with EC and stained using the 
Live / Dead ® assay.  
Photomicrographs A + B in Figure (51) again show large areas of confluent EC stained 
with calcein AM (green) indicating that the majority of seeded cells are viable on this 
scaffold. Again, there were only small areas of ethidium staining (red) indicating the 
presence of dead cells on the scaffold. 
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Figure 51. Photomicrographs of scaffold (3) seeded with EC and stained using the 
Live / Dead ® assay.  
The results confirmed that EC successfully adhered to all three scaffolds at a density of 
7.9 x 104 cells.ml-1 using the dynamic 3D seeding technique. Seeded cells were confluent 
on all scaffolds at 48 hours sampling. Live / Dead ® staining confirmed that the majority of 
EC cells were viable at 48 hours post seeding. Some dead cells were present in scaffolds 
two and three and this was not unexpected given that seeded cells would have been in 
differing phases of the cell “life” cycle.    
5.4.2.2 Ovine SMC  
Ovine SMC were also successfully seeded onto the luminal surface of all three replicate 
scaffolds as seen by the typical “spindle-shape” appearance of a confluent SMC 
monolayer on the luminal surface of each scaffold (Figures 52-54). In all three scaffolds, 
the majority of cells were stained with calcein-AM (green), indicating that these SMC were 
viable at 48 hours. In Figure (52), red staining from ethidium homodimer-1 was not seen 
indicating that no dead cells were present in the characterised area.     
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Figure 52. Photomicrographs of scaffold (1) seeded with SMC and stained using the 
Live / Dead ® assay. Photomicrographs A + B demonstrate large areas of confluent 
staining with calcein AM. 
Photomicrographs A + B in Figure (53) show large areas of confluent SMC stained with 
calcein AM (green) indicating that the majority of seeded cells were viable on this scaffold. 
There were minimal areas of ethidium staining (red) indicating the presence of dead cells 
on the scaffold. 
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Figure 53. Photomicrographs of scaffold (2) seeded with SMC and stained using the 
Live / Dead ® assay.  
Photomicrographs A + B in Figure (54) again show large areas of confluent staining with 
calcein AM (green) indicating that the majority of seeded cells were viable on this scaffold. 
There were minimal areas of ethidium staining (red) indicating the presence of dead cells 
on the scaffold. 
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Figure 54. Photomicrographs of scaffold (3) seeded with SMC and stained using the 
Live / Dead ® assay.  
The results confirmed that SMC successfully adhered to all three scaffolds in a confluent 
manner at a density of 7.9 x 104 cells.ml-1 using the dynamic 3D seeding technique. 
Live/Dead ® staining confirmed that the majority of cells were viable at 48 hours post 
seeding. Again, some dead cells were present in scaffolds two and three and this was not 
unexpected given that seeded cells will be in differing phases of the cell “life” cycle.    
 
5.4.3 Three dimensional dual dynamic cell seeding of decellularised porcine carotid 
arteries using ovine vascular cells  
Following successful dynamic 3D seeding for both types of ovine vascular cells, the next 
stage was to attempt dual seeding of SMC and EC onto the luminal surface. SMC were 
seeded first for 72 hours, followed by EC seeding for 48 hours.  
A Live / Dead ® assay was performed but did not demonstrate the presence of adherent 
cells. This could have occurred for three possible reasons; experimental error, loss of the 
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cell monolayer during processing or simply, a lack of cell adherence. Histological 
assessment was therefore performed to assess for the presence of adherent cells. H&E 
and DAPI staining of the seeded scaffolds confirmed the presence of cells on the surface 
of the scaffolds, however they were minimal in number and certainly well below 
confluence.  
Figure’s (55-56) show a small number of cells attached to the intimal surface with minimal 
penetration of cells into the medial layer. 
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Figure 55. Images of H&E and DAPI stained sections of acellular scaffold (1) seeded 
with both SMC and EC. A + B; H&E and DAPI assessment both confirm the presence of 
cells on the intimal surface of the scaffold only. 
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Figure 56. Images of H&E and DAPI stained sections of acellular scaffold (2) seeded 
with both SMC and EC. A + B; H&E and DAPI assessment both confirm the presence of 
cells on the intimal surface of the scaffold only.  
Figure (57) does show the presence of cells both on the intimal surface of scaffold three, 
but unlike scaffolds one and two, there was evidence of cell penetration into the deeper 
medial layers. Again however, cells were minimal in number and failed to show any degree 
of confluent growth.  
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Figure 57. Images of H&E and DAPI stained sections of acellular scaffold (3) seeded 
with both SMC and EC. A; H&E assessment of scaffold (3) confirms penetration of cells 
below intimal layer. B; DAPI assessment confirms the presence of cells on the intimal 
surface of the scaffold only.  
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Overall, the results for dual (3D) seeding of the scaffolds was disappointing when 
compared to the results for 2D and 3D single-layer seeding. Scaffolds failed to show 
significant levels of cell adherence with cell density well below confluence.   
5.5 Discussion  
It was decided to start seeding experiments with a 2D “static” approach to determine 
whether ovine vascular cells could successfully attach to the surfaces of the acellular 
porcine scaffolds. Both luminal and adluminal surfaces were assessed. Furthermore, 2D 
seeding allowed the determination of optimal seeding densities for subsequent 3D 
dynamic cell seeding. The seeding densities used in the study were based on densities 
used in successful seeding experiments on decellularised porcine arterial tissue reported 
in the literature (McFetridge et al., 2004; Shimizu et al., 2007; Heine et al., 2011; Nitsan et 
al., 2012).  
Results from 2D seeding confirmed successful attachment of both types of ovine vascular 
cells to the luminal matrix of the acellular scaffolds. This was an important finding as firstly, 
successful cell seeding was paramount in order to allow future experiments to continue, 
and secondly, the cells and scaffold required no functionalisation in order for cell 
adherence to occur. The latter was a particularly key finding if the graft were to become a 
clinically viable product as not having to modify cell adherence would reduce the time and 
expense required to seed the scaffold in a commercial setting.  
For both types of cells, a seeding density of 7.9 x 104 cell.ml-1 appeared superior, with 
large areas of spreading, subconfluent cells. This was consistent with similar experiments 
reported in the literature that focus on the seeding of vascular cells onto decellularised 
PCA. McFetridge et al (2004) and Heine et al (2011) for example, successfully seeded 
human EC and SMC seeded onto PCA using a seeding density of 103-104cells.ml-1.                                                 
In this study, a seeding density of 7.9 x103 cells.ml-1 resulted in areas of under-confluent 
cell growth following culture whilst a density of 105 cell.ml-1 resulted in overconfluence, 
potentially leading to over-competition for space and subsequent cell death. A seeding 
density of 7.9 X 104 cells.ml-1 was felt to be optimal and therefore used for subsequent 3D 
seeding experiments. SMC growth on the luminal surface was superior to the adluminal 
surface so it was decided that future 3D seeding experiments would be limited to the 
luminal surface only. The reduced cell adherence seen on the adluminal surface was likely 
secondary to the loose arrangement of collagen matrix found in the adventia as compared 
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to the basement membrane of the internal elastic lamina. A more loose arrangement of the 
collagen matrix would have reduced the effectiveness and increased the time required for 
cellular integration and adherence. Furthermore, the SMC would have to penetrate 
through the adventia, medial layer and through the basement membrane of the internal 
elastic lamina before reaching the intimal surface, significantly increasing the culture time if 
dual-seeding is to be performed.    
Following successful 2D seeding of acellular scaffolds and development of an optimal 
seeding density, 3D dynamic seeding experiments began. If the scaffold is to be 
successful as a SD graft, it is essential that the entire (3D) luminal surface is effectively 
seeded with vascular cells. The first set of dynamic 3D seeding experiments were 
performed on the luminal surfaces of the acellular scaffolds, seeding EC and SMC 
separately. This stage was performed to help determine efficacy of the dynamic seeding 
technique, determine seeded cell viability and to act as a control for potential future dual 
seeding experiments. A dynamic seeding approach was used to provide shear stress to 
the vascular cells which has been shown to increase cell adherence and proliferation in 
the literature (Bader et al., 2000; Hsu et al., 2005; Amiel et al., 2006; Nitsan et al., 2012).                                                                                                        
Using a dynamic seeding technique, again the scaffold surfaces became populated with 
seeded, viable cells as demonstrated with confluent cells stained with the Live/Dead® 
assay. As it was clear that the scaffolds could be successfully seeded in a 3D dynamic 
fashion, experiments then began to establish a dual seeding method. The rationale for 
dual-seeding was derived from current literature on vascular cell-seeding of a variety of 
biological scaffolds.     
As previously discussed, the formation of ECM on a graft surface is important for cell 
attachment and is secreted by both EC and SMC. Studies have shown that lining a graft 
with SMC prior to the seeding of EC improves the subsequent retention of EC to the graft 
(Yu et al., 2001, 2003; Stephan et al., 2006; Aper et al., 2007). The ECM laid down by 
SMC provides the graft with elastic recoil and tensile strength (Stephan et al., 2006), whilst 
the EC reciprocally interact with SMC, to maintain the ECM (Aper et al., 2007).  
 
The dual-seeding experiments failed to demonstrate that the scaffolds could be 
successfully dynamically seeded using the developed technique. Overall, a distinct lack of 
penetration of the SMC through the scaffold layers was seen, with only a small number of 
cells seeding onto the luminal surface. Many factors exist that may explain why the results 
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seen in static seeding were not reproduced in dual-seeding. Unfortunately, a lack of time 
severely limited the progress of dual-seeding experiments. If further time was available, 
longer incubation times prior to EC seeding may have allowed deeper penetration of the 
SMC into the scaffold layers and subsequently, a higher chance of EC adherence. Another 
possibility was that the SMC could not penetrate easily past the basement membrane of 
the intimal surface. Repeat experiments using longer seeding times would help clarify 
these two possibilities. Furthermore, immunohistochemical analysis of the scaffolds would 
demonstrate what population of cells had adhered to the scaffold and to what area.                                                                           
Although in vivo ovine SMC and EC are intimately related, it is unknown whether following 
the harvesting and seeding processes, the cells remain biocompatible to one another. It is 
also apparent in the literature that the interactions of EC and SMC show different species-
specific behavior (Wallace et al., 2007; Pang et al., 2010; Zhao et al., 2010). Again if 
further time was available, static 2D seeding of the vascular cells would help establish that 
both sets of cells remain biocompatible to one another following harvesting and can 
proliferate as a co-culture. In retrospect, performing this experiment prior to commencing 
dynamic 3D seeding would have provided useful information regarding biocompatibility 
and incubation times, helping to plan dynamic 3D experiments more accurately. 
In view of the numerous variables that may have affected the results of dynamic 3D 
seeding, if further time had been available, it would have been important to refine the 
technique (using some of the changes mentioned above) before declaring the technique 
unsuitable and attempting a different method. Certainly the dual-seeded scaffolds would 
have to show greater cell retention and scaffold penetration before pre-conditioning 
experiments in a vascular bioreactor could proceed.     
The key and exciting finding in this part of the study was that the acellular surface of the 
scaffolds did not require functionalisation prior to seeding, for example with adhesive 
proteins such as fibrin or alteration in chemistry such as collagen crosslinking. This finding 
alone provides good support for the use of decellularised PCA as a suitable conduit for cell 
seeding and possible use as a vascular graft as it minimizes both production time and 
costs whilst maximizing reproducibility.    
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Chapter 6 
Development of a perfusion bioreactor system 
6.1 Introduction 
Bioreactor’s have become essential hardware in the development of tissue-engineered 
constructs. They are designed to maintain a culture environment to help maintain correct 
cellular phenotypes e.g temperature, humidity, O2 and CO2 levels and circulation of media 
to provide nutrition to cells and to remove waste products of cellular metabolism. They 
may also be designed to provide biomechanical functions such as flow, pulsatility and 
shear stress which pre-condition the cells and construct (Rademacher et al., 2001; Rashid 
et al., 2008). Ultimately, the main design of a bioreactor for tissue engineering purposes is 
to closely mimic the in vivo physiological conditions in order to assess the performance 
and function of tissue engineered constructs in such an environment.                              
 
When studying a conduit for potential use in the human circulation, the bioreactor should 
be designed to match the physiological parameters of a typical fit, thirty year old, 70Kg 
male (the accepted model used in science used when performing studies pertaining to 
human physiological parameters). Such conditions would therefore require an 
environmental temperature of between 36.5-37ºC, pulsatile flow of between 70-80 strokes 
per minute generating a pressure of 100-120 mmHg. As such, many studies in the 
literature involving the use of bioreactors will aim for the parameters described ( Bader et 
al.,2000; Yu et al.,2001; Hsu et al., 2004; Liao et al., 2008; Yazdani et al., 2008). In many 
such studies the actual design and set up of the bioreactor is not well described, with often 
only the parameters and environmental conditions being reported. A few studies such as 
those of Butler et al. (2009) and Williams et al. (2004) describe their bioreactor set up in 
more detail but in all cases, the bioreactors are customised for purpose. In these studies, 
the only single common denominator of each bioreactor is that a peristaltic pump is used, 
but set up and design after that remains highly variable and experiment specific.        
    
A simple bioreactor developed by Wake Forest Institute for Regenerative Medicine, North 
Carolina in the United States was used in the study. The bioreactor has been used 
previously for exploratory experiments within IMBE and the rationale for its use in this 
study was that it was simple in design, would allow initial basic experiments to be 
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performed e.g assembly and sterility  and that the components were safe to sterilise for 
repeated use and consumable components were cheap to purchase. Due to the 
complexity of more sophisticated bioreactors, it was felt appropriate to become familiar 
with a bioreactor, simple in its design to perform initial experiments before progressing to 
the use of more complex systems and experiments.   
 
6.2 Aims and Objectives 
The aims and objectives of the chapter were the following: 
1) To assemble and operate the Wake Forest Vascular Bioreactor under aseptic 
conditions  
2) To evaluate the sterility and performance of the Wake Forest Vascular Bioreactor over 
an extended period of time   
 
6.3 Materials and Methods 
6.3.1 Bioreactor circuit 
The bioreactor perfusion circuit was simple in its design. A central pump circulated fluid / 
culture medium from a reservoir through the perfusion chamber (Figure 58).   
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Figure 58. Basic schematic of the Wake Forest bioreactor perfusion system. 
 
6.3.2 Bioreactor components  
The various components of the bioreactor are shown in Figure 59. 
Pump 
Medium Reservoir 
Silicon circuit 
Perfusion chamber 
Conduit 
Direction of flow 
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Figure 59. Photograph of assembled Wake Forest bioreactor housed within an 
incubator.  
The pump circulated medium housed in two x 500ml Pyrex glass reservoirs. To ensure an 
adequate supply of fresh medium, a 3-way valve controlled which reservoir medium was 
circulated from. Medium was then circulated through the perfusion chamber and back to 
the reservoir. Assembly and components of the perfusion chamber are shown in Figure 
(60).  
 
 
Pump 
Pyrex glass  
reservoirs (500ml) 
Silicon tubing  
Perfusion chamber 
3-way valve 
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Figure 60. Photograph demonstrating key components of the perfusion chamber. 
The presence of 3-way stopcocks allowed the temporary cessation of flow through the 
chamber (should the conduit need to be changed for example). The 2-way valves allowed 
sampling of the medium without having to cessate flow. 
6.3.3. Bioreactor assembly 
All bioreactor components were autoclaved at 121º, 15 psi for 20 minutes prior to use. The 
Class II safety cabinet and incubator were cleaned extensively with Virkon and then 
Trigene prior to use. Components were then assembled aseptically in the Class II safety 
cabinet (Figure 61). Once assembled, the bioreactor components were transferred into the 
incubator and attached to the pump. DMEM (500 ml) was placed into each of the medium 
reservoirs and 50 ml was injected into the system to prime the pump. After the pump had 
started and medium was circulating, the system was checked for leaks. Once the system 
had been checked for leaks, the whole system was sprayed with Trigene and incubated at 
37°C with 5% (v/v) CO2 in air.    
 
2-way valves for sampling 
3-way stopcocks 
Chamber housing conduit 
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Figure 61. Photograph demonstrating aseptic assembly of bioreactor components 
(note sterile drapes, gloves and gown). 
 
6.3.4 Sampling of Bioreactor for sterility assessment 
During all bioreactor runs, the bioreactor was kept within a closed incubator that was only 
opened during sampling to limit contamination. In addition to inspection of the medium for 
obvious contamination (cloudiness), 5 ml samples of medium were taken from the 
bioreactor at 24 hrs and 48 hours. Medium was aspirated from the two-way valves situated 
above the housing chamber (Figure 60) and this was performed as aseptically as possible 
using sterile gloves and syringes. Samples were plated out onto four different agar plates 
and incubated to assess for bacterial and fungal growth (nutrient, fresh blood, heated 
blood, sabouraud agar). 
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6.4 Results 
The bioreactor was assembled with medium three times and assessed for sterility. The 
first run with DMEM alone and the second and third runs with DMEM and antibiotics.  
 
6.4.1 Sterility of Bioreactor Run (1). DMEM only 
It was clear at 48 hours that the medium was contaminated as it had become cloudy. 
Following incubation for 48 hours, it was evident that plates from both samples at 24 and 
48 hours had become contaminated with micro-organisms (Figure 62). 
  
  
Figure 62. Representative plates from samples at 24 hours and 48 hours 
demonstrating bacterial and fungal growth.  A+C; Nutrient agar showing colonies of 
bacterial growth, B; Sabouraud agar showing fungal growth, D; Fresh blood agar showing 
colonies of bacterial growth. 
A B 
C D 
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6.4.2 Sterility of Bioreactor Run (2). DMEM and antibiotics 
It was evident from run 1 that the bioreactor perfusion system rapidly became 
contaminated with micro-organisms. For the second run, 15 ml of 100 U.ml-1 penicillin and 
100µg.ml-1 streptomycin was added to 500 ml of DMEM in an attempt to reduce 
contamination (300 U.ml-1 streptomycin, 300 U.ml-1 penicillin). Anti-fungals were not added 
to the medium at this stage. It was decided to not sample the circulating medium as 
frequently as sampling itself may have been a contributing factor towards contamination. 
Therefore the medium was viewed daily to asses for gross contamination and sampled at 
one week. Daily inspection of medium did not demonstrate evidence of gross 
contamination at one week. Samples were taken at seven days and again, plated onto four 
different agar plates (nutrient, fresh blood, heated blood and sabouraud agar) and 
incubated to assess for microbial growth for 48 hours (Figure 63).  
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Figure 63. Agar plates demonstrating a lack of micro-organism growth at one week 
post sampling at 48 hours post incubation. A; Nutrient agar, B; Fresh blood agar, C; 
Sabouraud agar; D; Heated blood agar. No microbial growth is visible on any of the four 
plates. 
At seven days, there was no evidence of microbial contamination of medium, therefore the 
run was continued for a further week. At day 18, medium appeared cloudy and so repeat 
samples were taken and plated onto agar to assess for microbial growth (Figure 64).  
 
A B 
C D 
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Figure 64. Agar plates demonstrating a lack of micro-organism growth at Day 18 
post sampling at 48 hours post incubation. A; Nutrient agar, B; Fresh blood agar 
(cracked due to heat), C; Sabouraud agar. D; Heated blood agar. No microbial growth is 
visible on any of the four plates. 
Results of run 2 confirmed that the addition of antibiotics to the circulating medium 
improved the contamination-free period from 24 hours to 18 days.  
A third run was performed to determine if the results seen in run 2 were reproducible.     
A 
B 
C D 
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6.4.3 Sterility of Bioreactor Run (3). DMEM and antibiotics 
Based on the success of run 2, it was decided to repeat the sterility run under the same 
bioreactor conditions to determine if sterility of the system was reproducible. As for the 
second run, 15 ml of 100 U.ml-1 penicillin and 100µg.ml-1 streptomycin was added to 500ml 
of DMEM. Anti-fungals were not added to the medium. Again, the circulating medium was 
viewed daily to asses for gross contamination and sampled at one week. Daily inspection 
of medium did not demonstrate evidence of gross contamination at one week. Samples 
were taken at seven days and again, plated onto four different agar plates (nutrient, fresh 
blood, heated blood and sabouraud agar) and incubated to assess for microbial growth for 
48 hours (Figure 65).  
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Figure 65. Agar plates demonstrating a lack of micro-organism growth at 48 hours 
post incubation. A; Nutrient agar, B; Fresh blood agar (cracked due to heat), C; 
Sabouraud agar. D; Heated blood agar (cracked due to heat). No microbial growth is 
visible on any of the four plates. 
 
 
A B 
C D 
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At seven days, there was no evidence of microbial contamination of the medium, therefore 
the run was continued for a further week. At day 14, medium appeared clear and repeat 
samples were taken and plated onto agar to assess for microbial growth.  
No growth was visible on the agar plates at 48 hours post incubation (Figure 66) 
confirming a lack of contamination of medium. Unfortunately there was a disturbance to 
the power supply to the bioreactor pump on the night of day 15 and so the experiment 
could not continue. 
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Figure 66. Agar plates demonstrating a lack of micro-organism growth at 48 hours 
post incubation. A; Nutrient agar, B; Fresh blood agar (cracked due to heat), C; 
Sabouraud agar. D; Heated blood agar (cracked due to heat). No microbial growth is 
visible in any of the four plates. 
 
A B 
C D 
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6.5 Discussion 
The aims of this part of the study were achieved, namely that it was possible to assemble 
a simple bioreactor circuit that could be kept free from bacterial and fungal contamination 
for approximately two weeks. Keeping circulating medium free from microbial growth is 
essential in any bioreactor to prevent the experiment and any subsequent data from being 
compromised. Housing the bioreactor within an incubator situated in a busy working 
laboratory was not ideal however and likely contributed to the speed of contamination 
found in the bioreactor run without antibiotics. On this matter alone, if further experiments 
were to be conducted using the Wake Forest bioreactor, especially using seeded grafts, it 
would need to be housed under more aseptic conditions.        
Ultimately, future experimentation on the seeded conduits would assess scaffold 
maintenance, pre-conditioning, cellular proliferation, viability and phenotype of the seeded 
cells once submitted to circumferential and shear stress. In order for these experiments to 
be performed, it would be necessary to upgrade the bioreactor system significantly with 
monitoring equipment to allow parameters such as flow rate and pressure to be measured 
which would allow for accurate biomechanical assessment and to develop optimal 
biomechanical parameters for the seeded conduits. I believe that firstly, due to the 
simplicity of its design, it would not be possible to upgrade the Wake Forest bioreactor with 
such equipment. Secondly, the development, purchasing and procurement of 
sophisticated monitoring systems would require a large amount of time and expense. 
Designing and procuring a more sophisticated bioreactor system with such monitoring built 
within (although it would be more expensive) would ultimately make further experiments on 
seeded scaffolds proceed in a more timely manner and provide much more robust, 
accurate and reliable data- essential requirements for the ongoing development of the 
scaffold as a potential TEVG. As previously discussed, no single universal bioreactor 
system exists for the specific use of assessing SD tissue-engineered scaffolds.    
Unfortunately, due to time constraints, it was not possible to proceed to further 
experiments to assess cell-seeded scaffolds in the bioreactor, however future projects 
within IMBE will use and take these preliminary results forward. 
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Chapter 7 
General Discussion 
To treat the increasing incidence of atherosclerosis, surgical bypass remains one of the 
standard surgical techniques (Nalysnyk, 2003; Klinkert et al., 2004). To date, autologous 
vein remains the gold standard graft of choice, mainly due it its length, ease of access and 
handling properties. Despite this, autologous vein may be unavailable or unsuitable to use 
in up to 30% of patients and in this scenario, surgeons often have to turn to the use of 
synthetic grafts to enable effective surgical bypass (Sayers et al.,1998). Synthetic 
materials (particularly as their diameter gets smaller) possess many drawbacks when 
compared to their venous counterparts, namely, thrombogenicity, reduced tissue handling, 
infection and biomechanical disadvantages such as compliance mismatch, a major cause 
of neointimal neoplasia and subsequent graft failure (Kannan et al., 2004). Such 
drawbacks are clearly seen when comparing the patency rates of autologous vein versus 
synthetic grafts such as ePTFE and Dacron. In AK and BK bypass for example, 5-year 
primary patency rates of 39% and 50% have been reported for ePTFE compared to 74% 
for saphenous vein (Albers et al., 2003; Klinkert et al., 2004).                                                             
In order to overcome these limitations when autologous vein is not available, surgeons and 
scientists have attempted to create a wide range of vascular grafts utilising three main 
strategies: to modify existing synthetic grafts, create new synthetic grafts or create blood 
vessels using tissue engineering. Tissue engineering strategies continue to evolve but 
mainly focus on the manipulation of tissues and cells to create a functional, living graft 
capable of remodeling and repair. In vascular tissue engineering such techniques include: 
the seeding of “old” and new synthetic materials with vascular cells (Meinhart et al, 2001; 
Rashid et al., 2004; Sarkar et al., 2007), the decellularisation and subsequent 
recellularisation of allogeneic and xenogeneic tissue (Schaner et al, 2004; Shimizu et al., 
2007; Zhao et al., 2010) and the creation of assembled constructs capable of cellular 
ingrowth and remodeling (Campbell et al., 1999; Aper et al., 2007;). All techniques to date 
however have failed to achieve wide-spread clinical use. 
The tissue engineering strategy used in this study was the decellularisation and 
subsequent re-cellularisation of porcine arterial tissue. The aim of the study was to create 
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a decellularised scaffold using PCA and assess its ability for re-cellularisation with 
xenogeneic vascular cells to aid in the development of a tissue engineered vascular graft.  
7.1 Creation of acellular PCA scaffolds 
The first objective of the study was to treat PCA with the established iMBE 
decellularisation protocol to produce acellular scaffolds and assess their biocompatability. 
Initial decellularisation runs failed to achieve acellular scaffolds but following modification 
of the protocol, histological analysis confirmed a lack of cell nuclei and double-stranded 
DNA within the treated arteries. DNA quantification confirmed a net DNA removal of 
between 90-99% (ng.mg-1) in treated arteries following the protocol modification confirming 
successful decellularisation. Preservation of native arterial histioarchitecture was also well 
demonstrated. Biocompatibility of the acellular scaffolds was confirmed using the ISO 
standard cell lines for the assessment of medical devices, BHK and 3T3 cells (10993-p5, 
2005).  
7.2 Isolation and characterisation of primary [xenogeneic] ovine vascular cells 
The next objective in the study was to isolate ovine vascular cells for future seeding 
experiments as such cells are not commercially available and ultimately it is intended that 
an ovine in vivo model will be used for future experiments. Isolation of ovine EC and SMC 
began in Chapter (4) and proved difficult as following harvesting and incubation, mixed cell 
populations of EC and SMC were seen on characterisation. Isolation of cells using 
magnetic beads was successful in isolating SMC but resulted in the death of EC isolates. 
To allow a timely continuation of the study, a peer within iMBE kindly gifted a population of 
pure ovine EC isolates. Before the ovine cells could be used experimentally, it was 
necessary to develop a reproducible, characterisation protocol to ensure correct cell 
phenotype and pure isolates. Very little work had been published on the characterisation of 
ovine vascular cells but what did exist focused heavily on indirect immunofluorescence 
and as such, was the technique used in this study. Anti-VWF antibody was the most 
commonly used antibody to identify ovine EC and for ovine SMC, anti-SMC α-actin 
antibody was the most commonly used. (Abdi et al., 1995; Grooby et al., 1997; Afting et 
al., 2003; Zhao et al., 2010;). These antibodies were used in the study alongside two 
antibodies to traditional markers of EC and SMC phenotype, namely CD31 and SMC-
Myosin Heavy Chain respectively. (Hutanu et al., 2007; Walpoth et al., 2007). Both sets of 
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antibodies for each cell type stained in a specific fashion and so a successful 
characterisation protocol was developed to identify ovine vascular cells.  
7.3 Ovine vascular cell-seeding of acellular scaffolds 
The objective of this part of the study was to seed ovine vascular cells characterised in 
Chapter (4) onto the luminal surfaces of the acellular scaffolds in a (static) 2D and 
(dynamic) 3D fashion. 2D cell seeding experiments were performed initially and confirmed 
that ovine vascular cells could successfully adhere to the surface of the acellular scaffolds 
and display subsequent confluent growth across it. Optimal seeding densities for 
subsequent 3D dynamic cell seeding were developed and were consistent with current 
literature reports (McFetridge et al., 2004; Shimizu et al., 2007; Heine et al., 2011; Nitsan 
et al., 2012). ‘Dynamic’ 3D seeding of the scaffolds was performed using a roller-mixer. A 
rotational seeding technique was used in the study to seed the acellular scaffolds as 
literature reports had demonstrated greater seeding efficiencies when this technique is 
utilised. Hsu et al. (2005) used a rotational dynamic seeding technique to seed human EC 
onto the surface of SD polyurethane using a roller-mixer. Compared to static seeding, 
dynamic seeding lead to a greater GAG content in the scaffolds and a seeding efficiency 
of up to 90%, compared  to10% for static. Rotational seeding subjects cells to shear 
stress, which leads to release of mediators that aid ECM formation, such as NO and 
calcium (Hsu et al., 2005).). In this current study, rotational seeding was effective in 
seeding individual populations of ovine vascular cells (EC or SMC) onto the luminal 
surface of the acellular scaffolds, suggesting that the findings of Hsu et al. may also apply 
to biological grafts.   
Studies have demonstrated that EC retention on the luminal surface of prosthetic grafts is 
enhanced when the lumen is pre-seeded with SMC as they secrete more ECM and allow 
for greater adherence (Yu et al., 2001; Yu et al., 2003). It was the results of these studies 
that lead to the decision to dual-seed the scaffolds with SMC first and then EC. In the dual-
seeding experiments, seeding was minimal and in a disorganised fashion with no evidence 
of monolayer formation seen in the experiments by Yu et al. (2003). One possibility is that 
as prosthetic grafts do not contain layers (just a porous matrix) the penetration of SMC is 
not limited. As histological assessment demonstrated, the internal elastic lamina was 
preserved in the acellular scaffolds and it may have been this structure that limited the 
penetration of SMC into deeper layers in this study.   
194 
 
7.4 Bioreactor development  
The final objective of the study was to assemble and develop a bioreactor that would 
augment 3D seeding of the acellular scaffolds by subjecting them to pre-conditioning. 
Unfortunately time constraints only allowed time for bioreactor assembly and sterility runs 
to be performed. It was clear at this stage that the Wake Forest bioreactor was too 
primitive to allow the accurate assessment and determination of optimal pre-conditioning 
parameters for the seeded scaffolds and that microbial contamination would limit any 
experimentation time to approximately two weeks.    
7.5 Discussion 
To a large extent, the main aims of the study were achieved and had more time been 
available, such aims could have been further met in assessing the efficacy of a re-
cellularised PCA being a potential candidate as a SD vascular bypass graft. The data that 
was generated from this study correlated with findings from  similar tissue engineering 
studies using porcine tissue, in particular PCA, that have been reported in the literature. It 
is clear from this study and others reported that decellularised porcine arterial tissue 
demonstrates a high level of biocompatibility with autologous and xenogeneic vascular 
cells and provides a suitable environment for subsequent cell adherence (Conklin et al., 
2002; McFetridge et al., 2004; Roy et al., 2005; Shimizu et al., 2007; Heine et al., 2011; 
Nitsan et al., 2012;). The ability of cells to adhere to a scaffold surface and in particularly in 
this case, form an endothelial monolayer, is a key attribute towards the development of an 
effective SD bypass graft.     
Unfortunately, severe time pressure prevented continuation of further planned 
experiments. A significant amount of further study and assessment is required to 
determine whether a tissue engineered, cell-seeded PCA can be developed using the 
strategy used in this study, in order to create a substitute graft for small-diameter arterial 
bypass.               
Decellularisation has been shown to be an effective technique with which to begin 
development of a SD tissue engineered graft. Removing host cells from a tissue ‘made-for-
purpose’, leaving behind a scaffold matrix largely unaltered both biochemically and 
biomechanically, carries many advantages. Effective removal of cells should render the 
scaffold non-immunogenic which would prevent rejection following implantation. The 
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biological nature of the scaffold should allow effective integration and remodeling within 
host tissues following implantation and carry a significantly reduced risk of infection 
compared to synthetic material. Provided the decellularisation process does not 
significantly alter the ECM of the tissue, the acellular scaffold created should provide a 
favourable environment for subsequent re-cellularisation and the re-instigation of scaffold 
functionality. The decellularisation protocol developed by iMBE and used in this study 
creates non-immunogenic, acellular scaffolds that retain their histioarchitecture and 
biomechanical properties providing a useful starting material onto which further 
engineering and scaffold functionalisation can take place (Derham et al., 2008; Wilshaw et 
al., 2011). The scaffolds generated using this technique have also been shown to 
regenerate in vivo and some are used clinically now in Europe and the USA (Stapleton et 
al., 2011; Gutierrez et al., 2015).   
The data presented in chapter five demonstrated that the current seeding strategy could 
work, but requires modifications in the technique. Firstly, further seeding work would be 
required with ovine vascular cells to assess whether a luminal dual-seeding approach is 
possible. Based on the results from the current study, greater seeding times would be 
required to help ascertain this. If luminal dual-seeding proved unsuccessful, then luminal 
seeding with EC and adluminal seeding with SMC could be attempted. Failing this, luminal 
seeding only of EC is an option, as the presence of a functioning endothelium is now well-
established as the gold-standard for achieving short and long-term vascular graft efficacy 
(Zilla et al., 1994; Clowes et al., 1997; Meinhart et al., 2001; Sarkar et al., 2007).   
With more time available, the study would have progressed to development of an effective 
3D seeding protocol and the beginning of preconditioning experiments with the Wake 
Forest bioreactor. For the current study, the Wake Forest bioreactor would have been 
useful in assessing how well cells adhered to the scaffold under pulsatile flow but would 
not have provided much more information. The Wake Forest bioreactor used in this study 
was deemed to be too primitive in its design to allow sophisticated measurements of flow, 
pressure and shear stress to be performed. Knowledge of such parameters would be vital 
for an effective pre-conditioning protocol to be developed for the seeded scaffolds. It was 
also clear from this study that microbial contamination was an ongoing issue and 
positioning the bioreactor within an incubator in a busy laboratory likely contributed to the 
contamination. For future work to progress effectively, a more sophisticated bioreactor 
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situated in a clean, minimal access area, capable of measuring key parameters is 
essential.   
7.5.1 Future work that is required 
The development of a successful 3D seeding technique is essential for the progression of 
the study. If a 3D seeding technique was achieved then it would be important to assess 
the biomechanical integrity of the scaffold at this stage before further studies were 
commenced. In particular, burst pressure, compliance and suture-retention strengths 
should be measured. Burst pressure is used as a surrogate marker of long-term graft 
durability and can be used to predict the risk of graft complications such as aneurysmal 
dilatation and rupture. Compliance is a measure of the distensibility or stiffness of the graft. 
A non-compliant graft would lead to a significant compliance mismatch at the anastomosis 
with native artery, predisposing the graft to NIH and subsequent mid-term graft failure. 
Knowledge of the suture-retention strength of the grafts is required to ensure the 
anastomotic ends of the implanted grafts could withstand physiological systolic pressures.     
If a successful 3D seeding and pre-conditioning protocol for the scaffolds could be 
developed, the next stage would be implant / explant of the scaffold into an in vivo ovine 
model to assess its efficacy as a vascular graft. An ovine model is suitable as the 
circulation in sheep is similar to humans; sheep possess a clotting system close to that of 
humans and also possess similar systolic and diastolic blood pressures and heart rates 
(Bianco et al., 2004; Konya et al., 2008). Ideally seeded grafts would be implanted as 
interposition grafts or extra-anatomic grafts in similar sized native vessels e.g ovine carotid 
artery or femoral artery to reduce compliance mismatch between graft and artery, which 
could otherwise predispose to thrombosis and NIH. The ‘common’ failures of vascular 
grafts are known to arise at specific time-points e.g early, mid-term and late, so it would be 
important to assess the grafts at these intervals, particularly the first two. Late failure in 
humans is secondary to atherosclerosis developing in the graft and so would be less 
important to assess in an animal model, particularly given the difficulties and costs 
involved in caring for an experimental animal model for up to five years. The primary 
endpoints to assess would be length of graft patency, and levels of thrombosis and 
neointimal hyperplasia. One protocol could be graft explantation at 30 days to assess for 
thrombosis and at one year for graft patency and for evidence of NIH. Secondary 
endpoints could be to determine the position of cells within their graft and their expressed 
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phenotype (does it possess a functioning endothelial monolayer) and graft function i.e 
does it possess vasomotor reactivity? The next stage following an ovine model should the 
scaffold demonstrate efficacy would ultimately be the seeding of acellular scaffolds with 
human vascular cells and if successful, reproducing the stages above. The final stage of 
the study would ultimately involve the implantation of a scaffold seeded with human 
vascular cells in human in vivo studies.   
Tissue engineering is a promising approach to tackling the difficulties faced with SD 
bypass, in particular, the approach of seeding grafts with cells. Studies using cell-seeded 
synthetic grafts have clearly shown efficacy over un-seeded grafts in terms of short and 
long-term graft patency and I believe such results can be achieved using acellular 
scaffolds. (Zilla et al.,1994 ; Meinhart et al., 1997, 2001; Deutsch et al., 1997,1999; Laube 
et al., 2000). One of the significant drawbacks of using synthetic grafts remains the risk of 
infection, a risk that would largely be resolved if biological grafts were used. 
In order to develop a graft that could display clinical and commercial success, it is vital that 
both costs and the time to produce the graft are kept as minimal as possible. The data 
presented in this thesis has demonstrated that the process of decellularising and re-
cellularising porcine arterial tissue is a viable start in the development of a tissue 
engineered graft. PCA in particular are cheap to acquire as they can be harvested from 
pigs slaughtered for human consumption at a minimal cost as they are not specifically bred 
or maintained for purpose. Furthermore with animal tissue comes an essentially unlimited 
supply. The decellularisation process is short at two weeks and large batches could be 
decellularised together on a more industrial scale, improving production efficiency.  
The scaffolds have demonstrated good initial seeding potential with xenogeneic cells 
without the need for functionalisation to improve seeding efficiency, again a major 
advantage in keeping production times and costs down. Despite this however, it is clear 
from the literature and my own personal view, that cell-seeding of grafts is the major 
barrier to the translation of this specific form of tissue engineering from getting from the 
bench to the bedside. Cell procurement from the patient, expansion of cells in culture and 
the seeding of grafts does take time (although as I have described, techniques are 
constantly evolving to improve this) and therefore excludes the cohort of patients that 
require coronary and peripheral arterial bypass in an urgent or semi-elective fashion. 
Should in-situ cell adhesion strategies improve so that grafts rapidly endothelialise 
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following implantation, then such a product could become an “off the shelf” medical device 
in the future. The reality is that this technology is still far away from achieving widespread 
success and for the current time, cell-seeded grafts remain a highly personalised, patient-
specific item.        
With regards to the scaffold itself as a bypass conduit, it does display excellent tissue 
handling properties would make it highly desirable to surgeons. It would be an excellent 
graft for coronary bypass but may have limited use in peripheral arterial bypass. The main 
drawback of PCA is its length and caliber change. At its origin from the aortic arch, the 
average length of PCA’s harvested during the study were approximately 10-12 cm. As it 
moves more proximally towards the brain, the diameter tapers from approx 6-8mm at its 
base to approximately 4mm at it’s proximal end. This length would be ideal for bypassing 
coronary vessels and the tapering would be of minimal consequence as it would match the 
natural tapering seen in the coronary arteries. It would however be too short in most cases 
for peripheral bypass, where a length of at least 15-25 cm would usually be required. It 
would be possible to anastomose two or even three grafts together, but this would 
significantly increase operating time. More importantly, the tapering would mean that any 
anastomosed grafts would not be completely uniform in diameter, likely impacting on the 
haemodynamics of the graft (where laminar flow is essential).  
This study and others (Bader et al., 2000; Kaushal et al., 2001; McFetridge et al., 2004; 
Amiel et al., 2006; Hinds et al., 2006; Liao et al., 2009; Heine et al., 2011) have 
demonstrated many key attributes that porcine arterial tissue does possess that makes it 
an attractive material for the development of tissue engineered vascular grafts. In addition 
to the important future work discussed earlier with regards to the development of a cell-
seeded PCA, applying and assessing the same techniques using porcine arterial tissues 
with greater length, such as femoral artery, may prove more suitable for human peripheral 
arterial bypass. 
Clearly at the current position, and not unsurprisingly, the study has not created a scaffold 
that possesses all the key attributes of the ‘Ideal’ Vascular Graft laid out in                  
Table 1, Chapter 1. 
Many of the attributes described in Table (1) remain unknown until further studies with the 
current scaffolds can be or are performed. At the current time, certainly no scaffolds have 
been developed that do indeed possess all attributes listed. The decellularisation and 
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subsequent re-cellularisation of tissue remains one of the most viable techniques we have 
to date in order to achieve a graft displaying such key attributes as: being non-
immunogenic, bacteriostatic, being easy to handle, having a potential unlimited size 
availability and importantly, retaining the biomechanical properties of native tissue. As the 
development of tissue engineering techniques increases, we may see improvement in 
other key areas such as production costs, transportation and storage.           
There are unfortunately some limitations that in particular, tissue-engineered grafts have. 
Firstly the use of animal tissue to create a biological graft for human use will not be 
accepted by all patient groups. Vegetarians and patients with particular religious faiths for 
example would be unlikely to accept the implantation of such grafts for vascular bypass. 
Other patients may be concerned regarding the possible transmission of disease from 
animal to human or the possibility of contaminated grafts being implanted. Porcine cells for 
example do contain porcine endogenous retroviruses that can potentially infect human 
cells. The decellularisation process if performed effectively would remove the risk of 
disease transmission by removing porcine cells, however stringent safeguards and 
monitoring would be required throughout the production process to ensure grafts were free 
from endogenous pathogens. In addition, regular quality assurance and sterility testing 
would be required to ensure that scaffolds remain clear from microbial contamination. Most 
sterilisation processes are industrial and use predominantly heat or chemicals. Such 
processes are unsuitable for cell seeded scaffolds. As such, production of such grafts 
would have to be performed in aseptic environments, potentially increasing the costs of 
production.          
7.6 Conclusion 
In final conclusion, I believe that this study has demonstrated the viability of using a 
decellularised xenograft for the development of a TEVG. In particular the study has 
demonstrated that porcine carotid tissue can be successfully decellularised and re-
cellularised using xenogeneic vascular cells. The scaffold created from PCA is an ideal 
size for use as a coronary arterial bypass conduit or as a SD interposition graft, but would 
be unsuitable for peripheral arterial bypass given its lack of length. Further work is required 
to establish if porcine scaffolds created by the decellularisation process can develop an 
endothelial monolayer with functionality and display efficacy as a SD graft in an in vivo 
model.       
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